



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.


Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Mendelian Randomization Analysis Reveals No Causal Relationship Between Nonalcoholic Fatty Liver Disease and Severe COVID-19



Jiuling Li,^{*} Aowen Tian,^{*} Haoxue Zhu,[‡] Lanlan Chen,[§] Jianping Wen,^{||} Wanqing Liu,^{¶,#,a} and Peng Chen^{*,||,a}

^{*}Department of Pathology, College of Basic Medical Sciences, Jilin University, Changchun, China; [‡]Teaching Department, First Affiliated Hospital of Jilin University, Changchun, China; [§]School of Clinical Medicine, Jilin University, Changchun, China; ^{||}Department of Genetics, College of Basic Medical Sciences, Jilin University, Changchun, China; [¶]Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan; and [#]Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan



BACKGROUND & AIMS:

The coronavirus disease 2019 (COVID-19) pandemic has witnessed more than 4.5 million deaths as of the time of writing. Whether nonalcoholic fatty liver disease (NAFLD) increases the risk for severe COVID-19 remains unclear. We sought to address this question using 2-sample Mendelian randomization (TSMR) analysis approaches in large cohorts.

METHODS:

We performed large-scale TSMR analyses to examine whether there is a causal relationship between NAFLD, serum alanine aminotransferase, grade of steatosis, NAFLD Activity Score, or fibrosis stage and severe COVID-19. To maximize the power of this analysis, we performed a genome-wide meta-analysis to identify single nucleotide polymorphisms associated with NAFLD. We also examined the impact of 20 major comorbid factors of NAFLD on severe COVID-19.

^aAuthors share co-corresponding authorship.

Abbreviations used in this paper: ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; FDR, false discovery rate; GWAS, genome-wide association studies; GWMA, genome-wide meta-analysis; IV, instrumental variable; MR, Mendelian randomization; MVP, Million Veteran Program; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD Activity Score; OR, odds ratio; SARS-CoV-2, severe acute respiratory

syndrome coronavirus 2; SBP, systolic blood pressure; SNP, single nucleotide polymorphism; T2D, type 2 diabetes; TSMR, 2-sample Mendelian randomization; UKB, UK Biobank.

Most current article

© 2022 by the AGA Institute
1542-3565/\$36.00

<https://doi.org/10.1016/j.cgh.2022.01.045>

RESULTS:

Univariate analysis of the UK Biobank data demonstrated a significant association between NAFLD and severe COVID-19 (odds ratio [OR], 3.06; $P = 1.07 \times 10^{-6}$). However, this association disappeared after demographic and comorbid factors were adjusted (OR, 1.57; $P = .09$). TSMR study indicated that NAFLD (OR, 0.97; $P = .61$), alanine aminotransferase level (OR, 1.03; $P = .47$), grade of steatosis (OR, 1.08; $P = .41$), NAFLD Activity Score (OR, 1.02; $P = .39$), and fibrosis stage (OR, 1.01; $P = .87$) were not associated with severe COVID-19. Among all NAFLD-related comorbid factors, body mass index (OR, 1.73; $P = 7.65 \times 10^{-9}$), waist circumference (OR, 1.76; $P = 2.58 \times 10^{-5}$), and hip circumference (OR, 1.33; $P = 7.26 \times 10^{-3}$) were the only ones demonstrated a causal impact on severe COVID-19.

CONCLUSIONS:

There is no evidence supporting that NAFLD is a causal risk factor for severe COVID-19. Previous observational associations between NAFLD and COVID-19 are likely attributed to the correlation between NAFLD and obesity.

Keywords: Nonalcoholic Fatty Liver Disease; Severe COVID-19; Genome-Wide Association Study; Mendelian Randomization.

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a serious threat to global health. The cumulative number of deaths reported globally is over 4 million by July 27, 2021.¹ Understanding the relationship between severe COVID-19 and other health conditions is key to COVID-19 treatment and management. Identifying risk factors, especially those that are modifiable can help develop strategies for disease prevention. Numerous studies thus far have suggested that severe COVID-19 is associated with older age,²⁻⁴ male sex,^{2,4} and several comorbidities such as obesity,^{2,4,5} type 2 diabetes,^{6,7} cardiovascular disease,^{7,8} and hypertension.⁹

It has estimated that about 25% of the world population has NAFLD, which is thereby the most common chronic liver disease.¹⁰ It has been a long debate whether NAFLD is a risk factor for severe COVID-19 disease. Clinical studies have consistently reported that patients with severe COVID-19 demonstrated altered liver function.^{11,12} A number of observational studies demonstrated that patients with NAFLD have a significantly increased risk for severe COVID-19.¹³⁻¹⁶ Two meta-analyses of multiple epidemiological studies indicated that NAFLD increased risk for severe COVID-19 for 2.6- or 5.2-fold.^{17,18} On the other hand, Mushtaq et al¹⁹ demonstrated that NAFLD was not associated with severe COVID-19 after adjusting other risk factors. The discrepancies in these results may reflect the impact of potential confounding factors, sample size, and population heterogeneity. Mendelian randomization (MR) analysis was considered to be advantageous to observational studies, as it avoids the confounding factor and reverse causation. A recent one-sample MR study using UK Biobank (UKB) data demonstrated that a genetic risk score for hepatic fat was not associated with an increased risk for COVID-19.²⁰ However, this study was limited by its one-sample based design, which can be potentially biased.²⁰ In addition, given that NAFLD has a broad spectrum of disease progression, focusing on the causal relationship between liver fat and COVID-19 may

not reflect the potential causal role of NAFLD severity on COVID-19. Meanwhile, severe COVID-19 leads to a greater challenge for patient management than mild symptoms and thus should be investigated more specifically. Here, we sought to address this question using TSMR analyses to comprehensively examine the causal role of NAFLD, NAFLD severity, as well as other NAFLD comorbid factors in severe COVID-19, by leveraging large-scale publicly available genome-wide association study (GWAS) data.

Materials And Methods

Observational study

The observational study was conducted in the UKB cohort. The details of the UKB cohort are available in the [Supplementary Materials](#). Disease codes for type 2 diabetes (T2D), cardiovascular disease (CVD), NAFLD, cirrhosis, and severe COVID-19 in the UKB are available in [Supplementary Table 1](#). As shown in [Figure 1](#), univariate logistic regression analysis was performed to detect the association of age, sex, body mass index (BMI), T2D, CVD, systolic blood pressure (SBP), NAFLD, and cirrhosis with severe COVID-19. A Benjamini-Hochberg false discovery rate (FDR) of 0.05 was used to define significant associations.²¹ The significant variables were subjected to a multivariate logistic regression analysis to identify the independent risk factors of severe COVID-19.

NAFLD Genome-Wide Meta-Analysis

We searched for NAFLD GWAS published before April 15, 2021 with “non-alcoholic fatty liver disease” as keywords in the GWAS catalog. We found that 13 GWASs on NAFLD have been published, but summary statistics of only 2 GWASs are available ([Supplementary Table 2](#)). Our team has also published an independent GWAS on NAFLD in UKB cohort. We performed a genome-wide meta-analysis (GWMA) of these 3 independent GWASs

on NAFLD,^{22–24} which in total covered 3711 NAFLD cases and 426,252 controls ([Supplementary Table 3](#)). Additional large-scale GWASs are also available, eg, the unpublished study in the Million Veteran Program (MVP) cohort.²⁵ However, the definition of NAFLD is primarily based on the liver function measurement of ALT levels. The single nucleotide polymorphism (SNPs) identified in this MVP cohort were then used as instrumental variables for ALT level to perform an additional TSMR to examine the causal role of ALT level (liver injury) and severe COVID-19. GWMA was performed using a fixed-effect inverse variance-weighted model with METAL.²⁶ The autosomal SNPs with the same direction of effect across the 3 GWASs were used in this study.

GWMA on Severe COVID-19 Based on the COVID-19 Host Genetics Initiative Study

The GWAS statistics with severe COVID-19 were obtained from the COVID-19 Host Genetics Initiative Study.²⁷ To avoid sample overlapping between the exposure and the outcome in our TSMR analysis, we used the round 5 release that does not involve the UKB cohort or the round 6 release that involves the UKB cohort as the outcome, depending on whether the exposure GWAS involved the UKB cohort ([Supplementary Table 4](#)). Two GWMA details are included in the [Supplementary Materials](#). The autosomal SNPs with minor allele frequency >0.01, imputation INFO score >0.6, and heterogeneity *P* value >.05 were used in this study.

Instrumental Variable Selection for TSMR

SNPs selected as instrumental variables (IVs) for TSMR analyses were chosen based on the following criteria: (1) associated with exposure at the genome wide-significant level ($P < 5 \times 10^{-8}$) in GWAS or GWMA with samples of European ancestry without sample overlap with the severe COVID-19 GWAS to our best knowledge or (2) independent from each other (linkage disequilibrium $r^2 < 0.05$, within 10-Mb distance).

Mendelian Randomization Analysis

As shown in [Figure 1](#), to comprehensively examine the causal role of NAFLD, NAFLD severity, as well as 20 NAFLD comorbid factors (exposures) in the development of severe COVID-19 (outcome), TSMR analyses were performed using the GWAS statistical summary data of each exposure and severe COVID-19, for which GWAS were performed in separate sample sets. Homogeneous genetic variant-exposure associations in the 2 samples are the basic assumption of TSMR and might be violated if samples are from different subpopulations (eg, age, sex, ethnicity). To hold this assumption, we limited our study in cohorts that are mainly of European ancestry and involve both sexes ([Supplementary Table 4](#)).

What You Need to Know

Background

Observational studies did not draw a clear conclusion on the association between nonalcoholic fatty liver disease (NAFLD) and coronavirus disease 2019 (COVID-19). Causal relationship between NAFLD and severe COVID-19 remains unclear.

Findings

There is no evidence supporting that NAFLD, alanine aminotransferase level, grade of steatosis, NAFLD Activity score, and fibrosis stage were causally associated with severe COVID-19. Among common NAFLD-related comorbid factors, body mass index, waist circumference, and hip circumference were the only ones demonstrated causal impact on severe COVID-19.

Implications for patient care

NAFLD may not be a causal risk factor for severe COVID-19. Bodyweight control in patients with NAFLD is important for the prevention of severe COVID-19.

We performed the primary TSMR via an inverse variance-weighted approach with an assumption that all SNPs are valid instrumental variables (eg, no pleiotropic effects).²⁸ However, the pleiotropy effects of instrumental variables are common and inevitable in practice. We performed the sensitivity analyses using the MR-Egger, weighted median, or MR-PRESSO methods to limit the bias of pleiotropic effects. The assumptions based on by each Mendelian randomization (MR) method are included in the [Supplementary Materials](#).

Statistical Analysis

The NAFLD GWMA was performed using METAL.²⁶ The TSMR analysis was conducted using the “TwoSampleMR” package of R (version 0.5.6). Univariate and multivariate logistic regression analysis were conducted using R software (version 4.0.2; R Foundation for Statistical Computing, Vienna, Austria). The calculation methods for the *F*-statistic, R^2 , and MR power are included in the [Supplementary Materials](#).

Results

Observational Association Between NAFLD and Severe COVID-19

As of May 13, 2021, the UKB recorded 8267 unrelated individuals of European ancestry with positive test results of SARS-CoV-2. Of these, 556 developed severe COVID-19. The detailed demographic information of these samples is summarized in [Supplementary Table 5](#).




Figure 1. A schematic diagram of the study design. Apo, apolipoprotein; CRP, C-reactive protein; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HC, hip circumference; HDL-C, high-density lipoprotein cholesterol; HGI, Host Genetics Initiative; HOMA-IR, homeostatic model assessment for insulin resistance; LD, linkage disequilibrium; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHR, waist-hip ratio.

We first investigated the association of NAFLD and nondisease risk factors (age, sex) with severe COVID-19. NAFLD is highly associated with a wide variety of metabolic perturbations that are risk factors for severe COVID-19, (eg, obesity, T2D, CVD, hypertension) (Figure 1). Previous observational associations between NAFLD and severe COVID-19 may be due to the confounding effect of these metabolic comorbid factors of NAFLD. We therefore also examined the association of these factors and severe COVID-19.

Our univariate regression analysis revealed that age (odds ratio [OR], 1.13; $P = 1.27 \times 10^{-82}$; FDR = 1.02×10^{-81}), male sex (OR, 2.08; $P = 2.02 \times 10^{-15}$; FDR = 2.69×10^{-15}), BMI (OR, 1.07; $P = 3.34 \times 10^{-19}$; FDR = 6.68×10^{-19}), T2D (OR, 3.63; $P = 1.36 \times 10^{-33}$; FDR = 5.44×10^{-33}), CVD (OR, 3.71; $P = 2.12 \times 10^{-45}$; FDR = 8.49×10^{-45}), SBP (OR, 1.02; $P = 1.43 \times 10^{-16}$; FDR = 2.29×10^{-16}), NAFLD (OR, 3.06; $P = 1.07 \times 10^{-6}$; FDR = 1.07×10^{-6}), and cirrhosis (OR, 7.59; $P = 9.24 \times 10^{-11}$; FDR = 1.06×10^{-10}) were all significantly associated with the risk for severe COVID-19 (Figure 2, Supplementary Table 6). However, in our multivariate regression analysis including these 8 risk factors, NAFLD was not associated with severe COVID-19 (OR, 1.57; $P = .09$), while age, male sex, BMI, T2D, CVD, and cirrhosis still remained significantly associated with severe COVID-19 ($P < .05$) (Figure 2, Supplementary Table 6). While this result may be

limited by the small sample size as well as by other unknown clinical covariates, it suggests that NAFLD is not an independent risk factor for severe COVID-19.

GWMA for NAFLD and Selection Of Instrumental Variables Associated With NAFLD, ALT Level, Grade of Steatosis, NAFLD Activity Score, and Fibrosis Stage

We next aimed to examine the causal relationship between NAFLD, as well as multiple NAFLD severity traits, and severe COVID-19 using TSMR analyses. The NAFLD severity traits include degree of liver injury (ALT level), grade of steatosis, NAFLD Activity Score (NAS), and fibrosis stage. To maximize the power of our analyses, we first conducted a GWMA of 3 independent, large-scale GWASs on NAFLD (Supplementary Table 3). Five independent SNPs ($r^2 < 0.05$) reached genome-wide significance ($P < 5 \times 10^{-8}$) in the GWMA were selected as instrumental variables of NAFLD. These included rs738409 in *PNPLA3*, rs1260326 in *GCKR*, rs112875651 near *TRIB1*, rs58542926 in *TM6SF2*, and rs429358 in *APOE* (Table 1). While variants in *PNPLA3*, *GCKR*, and *TM6SF2* were well established among multiple GWAS, the variants in *TRIB1* and *APOE* loci were recently demonstrated to be associated with NAFLD in large-scale GWMA.²⁹ rs738408 was used as a proxy for rs738409




Figure 2. Observational association between 8 risk factors and severe COVID-19. Univariate association between 8 risk factors and severe COVID-19 (gray) and multivariate regression analysis after being adjusted for the remaining risk factors (black).

in the TSMR analysis because the latter is a palindromic SNP. The instrumental variables for NAFLD severity traits were identified in largest-to-date GWAS of the respective trait.^{22,23} All candidate IVs are summarized in [Supplementary Table 7](#). The instrument strength and MR power are available in [Supplementary Table 8](#).

Causal Association Between NAFLD, ALT Level, Grade of Steatosis, NAS, Fibrosis Stage, and Severe COVID-19

Our TSMR analysis revealed that there is no significant causal relationship between NAFLD and severe COVID-19 based on the aforementioned 5 IVs (OR, 0.97; 95% confidence interval [CI], 0.88–1.08; $P = .61$, the change in severe COVID-19 for each 2.72-fold increase in NAFLD). The result also remained insignificant (OR, 1.03; 95% CI, 0.95–1.13; $P = .47$) when using all 40 SNPs associated with ALT level (liver injury) based on the MVP study as IVs. We found that other NAFLD severity traits, ie, grade of steatosis (OR, 1.08; 95% CI, 0.90–1.29; $P = .41$), NAS (OR, 1.02; 95% CI, 0.98–1.05; $P = .39$), and fibrosis stage (OR, 1.01; 95% CI, 0.94–1.08; $P = .87$), were also not associated with severe COVID-19 ([Figure 3](#), [Supplementary Table 9](#)). To maximize power, we also used SNPs associated with NAS

and fibrosis stage at a relaxed significance level ($P < 1 \times 10^{-5}$) as IVs. No significant association was observed either ([Supplementary Table 9](#)). The MR-Egger, weighted median estimates, and MR-PRESSO also showed the consistent results.

Causal Association Between Common NAFLD Comorbid Factors and Severe COVID-19

To further test the hypothesis that other NAFLD-associated comorbid factors may causally confound the positive associations observed between NAFLD and severe COVID-19, we further performed TSMR analyses to examine the causal association between common NAFLD comorbid factors and severe COVID-19. These factors, including obesity, glycemic, lipidemic, and cardiometabolic features, have been broadly reported to be associated with NAFLD.^{10,30} Candidate IVs were selected from large GWASs or GWMA of multiple GWASs, and the associations of IVs with exposures and severe COVID-19 are available in [Supplementary Table 7](#). The instrument strength and MR power are available in [Supplementary Table 8](#).

Our TSMR analysis revealed that among all 20 common NAFLD comorbid factors, BMI (OR, 1.73; 95% CI, 1.44–2.08; $P = 7.65 \times 10^{-9}$), waist circumference (OR,

Table 1. Five Independent Significant SNPs Associated With NAFLD

SNP	EA	AA	Gene	Beta	SE	P Value
rs1260326	T	C	GCKR	0.19	0.03	7.35×10^{-14}
rs112875651	G	A	TRIB1	0.20	0.03	6.81×10^{-13}
rs429358	T	C	APOE	0.20	0.04	4.92×10^{-08}
rs58542926	T	C	TM6SF2	0.39	0.05	3.08×10^{-16}
rs738409	G	C	PNPLA3	0.52	0.03	2.57×10^{-73}

AA, alternative allele; EA, effect allele; NAFLD, nonalcoholic fatty liver disease; SNP, single nucleotide polymorphism.

1.76; 95% CI, 1.35–2.29; $P = 2.58 \times 10^{-5}$), and hip circumference (OR, 1.33; 95% CI, 1.08–1.65; $P = 7.26 \times 10^{-3}$) were the only ones significantly associated with severe COVID-19 (Figure 3, Supplementary Table 9). For these, the weighted median estimates and MR-PRESSO

were also demonstrated to be significant with the same direction of the causal effects ($P < .05$). The estimates of MR-Egger were not significant but were in the same direction (Supplementary Table 9).

Discussion

In this study, we comprehensively examined the relationship between NAFLD and severe COVID-19. Our study demonstrated that while at the population level NAFLD may be associated with severe COVID-19 disease, this association is likely confounded by other metabolic perturbations underlying the comorbidities of NAFLD. This notion is particularly supported by the lack of causal association between NAFLD and severe COVID-19. Our thorough analyses utilizing large-scale independent sets of samples and data do not support the notion that NAFLD or histologic severity of NAFLD, eg, grade of steatosis, fibrosis or liver injury (ALT level), and NAS

Exposure	Nsnp
Body mass index	81
Waist circumference	44
Hip circumference	54
Waist-to-hip ratio	34
Type 2 diabetes	29
Fasting glucose	98
Fasting insulin	40
2h glucose	13
HbA1c	106
HOMA-B	11
HOMA-IR	9
Coronary heart disease	43
Dastolic blood pressure	689
Systolic blood pressure	650
Serum total cholesterol	29
Serum total triglycerides	11
Total cholesterol in LDL	39
Total cholesterol in HDL	18
Apolipoprotein B	23
C-reactive protein	410
Serum alanine aminotransferase level	40
Grade of steatosis (IVs provided by Anstee QM et al)	2
NAFLD activity score (IVs provided by Namjou B et al)	2
Fibrosis stage (IVs provided by Namjou B et al)	3
Nonalcoholic fatty liver diseases	5




Figure 3. The causal association between NAFLD, ALT level (liver injury), grade of steatosis, NAS, fibrosis stage, other risk factors and severe COVID-19. HOMA-B, homeostatic model assessment for beta cell function; Nsnp, the number of IVs used in MR.

play a causal role in the development of severe COVID-19. On the other hand, our screening on 20 common metabolic factors associated with NAFLD revealed that obesity (indexed by BMI, waist circumference, and hip circumference) is the only causal risk factor for severe COVID-19. Our finding has important implications on the relationship between chronic liver conditions and the severity of COVID-19, which may help direct the clinical management for NAFLD patients who experience SARS-CoV-2 infection. The causal relationship between obesity and severe COVID-19 further highlighted the importance of body weight control in the prevention of severe COVID-19.

Given the large impact of both NAFLD and COVID-19 on human health, understanding the relationship between NAFLD and COVID-19, especially the severe form of COVID-19, is of importance for disease treatment and prevention. Unfortunately, despite numerous epidemiological studies thus far in the area, this relationship remains controversial, which is mainly due to the limitation of observational studies where the causal relationship between NAFLD and severe COVID-19 cannot be examined. MR analysis provides a possibility to examine such a causal relationship, and a previous MR study has suggested a nonsignificant causal role of NAFLD in the infection of SARS-CoV-2.²⁰ However, this study was mainly focused on risk for COVID-19 rather than the severe forms, which is more relevant to public health. It also primarily utilized the UKB samples and data in which many confounding factors may influence the statistical estimation. Meanwhile, this study only studied liver fat as the exposure, which does not allow examining whether histologic severity of NAFLD is more likely to contribute to the risk for severe COVID-19. More importantly, this one-sample-based MR analysis design may be vulnerable to bias, and the conclusion may be limited to the specific population.²⁰ Two-sample MR analysis utilizes nonoverlapping, independent data and sample sets for exposure and outcome groups, provided a more powerful and potentially more generalizable assessment for the causal relationship between the 2 diseases.³¹ Nevertheless, our data indicated that there is no sufficient evidence to support that key features of NAFLD progression spectrum are causal to severe COVID-19.

Consistent with previous TSMR studies,^{32–34} our TSMR analysis demonstrated that systemic obesity related indexes (BMI, waist circumference, and hip circumference) were the only causal comorbid risk factor for severe COVID-19, while T2D, CVD, and SBP were all not causally associated with severe COVID-19. On the contrary, the previous observational studies^{7,8} and our multivariate analysis in the UKB cohorts showed that T2D and CVD are independent risk factors for severe COVID-19. The discrepant findings of TSMR analysis and the observational studies might be attributed to the low proportion of variances in T2D and CVD (F statistics < 100) explained by the instrumental variable in the MR analysis, which is in contrast to that of NAFLD (F

statistics = 16572.45) and obesity (F statistics > 250) indexes. Therefore, the causal relationship between T2D or CVD and severe COVID-19 may not be ruled out. Another potential limitation of our study is the unavailability of the causal relationship between liver cirrhosis and severe COVID-19. While cirrhosis was demonstrated as a potential independent risk factor for severe COVID-19 in our multivariate analysis, unfortunately, there are current no appropriate IVs for liver cirrhosis to examine their causal relationship using MR. Whether cirrhosis is a pathogenic risk factor for severe COVID-19 needs to be investigated in future studies.

It is now plausible that overall obesity, rather than NAFLD, plays a causal role in the development of severe COVID-19 symptoms. The potential mechanism underlying the increased risk of severe COVID-19 with BMI remains unclear, thus requiring urgent investigation. Preliminary hypotheses proposed for this mechanism included the lower cardiorespiratory reserve and immune dysregulation in patients with high BMI that worsen the symptoms of COVID-19.³⁵ Taken together, weight control may be the most critical modifiable risk factors for preventing the development of severe COVID-19.

In conclusion, our study suggests that NAFLD or its disease severity is unlikely a causal risk factor for severe COVID-19.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at www.cghjournal.org, and at <https://doi.org/10.1016/j.cgh.2022.01.045>.

References

1. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update (2020). Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>. Accessed July 27, 2021.
2. Rapp JL, Lieberman-Cribbin W, Tuminello S, et al. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. *Chest* 2021;159:112–115.
3. Zhang JJ, Cao YY, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. *Allergy* 2021; 76:533–550.
4. Ebinger JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity. *PLoS One* 2020;15: e0236240.
5. Gao F, Zheng KI, Wang XB, et al. Obesity is a risk factor for greater COVID-19 severity. *Diabetes Care* 2020;43(7):e72–e74.
6. Dennis JM, Mateen BA, Sonabend R, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March–July 2020. *Diabetes Care* 2021; 44:50–57.
7. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality

- from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ (Clinical Res Ed)* 2020;371:m3731.
8. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020;584:430–436.
 9. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020;146:110–118.
 10. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64:73–84.
 11. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708–1720.
 12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
 13. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020;73:451–453.
 14. Mahamid M, Nseir W, Khoury T, et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. *Eur J Gastroenterol Hepatol* 2021;33:1578–1581.
 15. Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. *Liver Int* 2020;40(10):2515–2521.
 16. Bramante C, Tignanelli CJ, Dutta N, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv. <https://doi.org/10.1101/2020.09.01.20185850>.
 17. Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis. *Diabetes Metab Syndr* 2021;15:813–822.
 18. Hegyi PJ, Vánca S, Ocskay K, et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis. *Front Med* 2021;8:626425.
 19. Mushtaq K, Khan MU, Iqbal F, et al. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. *J Hepatol* 2021;74:482–484.
 20. Valenti L, Jamialahmadi O, Romeo S. Lack of genetic evidence that fatty liver disease predisposes to COVID-19. *J Hepatol* 2020;73:709–711.
 21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* 1995;57:289–300.
 22. Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. *J Hepatol* 2020;73:505–515.
 23. Namjou B, Lingren T, Huang Y, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. *BMC Med* 2019;17:135.
 24. Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. *J Hepatol* 2020;73:263–276.
 25. Vujkovic M, Ramdas S, Lorenz KM, et al. A genome-wide association study for nonalcoholic fatty liver disease identifies novel genetic loci and trait-relevant candidate genes in the Million Veteran Program. bioRxiv <https://doi.org/10.1101/2020.12.26.20248491>.
 26. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010;26:2190–2191.
 27. COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* 2020;28:715–718.
 28. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;37:658–665.
 29. Ghodsian N, Abner E, Emdin CA, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. *Cell Rep Med* 2021;2:100437.
 30. Perdomo C, D'Ingianna P, Escalada J, et al. Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. *Polish Arch Intern Med* 2020;130:975–985.
 31. Lawlor DA. Commentary: two-sample Mendelian randomization: opportunities and challenges. *Int J Epidemiol* 2016;45:908–915.
 32. Ponsford MJ, Gkatzionis A, Walker VM, et al. Cardiometabolic traits, sepsis, and severe COVID-19: a Mendelian randomization investigation. *Circulation* 2020;142:1791–1793.
 33. Leong A, Cole JB, Brenner LN, et al. Cardiometabolic risk factors for COVID-19 susceptibility and severity: a Mendelian randomization analysis. *PLoS Med* 2021;18:e1003553.
 34. Freuer D, Linseisen J, Meisinger C. Impact of body composition on COVID-19 susceptibility and severity: a two-sample multi-variable Mendelian randomization study. *Metabolism* 2021;118:154732.
 35. Sattar N, McInnes IB, McMurray JJV. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. *Circulation* 2020;142:4–6.

Reprint Requests

Address requests for reprints to: Wanqing Liu, PhD, Integrative Biosciences Center, Room 2401, Wayne State University, 6135 Woodward Ave, Detroit, Michigan 48202. tel:1-313-577-3375. e-mail: wliu@wayne.edu. or Peng Chen, PhD, College of Basic Medical Sciences, Room 413, Jilin University, 126 Xinmin Street, Changchun, Jilin 130021, China. e-mail: pchen@jlu.edu.cn; fax: 0086 431 85619469.

Acknowledgments

The observational study was conducted in the UK Biobank cohort under the application number 71668. The authors thank the COVID-19 Host Genetics Initiative for providing public COVID-19 genome-wide association study summary statistics, as well as those groups that shared genome-wide association study summary data. The authors thank the Servier Medical Art for free medical images (<https://smart.servier.com/>).

Conflicts of interest

The authors disclose no conflicts.

Funding

This work was supported by the “Changbai Mountain Scholar” Distinguished Professor Awarding Program of the Department of Education of Jilin Province, China. W.L. is currently supported in part by the NIH grants R01DK106540 and R01DK124612, as well as the MI-SAPPHIRE grant from Michigan Department of Health and Human Services (MDHHS).

SUPPLEMENTARY MATERIALS

METHODS

Observational study. The UK Biobank (UKB) cohort included over 500,000 adult individuals recruited from the UK population between 2006 and 2010. The extensive phenotypic and genotypic data were publicly available among all participants.¹ The UKB released coronavirus disease 2019 (COVID-19) test results and hospital inpatient data in April 2020.

Genome-Wide Meta-Analysis on Severe COVID-19 based on the COVID-19 Host Genetics Initiative Study. Severe COVID-19 was defined by death, hospitalization or respiratory support due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Control samples were individuals who were not confirmed for SARS-CoV-2 infection. A total of 1,161,073 participants (5870 cases and 1,155,203 controls) and 7,564,248 variants were evaluated for genome-wide meta-analysis of severe COVID-19 in the round 5 release. For the round 6 release, a total of 1,010,654 participants (8779 cases and 1,001,875 controls) and 8,141,091 variants were evaluated for severe COVID-19 genome-wide association study meta-analysis. The round 6 release includes the UKB cohort (417 [4.7%] cases and 420,114 [41.9%] controls).

Mendelian Randomization Analysis. The MR-Egger regression estimates the effects of pleiotropy and produces a pleiotropy-corrected causal estimate which is a more robust method for causal estimates under the assumptions that NOME (NO Measurement Error) and the InSIDE (Instrument Strength Independent of Direct Effect).² We assessed the NOME assumption by the I^2 statistic before implementing the MR-Egger analysis. If I^2 is <90%, we calculated the causal estimates using MR-Egger SIMEX.³ The MR-Egger estimate might be biased when NOME holds but InSIDE is violated. Therefore, we complemented the MR-Egger estimate using the weighted median approach that does not rely on the InSIDE assumption and provides a consistent causal effect even when <50% of instrumental variables are valid.⁴ In addition, we conducted MR-PRESSO tests to

correct for horizontal pleiotropic effect by removing IV outliers.⁵ Furthermore, we estimated the heterogeneity of instrumental variables using Cochran's Q test.

Statistical Analysis. The F statistic was calculated by the following formula to estimate the statistical power of instrumental variables:

$$F = \frac{N - K - 1}{K} \times \frac{R^2}{1 - R^2}$$

where N is the sample size, K is the number of instrumental variables, and R^2 is the proportion of the variability of the exposure explained by instrumental variables. R^2 was calculated with reference to the work of Papadimitriou et al.⁶ MR Power calculation was performed using mRnd.⁷

References

1. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015;12:e1001779.
2. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol* 2017;32:377–389.
3. Bowden J, Del Greco MF, Minelli C, et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I^2 statistic. *Int J Epidemiol* 2016;45:1961–1974.
4. Bowden J, Davey Smith G, Haycock PC, et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 2016;40(4):304–314.
5. Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018;50:693–698.
6. Papadimitriou N, Dimou N, Tsilidis KK, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. *Nat Commun* 2020;11:597.
7. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol* 2013;42:1497–1501.

Supplementary Table 1. Disease Codes for Severe COVID-19, NAFLD, Cirrhosis, Type 2 Diabetes, and Cardiovascular Disease in UK Biobank

Disease	Diagnoses of ICD-10	Diagnoses of ICD-9	Noncancer Illness Code, Self-Reported	Other
Severe COVID-19	U071			Intensive care unit admission and ventilation machine use from 7 days before and up to 30 days after a patient's first positive test for SARS-CoV-2
NAFLD	K760			
Cirrhosis	K741–K746, K703, K717	5712, 5716, 57150–57152, 57159		
Type 2 diabetes	E11	25000, 25010	1223	
Cardiovascular disease	F01, G45, G46, I20–I25, I60–64, I690–I692, I694, I698, I699	410–414, 4292, 430–436	1074–1076, 1081–1083, 1086, 1491, 1583	

COVID-19, coronavirus disease 2019; ICD-9, International Classification of Diseases–Ninth Revision; ICD-10, International Classification of Diseases–Tenth Revision; NAFLD, nonalcoholic fatty liver disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Supplementary Table 2. NAFLD GWAS Published in GWAS Catalog Before April 15, 2021

First Author	PMID	Publication Date	Reported Trait	Summary Statistics
Adams LA	23213074	2012/12/5	NAFLD histology (other)	Not available
Anstee QM	32298765	2020/4/13	NAFLD	Available
Chalasani N	20708005	2010/8/10	NAFLD histology	Not available
Chung GE	29271184	2017/12/26	NAFLD	Not available
Kawaguchi T	29385134	2018/1/31	NAFLD	Not available
Kawaguchi T	22719876	2012/6/14	NAFLD	Not available
Kitamoto T	23535911	2013/3/28	Pediatric NAFLD score	Not available
Kozlitina J	24531328	2014/2/16	NAFLD	Not available
Namjou B	31311600	2019/7/17	NAFLD	Available
Park SL	32766472	2020/6/25	NAFLD	Not available
Speliotes EK	21423719	2011/3/10	NAFLD	Not available
Wattacheril J	28918882	2017/9/14	Pediatric nonalcoholic steatohepatitis	Not available
Yoshida K	32766473	2020/5/19	Lean NAFLD	Not available

GWAS, genome-wide association study; NAFLD, nonalcoholic fatty liver disease.

Supplementary Table 3. Characteristics of NAFLD GWAS Included in Our GWMA

PMID	32298765	31311600	32165250
First author, Year	Quentin M Anstee, 2020	Bahram Namjou, 2019	Zhipeng Liu, 2020
Population	European	European	European
Sample size	17,781 controls and 1483 cases	8571 controls and 1106 cases	399,900 controls and 1122 cases
NAFLD assessment	Liver biopsy	Imaging or histology	ICD-9 5718 and ICD-10 K760
Quality control for GWAS	SNPs with a MAF $\geq 0.1\%$, Hardy- $P \geq 10^{-7}$, INFO ≥ 0.8 , call rate $\geq 95\%$ were included	SNPs with a MAF $> 1\%$, Hardy- $P > 10^{-4}$, INFO ≥ 0.7 , call rate $> 99\%$ were included	Not available

GWAS, genome-wide association study; MAF, minor allele frequency; ICD-9, International Classification of Diseases–Ninth Revision; ICD-10, International Classification of Diseases–Tenth Revision; NAFLD, nonalcoholic fatty liver disease; SNP, single nucleotide polymorphism.

Supplementary Table 4. Description of GWAS Used for Each Exposure

Exposure	Involved UKB Cohort	First Author (Year)	Consortium	PMID	Sample Size	Population	Sex
NAFLD	Yes	Not applicable	NA	Not applicable	3,711 cases and 426,252 controls	European	Males and females
Grade of steatosis	No	Quentin M Anstee (2020)	NA	32298765	1483 cases	European	Males and females
NAFLD activity score	No	Bahram Namjou (2019)	NA	31311600	235 cases	European	Males and females
NAFLD activity score	No	Quentin M Anstee (2020)	NA	32298765	1483 cases	European	Males and females
Fibrosis stage	No	Bahram Namjou (2019)	NA	31311600	235 cases	European	Males and females
Fibrosis stage	No	Quentin M Anstee (2020)	NA	32298765	1483 cases	European	Males and females
Diastolic/systolic blood pressure	Yes	Evangelos Evangelou (2018)	NA	30224653	757,601	European	Males and females
C-reactive protein	Yes	Xikun Han (2020)	NA	31900758	418,642	European	Males and females
Serum ALT levels	No	Marijana Vujkovic (2020)	NA	medRxiv	164,197	European	Males and females
Body mass index	No	Adam E Locke (2015)	GIANT	25673413	322,154	European	Males and females
Waist circumference	No	Dmitry Shungin (2015)	GIANT	25673412	232,101	European	Males and females
Hip circumference	No	Dmitry Shungin (2015)	GIANT	25673412	213,038	European	Males and females
Waist-to-hip ratio	No	Dmitry Shungin (2015)	GIANT	25673412	212,248	European	Males and females
Type 2 diabetes	No	Robert A Scott (2017)	DIAGRAM	28566273	111,309	European	Males and females
Fasting glucose	No	Ji Chen (2021)	MAGIC	34059833	200,622	European	Males and females
Fasting insulin	No	Ji Chen (2021)	MAGIC	34059833	151,013	European	Males and females
2-h glucose postchallenge	No	Ji Chen (2021)	MAGIC	34059833	63,396	European	Males and females
HbA1c	No	Ji Chen (2021)	MAGIC	34059833	146,806	European	Males and females
HOMA-B	No	Josée Dupuis (2010)	MAGIC	20081858	36,466	European	Males and females
HOMA-IR	No	Josée Dupuis (2010)	MAGIC	20081858	37,037	European	Males and females
Coronary heart disease	No	Majid Nikpay (2015)	CARDIoGRAMplusC4D	26343387	60,801 cases and 123,504 controls	75.3% European	Males and females
Serum total cholesterol	No	Johannes Kettunen (2016)	NA	27005778	21,491	European	Males and females
Serum total triglycerides	No	Johannes Kettunen (2016)	NA	27005778	21,545	European	Males and females
Total cholesterol in LDL	No	Johannes Kettunen (2016)	NA	27005778	21,559	European	Males and females
Total cholesterol in HDL	No	Johannes Kettunen (2016)	NA	27005778	21,555	European	Males and females

Supplementary Table 4. Continued

Exposure	Involved UKB Cohort	First Author (Year)	Consortium	PMID	Sample Size	Population	Sex
Serum apolipoprotein B	No	Johannes Kettunen (2016)	NA	27005778	20,690	European	Males and females
Severe COVID-19 (the round 5 release)	No	Not applicable	COVID-19 Host Genetics Initiative	32404885	5870 cases and 1,155,203 controls	91.2% European	Males and females
Severe COVID-19 (the round 6 release)	Yes	Not applicable	COVID-19 Host Genetics Initiative	32404885	8779 cases and 1,001,875 controls	94.9% European	Males and females

ALT, alanine aminotransferase; COVID-19, coronavirus disease 2019; GWAS, genome-wide association study; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-B, homeostatic model assessment for beta cell function; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease.

Supplementary Table 5. Sample Characteristics of UKB COVID-19 Cohort

	Non-severe (n = 7711)	Severe (n = 556)
Age, y	65.80 ± 8.51	73.87 ± 6.65
Male	3666 (47.54)	363 (65.29)
Body mass index, kg/m ²	28.11 ± 4.96	30.13 ± 5.65
NAFLD	112 (1.45)	24 (4.31)
Cirrhosis	30 (0.39)	16 (2.8)
Type 2 diabetes	637 (8.26)	137 (24.64)
Cardiovascular disease	1135 (14.72)	217 (39.03)
Systolic blood pressure, mm Hg	137.60 ± 19.20	144.7 ± 19.45

Values are mean ± SD or n (%). Nonsevere patients who did not die and were not admitted to for SARS-CoV-2 in the intensive care unit; severe patients who died or entered the intensive care unit due to SARS-COV-2.

NAFLD, nonalcoholic fatty liver disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Supplementary Table 6. The Association Between the Risk Factors and Severe COVID-19 by Logistic Regression Analysis

	Univariate Logistic Regression Analysis				FDR	Multivariate Logistic Regression Analysis			
	OR	Lower 95% CI	Upper 95% CI	P Value		OR	Lower 95% CI	Upper 95% CI	P Value
Age	1.13	1.12	1.15	1.27E-82	1.02E-81	1.12	1.10	1.14	1.11E-55
Male	2.08	1.73	2.49	2.02E-15	2.69E-15	1.71	1.41	2.08	6.14E-08
Body mass index	1.07	1.06	1.09	3.34E-19	6.68E-19	1.06	1.04	1.08	8.76E-10
NAFLD	3.06	1.95	4.80	1.07E-06	1.07E-06	1.57	0.93	2.67	.09
Cirrhosis	7.59	4.11	14.00	9.24E-11	1.06E-10	4.44	2.13	9.24	6.68E-05
Type 2 diabetes	3.63	2.95	4.48	1.36E-33	3.63E-33	1.42	1.11	1.82	5.05E-03
Cardiovascular disease	3.71	3.09	4.45	2.12E-45	8.49E-45	1.62	1.32	1.99	3.52E-06
Systolic blood pressure	1.02	1.01	1.02	1.43E-16	2.29E-16	1.00	0.99	1.00	.71

CI, confidence interval; COVID-19, coronavirus disease 2019; FDR, false discovery rate; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio.

Supplementary Table 7. The Association of IVs With Exposure and Severe COVID-19

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
NAFLD	rs1260326	T	C	0.19	0.03	7.35E-14	-0.02	0.03	.45
NAFLD	rs112875651	G	A	0.19	0.03	6.81E-13	-0.02	0.03	.64
NAFLD	rs738408	T	C	0.52	0.03	2.28E-73	0.04	0.04	.27
NAFLD	rs429358	T	C	0.20	0.04	4.92E-08	0.04	0.04	.27
NAFLD	rs58542926	T	C	0.39	0.05	3.08E-16	0.01	0.05	.77
Serum alanine aminotransferase level	rs10195619	T	C	-0.05	0.01	8.78E-11	-0.03	0.02	.07
Serum alanine aminotransferase level	rs10201587	G	A	-0.05	0.01	4.11E-10	-0.01	0.02	.63
Serum alanine aminotransferase level	rs10883451	C	T	-0.16	0.01	3.60E-106	-0.01	0.02	.74
Serum alanine aminotransferase level	rs112128680	A	G	0.06	0.01	3.70E-09	0.01	0.03	.59
Serum alanine aminotransferase level	rs11601507	A	C	0.09	0.01	2.16E-10	-0.03	0.04	.36
Serum alanine aminotransferase level	rs11621792	T	C	0.04	0.01	1.11E-08	-0.03	0.02	.15
Serum alanine aminotransferase level	rs1169292	T	C	0.05	0.01	4.45E-12	0.02	0.02	.35
Serum alanine aminotransferase level	rs12500824	A	G	0.05	0.01	1.37E-09	0.00	0.02	.90
Serum alanine aminotransferase level	rs132665	G	A	-0.07	0.01	1.84E-11	0.01	0.03	.73
Serum alanine aminotransferase level	rs1337101	T	G	-0.05	0.01	1.95E-10	0.00	0.02	.98
Serum alanine aminotransferase level	rs13409360	A	G	-0.06	0.01	1.95E-15	-0.04	0.02	.08
Serum alanine aminotransferase level	rs148015593	G	T	-0.04	0.01	8.69E-09	-0.01	0.02	.63
Serum alanine aminotransferase level	rs1497406	A	G	-0.04	0.01	1.46E-08	0.00	0.02	.95
Serum alanine aminotransferase level	rs168144	C	T	-0.05	0.01	3.45E-12	0.02	0.02	.39
Serum alanine aminotransferase level	rs174535	C	T	-0.06	0.01	3.11E-15	-0.01	0.02	.73
Serum alanine aminotransferase level	rs1801689	C	A	0.18	0.02	1.39E-17	-0.09	0.05	.09
Serum alanine aminotransferase level	rs2138157	A	C	-0.06	0.01	3.49E-17	0.00	0.02	.85
Serum alanine aminotransferase level	rs2207132	A	G	0.19	0.03	7.96E-11	-0.06	0.05	.27
Serum alanine aminotransferase level	rs2377957	A	G	-0.05	0.01	1.53E-11	-0.02	0.02	.29
Serum alanine aminotransferase level	rs2642438	A	G	-0.08	0.01	8.04E-23	0.02	0.02	.38

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Serum alanine aminotransferase level	rs2792751	T	C	0.07	0.01	1.28E-19	0.03	0.02	.09
Serum alanine aminotransferase level	rs28929474	T	C	0.48	0.03	1.03E-65	0.12	0.08	.17
Serum alanine aminotransferase level	rs2954038	C	A	0.14	0.01	2.12E-70	0.02	0.02	.25
Serum alanine aminotransferase level	rs3810367	G	T	0.05	0.01	3.51E-09	0.00	0.02	.92
Serum alanine aminotransferase level	rs4148824	G	A	-0.06	0.01	2.62E-09	-0.02	0.02	.31
Serum alanine aminotransferase level	rs429358	C	T	-0.09	0.01	4.72E-19	-0.01	0.03	.68
Serum alanine aminotransferase level	rs4484649	C	A	0.05	0.01	2.16E-09	0.01	0.02	.66
Serum alanine aminotransferase level	rs4684847	T	C	-0.07	0.01	1.11E-10	0.03	0.03	.28
Serum alanine aminotransferase level	rs4734654	G	A	-0.05	0.01	1.48E-11	0.00	0.02	.90
Serum alanine aminotransferase level	rs4841133	A	G	0.13	0.01	1.02E-24	-0.05	0.03	.11
Serum alanine aminotransferase level	rs4919741	A	G	-0.06	0.01	1.72E-13	0.00	0.02	.96
Serum alanine aminotransferase level	rs4940689	A	G	0.05	0.01	1.21E-08	0.01	0.02	.76
Serum alanine aminotransferase level	rs55868793	G	T	0.06	0.01	8.92E-15	-0.01	0.02	.46
Serum alanine aminotransferase level	rs58542926	T	C	0.22	0.01	2.13E-59	-0.02	0.04	.51
Serum alanine aminotransferase level	rs6717858	C	T	-0.05	0.01	2.04E-11	-0.02	0.02	.32
Serum alanine aminotransferase level	rs7117339	T	C	-0.13	0.01	2.26E-30	-0.03	0.03	.37
Serum alanine aminotransferase level	rs72754571	A	C	-0.08	0.01	2.47E-09	0.00	0.04	.96
Serum alanine aminotransferase level	rs73024760	T	C	0.11	0.02	4.64E-08	-0.10	0.05	4.36E-02
Serum alanine aminotransferase level	rs7604422	C	A	-0.05	0.01	1.24E-12	0.02	0.02	.40
Serum alanine aminotransferase level	rs79598313	T	C	0.18	0.02	3.37E-13	0.03	0.07	.63
NAS (IVs provided by Namjou B et al)	rs5748926	T	C	0.91	0.16	3.81E-08	0.02	0.02	.23
NAS (IVs provided by Namjou B et al)	rs738408	T	C	0.85	0.15	3.94E-08	0.00	0.02	.91
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs112279484	A	G	-0.91	0.20	9.76E-06	-0.04	0.03	.21
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs1319222	G	T	-0.80	0.17	7.46E-06	0.01	0.02	.66

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs1456131	T	C	1.57	0.33	3.48E-06	0.01	0.04	.83
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs2074800	A	G	1.62	0.34	4.42E-06	-0.06	0.05	.19
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs265994	T	C	0.88	0.18	1.55E-06	-0.01	0.03	.80
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs35888925	G	T	-0.89	0.19	8.89E-06	-0.01	0.03	.65
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs3788621	T	C	1.52	0.30	9.28E-07	-0.02	0.03	.62
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs4843577	C	T	1.09	0.23	4.52E-06	-0.03	0.03	.45
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs56166152	G	A	-0.85	0.19	9.75E-06	0.05	0.03	.13
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs5748926	T	C	0.91	0.16	3.81E-08	0.02	0.02	.23
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs615854	C	T	0.83	0.17	1.77E-06	0.00	0.02	.96
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs61861255	A	G	1.21	0.26	6.05E-06	-0.04	0.04	.30
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs75107135	C	T	1.46	0.32	9.92E-06	-0.03	0.03	.44
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs7867164	C	T	1.25	0.26	2.90E-06	0.02	0.04	.56
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs7903018	A	G	0.76	0.16	2.25E-06	-0.04	0.02	4.46E-02
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	rs9920556	T	G	1.00	0.22	8.38E-06	0.00	0.03	.92
Fibrosis stage (IVs provided by Namjou B et al)	rs117886001	A	G	2.34	0.38	5.37E-09	-0.05	0.07	.50
Fibrosis stage (IVs provided by Namjou B et al)	rs698718	A	G	0.83	0.12	2.74E-11	0.05	0.02	3.23E-02
Fibrosis stage (IVs provided by Namjou B et al)	rs73055425	C	T	1.64	0.29	3.74E-08	-0.09	0.06	.17
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs114099685	T	C	1.58	0.33	4.07E-06	0.06	0.06	.34
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs116276034	C	T	1.71	0.37	6.82E-06	-0.10	0.08	.22
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs116508175	C	T	2.18	0.47	7.49E-06	-0.08	0.10	.40
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs116978893	C	A	1.18	0.24	2.17E-06	-0.02	0.06	.75
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs117124075	C	T	1.28	0.27	4.00E-06	0.02	0.05	.72
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs117198762	G	T	1.81	0.40	9.33E-06	0.05	0.07	.53
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs117672359	T	C	2.49	0.46	1.87E-07	0.19	0.07	1.20E-02

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs117886001	A	G	2.34	0.38	5.37E-09	-0.05	0.07	.50
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs11789840	T	C	0.87	0.18	2.00E-06	0.02	0.04	.73
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs11794552	T	C	0.62	0.12	1.41E-06	0.01	0.03	.79
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs118128699	C	T	2.23	0.47	3.58E-06	-0.02	0.07	.75
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs12373751	T	C	0.58	0.12	1.31E-06	0.00	0.02	.95
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs13132061	C	A	0.55	0.11	1.59E-06	0.02	0.02	.27
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs139097639	G	A	1.29	0.28	8.56E-06	0.08	0.08	.32
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs140963555	A	G	1.81	0.38	2.61E-06	0.06	0.09	.49
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs144512335	A	G	1.83	0.37	1.54E-06	0.00	0.06	.99
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs145282424	A	G	1.86	0.40	4.92E-06	-0.01	0.06	.88
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs145689272	T	C	1.39	0.29	3.65E-06	-0.10	0.06	.10
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs146387929	A	G	1.71	0.37	7.60E-06	-0.05	0.05	.36
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs146434237	C	T	1.22	0.23	4.23E-07	0.00	0.07	.94
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs17741551	G	A	1.19	0.26	8.78E-06	0.00	0.04	.99
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs344507	A	G	1.78	0.37	2.98E-06	0.00	0.06	1.00
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs34637163	A	C	0.70	0.15	8.09E-06	-0.03	0.03	.25
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs4904585	C	T	-0.59	0.13	9.42E-06	-0.04	0.03	.15
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs55756435	T	C	1.04	0.22	3.69E-06	0.02	0.04	.71
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs56284191	C	T	1.69	0.35	2.65E-06	0.05	0.07	.48
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs56755407	A	G	1.79	0.39	5.94E-06	0.00	0.06	.95
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs56872492	A	G	0.93	0.20	5.45E-06	-0.02	0.04	.58
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs59531931	G	A	0.74	0.15	3.10E-06	0.00	0.03	.99
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs60166288	C	T	1.55	0.32	2.01E-06	-0.01	0.05	.78
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs6545337	T	C	1.26	0.27	4.47E-06	0.05	0.05	.38

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs698718	A	G	0.83	0.12	2.74E-11	0.05	0.02	3.23E-02
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs72680117	A	G	-0.42	0.09	7.83E-06	-0.05	0.02	1.65E-02
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs72943235	A	G	2.38	0.43	8.18E-08	-0.05	0.06	.46
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs72951651	C	T	1.33	0.26	8.28E-07	0.03	0.05	.55
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs72991078	A	G	1.40	0.28	9.82E-07	-0.06	0.05	.22
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs73018373	G	T	1.75	0.38	7.07E-06	-0.10	0.09	.26
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs73055425	C	T	1.64	0.29	3.74E-08	-0.09	0.06	.17
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs75434839	G	A	1.37	0.28	2.78E-06	-0.01	0.05	.88
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs75986527	A	G	1.48	0.32	7.54E-06	0.08	0.06	.14
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs76210196	C	T	0.93	0.19	2.25E-06	0.03	0.05	.56
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs76219423	C	T	1.75	0.37	4.66E-06	-0.02	0.06	.78
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs76672291	C	T	1.82	0.36	7.34E-07	-0.03	0.05	.60
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs76966989	C	T	1.08	0.23	3.60E-06	0.05	0.05	.30
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs77602516	C	T	2.05	0.40	6.31E-07	-0.03	0.06	.65
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs78210118	C	T	1.23	0.25	1.86E-06	0.00	0.06	.99
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs78613755	G	T	2.46	0.45	1.44E-07	0.01	0.06	.87
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs78999778	G	A	0.76	0.16	4.70E-06	-0.01	0.05	.76
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs7941548	A	C	1.66	0.34	2.31E-06	0.05	0.05	.32
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs79673099	G	A	1.45	0.31	6.26E-06	0.10	0.06	.08
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs79859092	C	T	1.12	0.23	1.57E-06	0.03	0.05	.61
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	rs859472	G	A	0.46	0.10	4.80E-06	0.03	0.02	.17
Grade of steatosis (IVs provided by Anstee QM et al)	rs62021874	T	C	-0.30	0.06	8.16E-08	-0.05	0.04	.21
Grade of steatosis (IVs provided by Anstee QM et al)	rs738408	T	C	0.18	0.03	2.37E-09	0.00	0.02	.91
NAS (IVs provided by Anstee QM et al)	rs738408	T	C	0.36	0.06	8.78E-09	0.00	0.02	.91

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Fibrosis stage (IVs provided by Anstee QM et al)	rs738408	T	C	0.32	0.05	7.58E-11	0.00	0.02	.91
Body mass index	rs1000940	G	A	0.02	0.00	1.28E-08	0.01	0.02	.51
Body mass index	rs10132280	A	C	-0.02	0.00	1.14E-11	0.03	0.02	.17
Body mass index	rs1016287	T	C	0.02	0.00	2.25E-11	0.02	0.02	.38
Body mass index	rs10182181	A	G	-0.03	0.00	8.78E-24	-0.01	0.02	.67
Body mass index	rs10733682	A	G	0.02	0.00	1.83E-08	-0.01	0.02	.72
Body mass index	rs10938397	A	G	-0.04	0.00	3.21E-38	-0.03	0.02	.13
Body mass index	rs10968576	G	A	0.02	0.00	6.61E-14	0.06	0.02	2.48E-03
Body mass index	rs11030066	C	T	-0.03	0.00	2.14E-09	-0.02	0.03	.51
Body mass index	rs11030104	A	G	0.04	0.00	5.56E-28	0.03	0.02	.15
Body mass index	rs11057405	A	G	-0.03	0.01	2.02E-08	0.04	0.04	.33
Body mass index	rs11074446	C	T	-0.03	0.00	1.31E-08	0.03	0.03	.26
Body mass index	rs11126666	G	A	-0.02	0.00	1.33E-09	-0.01	0.02	.54
Body mass index	rs11165643	C	T	-0.02	0.00	2.07E-12	0.02	0.02	.25
Body mass index	rs11191560	T	C	-0.03	0.01	8.45E-09	0.01	0.03	.67
Body mass index	rs11643744	A	G	0.03	0.00	8.77E-17	0.02	0.02	.30
Body mass index	rs1167827	A	G	-0.02	0.00	6.33E-10	-0.01	0.02	.62
Body mass index	rs11688816	A	G	-0.02	0.00	1.89E-08	0.01	0.02	.56
Body mass index	rs11727676	C	T	-0.04	0.01	2.55E-08	-0.01	0.03	.86
Body mass index	rs11847697	T	C	0.05	0.01	3.99E-09	-0.05	0.04	.24
Body mass index	rs12286929	G	A	0.02	0.00	1.31E-12	0.01	0.02	.48
Body mass index	rs12401738	A	G	0.02	0.00	1.15E-10	0.02	0.02	.28
Body mass index	rs12429545	G	A	-0.03	0.00	1.09E-12	-0.08	0.03	5.91E-03
Body mass index	rs12446632	A	G	-0.04	0.00	1.48E-18	0.04	0.03	.11
Body mass index	rs12566985	G	A	0.02	0.00	3.28E-15	0.01	0.02	.60
Body mass index	rs12714411	T	G	-0.02	0.00	2.77E-08	-0.05	0.03	3.15E-02
Body mass index	rs12885454	C	A	0.02	0.00	1.94E-10	0.04	0.02	1.92E-02
Body mass index	rs12940622	A	G	-0.02	0.00	2.49E-09	-0.01	0.02	.47
Body mass index	rs13021737	A	G	-0.06	0.00	1.11E-50	-0.01	0.02	.62
Body mass index	rs13078960	T	G	-0.03	0.00	1.74E-14	0.02	0.02	.31
Body mass index	rs13107325	C	T	-0.05	0.01	1.83E-12	-0.06	0.04	.08
Body mass index	rs13191362	A	G	0.03	0.00	7.34E-09	0.00	0.03	.94
Body mass index	rs1477199	A	G	-0.02	0.00	4.56E-08	-0.04	0.03	.09
Body mass index	rs1516725	T	C	-0.05	0.00	1.89E-22	-0.02	0.03	.49
Body mass index	rs1528435	T	C	0.02	0.00	1.20E-08	0.01	0.02	.69
Body mass index	rs16851483	G	T	-0.05	0.01	3.55E-10	-0.03	0.03	.30
Body mass index	rs16951275	C	T	-0.03	0.00	1.91E-17	0.00	0.02	.94
Body mass index	rs17024393	C	T	0.07	0.01	7.03E-14	0.04	0.06	.46

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Body mass index	rs17066842	G	A	0.06	0.01	6.40E-14	0.05	0.04	.23
Body mass index	rs17094222	C	T	0.02	0.00	5.94E-11	0.03	0.02	.24
Body mass index	rs17405819	C	T	-0.02	0.00	2.07E-11	0.00	0.02	.89
Body mass index	rs17724992	A	G	0.02	0.00	3.42E-08	0.00	0.02	0.92
Body mass index	rs1808579	T	C	-0.02	0.00	4.17E-08	-0.05	0.02	6.15E-03
Body mass index	rs1928295	C	T	-0.02	0.00	7.91E-10	-0.01	0.02	.47
Body mass index	rs2033732	C	T	0.02	0.00	4.89E-08	0.02	0.02	.44
Body mass index	rs205262	A	G	-0.02	0.00	1.75E-10	-0.02	0.02	.33
Body mass index	rs2075650	A	G	0.03	0.00	1.25E-08	0.02	0.03	.43
Body mass index	rs2112347	G	T	-0.03	0.00	6.19E-17	-0.01	0.02	.43
Body mass index	rs2121279	T	C	0.02	0.00	2.31E-08	-0.04	0.03	.16
Body mass index	rs2176598	T	C	0.02	0.00	2.97E-08	0.02	0.02	.27
Body mass index	rs2207139	G	A	0.04	0.00	4.13E-29	0.02	0.02	.35
Body mass index	rs2245368	T	C	-0.03	0.01	3.19E-08	-0.01	0.02	.82
Body mass index	rs2287019	C	T	0.04	0.00	4.59E-18	0.08	0.03	1.13E-03
Body mass index	rs2365389	C	T	0.02	0.00	1.63E-10	0.04	0.02	4.05E-02
Body mass index	rs2820292	A	C	-0.02	0.00	1.83E-10	-0.04	0.02	1.96E-02
Body mass index	rs29941	A	G	-0.02	0.00	2.41E-08	0.04	0.02	.08
Body mass index	rs3101336	T	C	-0.03	0.00	2.66E-26	-0.01	0.02	.72
Body mass index	rs3736485	A	G	0.02	0.00	7.41E-09	0.02	0.02	.35
Body mass index	rs3810291	A	G	0.03	0.00	4.81E-15	0.04	0.02	4.79E-02
Body mass index	rs3817334	C	T	-0.03	0.00	5.15E-17	-0.02	0.02	.24
Body mass index	rs3849570	A	C	0.02	0.00	2.60E-08	0.01	0.02	.55
Body mass index	rs3888190	A	C	0.03	0.00	3.14E-23	0.02	0.02	.25
Body mass index	rs4740619	T	C	0.02	0.00	4.56E-09	0.06	0.02	1.40E-03
Body mass index	rs543874	G	A	0.05	0.00	2.62E-35	0.03	0.02	.23
Body mass index	rs6477694	C	T	0.02	0.00	2.67E-08	0.02	0.02	.25
Body mass index	rs6567160	C	T	0.06	0.00	3.93E-53	0.03	0.02	.22
Body mass index	rs657452	A	G	0.02	0.00	5.48E-13	0.00	0.02	.88
Body mass index	rs6804842	A	G	-0.02	0.00	2.48E-09	0.00	0.02	.95
Body mass index	rs7138803	G	A	-0.03	0.00	8.15E-24	0.00	0.02	.95
Body mass index	rs7141420	T	C	0.02	0.00	1.23E-14	0.00	0.02	.89
Body mass index	rs7243357	G	T	-0.02	0.00	3.86E-08	-0.05	0.02	4.40E-02
Body mass index	rs758747	C	T	-0.02	0.00	7.47E-10	0.01	0.02	.69
Body mass index	rs7599312	G	A	0.02	0.00	1.17E-10	0.02	0.02	.33
Body mass index	rs7899106	A	G	-0.04	0.01	2.96E-08	-0.03	0.04	.48
Body mass index	rs7903146	T	C	-0.02	0.00	1.11E-11	-0.01	0.02	.72
Body mass index	rs8097783	A	G	-0.04	0.01	4.20E-11	-0.02	0.03	.47
Body mass index	rs879620	C	T	-0.02	0.00	1.06E-09	-0.01	0.02	.55

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Body mass index	rs9400239	C	T	0.02	0.00	1.61E-08	-0.01	0.02	.75
Body mass index	rs9675886	G	A	0.03	0.00	6.92E-25	0.02	0.02	.46
Body mass index	rs9925964	G	A	-0.02	0.00	8.11E-10	-0.01	0.02	.49
Body mass index	rs9945063	C	T	-0.02	0.00	1.35E-08	-0.01	0.02	.51
Body mass index	rs9947301	T	C	-0.04	0.01	3.70E-11	0.00	0.04	.95
Waist circumference	rs10132280	A	C	-0.02	0.00	2.20E-09	0.03	0.02	.17
Waist circumference	rs10742178	G	A	0.03	0.00	2.10E-12	0.02	0.02	.37
Waist circumference	rs10840100	G	A	0.02	0.00	5.40E-09	-0.01	0.02	.55
Waist circumference	rs10938397	A	G	-0.03	0.00	6.10E-20	-0.03	0.02	.13
Waist circumference	rs10968576	G	A	0.03	0.00	1.20E-11	0.06	0.02	2.48E-03
Waist circumference	rs11165623	A	G	0.02	0.00	5.20E-09	-0.01	0.02	.52
Waist circumference	rs11643744	A	G	0.03	0.00	4.10E-14	0.02	0.02	.30
Waist circumference	rs11873305	A	C	0.06	0.01	3.10E-10	0.05	0.04	.29
Waist circumference	rs12429545	G	A	-0.03	0.01	2.50E-09	-0.08	0.03	5.91E-03
Waist circumference	rs12446632	A	G	-0.04	0.01	5.20E-13	0.04	0.03	.11
Waist circumference	rs12885454	C	A	0.02	0.00	2.60E-08	0.04	0.02	1.92E-02
Waist circumference	rs1516725	T	C	-0.03	0.01	1.70E-09	-0.02	0.03	.49
Waist circumference	rs1549293	T	C	-0.02	0.00	7.30E-09	-0.03	0.02	.16
Waist circumference	rs16894959	C	T	0.03	0.00	3.40E-08	0.01	0.03	.66
Waist circumference	rs16996700	T	C	0.02	0.00	1.50E-09	0.02	0.02	.39
Waist circumference	rs2075650	A	G	0.03	0.01	8.90E-10	0.02	0.03	.43
Waist circumference	rs2112347	G	T	-0.03	0.00	3.20E-13	-0.01	0.02	.43
Waist circumference	rs2287019	C	T	0.04	0.00	1.70E-14	0.08	0.03	1.13E-03
Waist circumference	rs2325036	A	C	0.02	0.00	2.10E-11	0.01	0.02	.73
Waist circumference	rs2489623	C	A	0.02	0.00	3.40E-08	-0.03	0.02	.14
Waist circumference	rs2531992	A	G	-0.03	0.00	3.00E-09	-0.04	0.03	.24
Waist circumference	rs2820292	A	C	-0.02	0.00	2.40E-08	-0.04	0.02	1.96E-02
Waist circumference	rs3127553	G	A	0.02	0.00	1.60E-10	-0.01	0.02	.67
Waist circumference	rs3810291	A	G	0.03	0.00	1.70E-10	0.04	0.02	4.79E-02
Waist circumference	rs3849570	A	C	0.02	0.00	2.20E-08	0.01	0.02	.55
Waist circumference	rs4130548	C	T	0.02	0.00	3.40E-10	0.02	0.02	.27
Waist circumference	rs6163	C	A	-0.02	0.00	3.70E-08	0.00	0.02	.89
Waist circumference	rs633715	C	T	0.04	0.00	3.30E-23	0.03	0.02	.26
Waist circumference	rs6440003	G	A	-0.02	0.00	2.90E-10	0.04	0.02	2.33E-02
Waist circumference	rs6545714	G	A	0.02	0.00	1.90E-10	0.02	0.02	.35
Waist circumference	rs6567160	C	T	0.05	0.00	2.60E-33	0.03	0.02	.22
Waist circumference	rs6755502	T	C	-0.05	0.00	2.00E-30	-0.01	0.02	.67
Waist circumference	rs7138803	G	A	-0.03	0.00	1.60E-15	0.00	0.02	.95
Waist circumference	rs7144011	T	G	0.03	0.00	9.40E-16	0.01	0.02	.63

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Waist circumference	rs7239883	G	A	0.02	0.00	2.30E-09	0.01	0.02	.67
Waist circumference	rs7498665	G	A	0.03	0.00	1.40E-22	0.02	0.02	.31
Waist circumference	rs7531118	T	C	-0.03	0.00	1.50E-14	-0.01	0.02	.81
Waist circumference	rs7550711	T	C	0.06	0.01	3.40E-09	0.07	0.06	.25
Waist circumference	rs7903146	T	C	-0.02	0.00	3.90E-09	-0.01	0.02	.72
Waist circumference	rs806794	G	A	-0.02	0.00	2.10E-09	-0.02	0.02	.28
Waist circumference	rs929641	A	G	0.02	0.00	1.20E-09	0.03	0.02	.05
Waist circumference	rs9400239	C	T	0.02	0.00	1.90E-11	-0.01	0.02	.75
Waist circumference	rs943005	T	C	0.04	0.00	7.20E-19	0.02	0.02	.42
Waist circumference	rs9675376	A	G	0.04	0.00	3.80E-21	0.02	0.02	.48
Hip circumference	rs10132280	A	C	-0.02	0.00	4.80E-09	0.03	0.02	.17
Hip circumference	rs10835197	T	C	0.03	0.00	3.20E-12	0.03	0.02	.23
Hip circumference	rs10929925	C	A	0.02	0.00	4.50E-08	0.03	0.02	.15
Hip circumference	rs10938397	A	G	-0.03	0.00	9.30E-17	-0.03	0.02	.13
Hip circumference	rs11057405	A	G	-0.04	0.01	2.10E-10	0.04	0.04	.33
Hip circumference	rs11165623	A	G	0.02	0.00	3.00E-10	-0.01	0.02	.52
Hip circumference	rs11672660	C	T	0.03	0.00	7.10E-10	0.04	0.02	4.98E-02
Hip circumference	rs12086130	T	C	0.04	0.01	2.60E-09	-0.02	0.03	.48
Hip circumference	rs12446632	A	G	-0.04	0.01	1.10E-11	0.04	0.03	.11
Hip circumference	rs13098327	G	A	-0.03	0.00	1.20E-09	0.03	0.02	.29
Hip circumference	rs13333228	C	T	0.02	0.00	2.80E-10	0.03	0.02	.22
Hip circumference	rs1351394	T	C	0.02	0.00	6.40E-11	0.01	0.02	.78
Hip circumference	rs13695	C	T	-0.02	0.00	4.30E-08	-0.01	0.02	.63
Hip circumference	rs143384	A	G	-0.03	0.00	3.90E-12	0.01	0.02	.68
Hip circumference	rs1516725	T	C	-0.03	0.01	1.00E-08	-0.02	0.03	.49
Hip circumference	rs1548457	T	C	-0.03	0.00	1.70E-08	0.03	0.02	.15
Hip circumference	rs1561277	C	A	0.02	0.00	6.00E-09	-0.03	0.03	.20
Hip circumference	rs16894959	C	T	0.04	0.00	9.60E-14	0.01	0.03	.66
Hip circumference	rs16905212	C	T	-0.02	0.00	1.90E-08	0.02	0.02	.37
Hip circumference	rs17024393	C	T	0.06	0.01	2.80E-10	0.04	0.06	.46
Hip circumference	rs17066842	G	A	0.06	0.01	1.70E-09	0.05	0.04	.23
Hip circumference	rs17391694	T	C	0.04	0.01	3.00E-10	0.08	0.03	8.29E-03
Hip circumference	rs1808579	T	C	-0.02	0.00	2.10E-10	-0.05	0.02	6.15E-03
Hip circumference	rs2112347	G	T	-0.03	0.00	9.70E-12	-0.01	0.02	.43
Hip circumference	rs2206277	T	C	0.04	0.00	3.10E-17	0.03	0.02	.19
Hip circumference	rs2301573	T	C	-0.04	0.01	2.10E-08	0.01	0.03	.69
Hip circumference	rs2820443	C	T	0.03	0.00	4.90E-18	0.02	0.02	.31
Hip circumference	rs3087591	A	G	-0.02	0.00	2.50E-08	0.01	0.02	.66
Hip circumference	rs355838	T	G	-0.02	0.00	1.60E-09	0.02	0.02	.44

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Hip circumference	rs3800229	T	G	0.02	0.00	3.20E-08	-0.01	0.02	.64
Hip circumference	rs3810291	A	G	0.02	0.00	2.40E-08	0.04	0.02	4.79E-02
Hip circumference	rs3888190	A	C	0.04	0.00	9.40E-22	0.02	0.02	.25
Hip circumference	rs4132228	C	T	-0.02	0.00	3.10E-08	0.04	0.02	.08
Hip circumference	rs4883723	G	A	-0.03	0.01	5.20E-10	-0.05	0.02	4.46E-02
Hip circumference	rs4889606	G	A	-0.02	0.00	8.80E-09	-0.02	0.02	.43
Hip circumference	rs543874	G	A	0.05	0.00	1.80E-23	0.03	0.02	.23
Hip circumference	rs6163	C	A	-0.02	0.00	1.60E-08	0.00	0.02	.89
Hip circumference	rs6265	C	T	0.03	0.00	1.50E-14	0.03	0.02	.18
Hip circumference	rs6569648	T	C	-0.03	0.00	6.50E-12	0.00	0.02	.93
Hip circumference	rs663129	A	G	0.05	0.00	1.40E-32	0.03	0.02	.21
Hip circumference	rs6755502	T	C	-0.05	0.00	2.40E-30	-0.01	0.02	.67
Hip circumference	rs7138803	G	A	-0.03	0.00	1.90E-15	0.00	0.02	.95
Hip circumference	rs7144011	T	G	0.03	0.00	8.60E-13	0.01	0.02	.63
Hip circumference	rs7183263	G	T	0.02	0.00	4.80E-08	0.01	0.02	.67
Hip circumference	rs7531118	T	C	-0.02	0.00	4.00E-11	-0.01	0.02	.81
Hip circumference	rs7632381	T	C	-0.04	0.00	5.30E-24	0.05	0.02	1.40E-02
Hip circumference	rs7903146	T	C	-0.03	0.00	2.10E-11	-0.01	0.02	.72
Hip circumference	rs798528	A	C	0.02	0.00	1.70E-08	0.00	0.02	.91
Hip circumference	rs806794	G	A	-0.03	0.00	2.80E-16	-0.02	0.02	.28
Hip circumference	rs879620	C	T	-0.03	0.00	8.90E-10	-0.01	0.02	.55
Hip circumference	rs887912	T	C	0.02	0.00	1.60E-08	0.02	0.02	.43
Hip circumference	rs951252	G	A	-0.03	0.00	4.50E-15	-0.04	0.02	3.34E-02
Hip circumference	rs9675886	G	A	0.04	0.00	6.80E-19	0.02	0.02	.46
Hip circumference	rs9939973	A	G	0.07	0.00	2.30E-86	0.01	0.02	.73
Waist-to-hip ratio	rs1011731	G	A	0.02	0.00	1.10E-08	-0.03	0.02	.24
Waist-to-hip ratio	rs10245353	A	C	0.03	0.00	1.60E-10	0.02	0.02	.49
Waist-to-hip ratio	rs10783615	G	A	0.04	0.00	7.00E-13	0.01	0.03	.61
Waist-to-hip ratio	rs10876528	A	C	0.03	0.00	1.10E-12	-0.01	0.02	.62
Waist-to-hip ratio	rs11048470	T	G	0.03	0.00	6.30E-12	0.03	0.02	.20
Waist-to-hip ratio	rs1121980	A	G	0.04	0.00	1.30E-38	0.01	0.02	.64
Waist-to-hip ratio	rs1128249	G	T	0.02	0.00	1.60E-09	0.02	0.02	.23
Waist-to-hip ratio	rs11643744	A	G	0.02	0.00	3.50E-08	0.02	0.02	.30
Waist-to-hip ratio	rs11663816	C	T	0.03	0.00	2.70E-11	0.01	0.02	.55
Waist-to-hip ratio	rs11755724	G	A	0.02	0.00	1.70E-08	-0.01	0.02	.50
Waist-to-hip ratio	rs12549058	G	T	0.04	0.01	3.20E-10	0.01	0.04	.78
Waist-to-hip ratio	rs1294421	G	T	0.03	0.00	6.90E-14	0.00	0.02	.98
Waist-to-hip ratio	rs1316952	T	C	0.03	0.00	7.30E-09	-0.06	0.03	1.10E-02
Waist-to-hip ratio	rs1440372	C	T	0.02	0.00	7.60E-09	-0.02	0.02	.30

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Waist-to-hip ratio	rs1563355	T	C	-0.03	0.00	1.70E-12	0.01	0.02	.60
Waist-to-hip ratio	rs1569135	A	G	0.02	0.00	1.00E-12	0.00	0.02	.79
Waist-to-hip ratio	rs16996700	T	C	0.02	0.00	1.60E-08	0.02	0.02	.39
Waist-to-hip ratio	rs17109256	A	G	0.02	0.00	3.00E-08	0.01	0.02	.65
Waist-to-hip ratio	rs17451107	T	C	0.02	0.00	3.50E-11	-0.03	0.02	.11
Waist-to-hip ratio	rs2075650	A	G	0.03	0.00	6.40E-09	0.02	0.03	.43
Waist-to-hip ratio	rs2179129	A	G	0.02	0.00	1.20E-09	0.01	0.02	.47
Waist-to-hip ratio	rs2207139	G	A	0.03	0.00	1.40E-08	0.02	0.02	.35
Waist-to-hip ratio	rs2287019	C	T	0.03	0.00	4.30E-09	0.08	0.03	1.13E-03
Waist-to-hip ratio	rs2745359	C	T	0.06	0.01	3.80E-13	-0.10	0.04	1.70E-02
Waist-to-hip ratio	rs2765539	C	T	-0.03	0.00	1.10E-12	0.02	0.02	.35
Waist-to-hip ratio	rs2972164	C	T	0.02	0.00	2.40E-08	0.00	0.02	.97
Waist-to-hip ratio	rs3786897	G	A	0.02	0.00	4.00E-11	-0.02	0.02	.27
Waist-to-hip ratio	rs459193	A	G	0.03	0.00	6.00E-12	-0.02	0.02	.41
Waist-to-hip ratio	rs4640244	G	A	0.02	0.00	3.10E-08	0.01	0.02	.66
Waist-to-hip ratio	rs4929927	G	A	0.02	0.00	7.60E-09	-0.01	0.02	.53
Waist-to-hip ratio	rs904453	T	G	0.02	0.00	4.30E-08	-0.01	0.02	.43
Waist-to-hip ratio	rs929641	A	G	0.02	0.00	4.20E-09	0.03	0.02	.05
Waist-to-hip ratio	rs9860730	A	G	0.02	0.00	2.80E-10	0.04	0.02	.06
Waist-to-hip ratio	rs998584	A	C	0.03	0.00	5.00E-15	0.03	0.02	.15
Type 2 diabetes	rs10510110	T	C	0.09	0.02	8.30E-10	-0.01	0.02	.72
Type 2 diabetes	rs10882098	T	C	-0.14	0.02	1.70E-20	0.02	0.02	.24
Type 2 diabetes	rs10885410	A	G	-0.11	0.02	3.40E-10	-0.01	0.03	.81
Type 2 diabetes	rs10965250	A	G	-0.13	0.02	4.70E-12	0.01	0.02	.54
Type 2 diabetes	rs11616380	T	G	-0.09	0.02	4.80E-08	-0.02	0.02	.40
Type 2 diabetes	rs11708067	A	G	0.12	0.02	2.20E-11	-0.02	0.02	.39
Type 2 diabetes	rs11709077	A	G	-0.15	0.02	3.50E-12	0.03	0.03	.38
Type 2 diabetes	rs11759026	A	G	-0.11	0.02	5.90E-10	0.02	0.02	.47
Type 2 diabetes	rs1333045	T	C	-0.09	0.02	4.20E-09	-0.01	0.02	.44
Type 2 diabetes	rs140820620	A	G	0.40	0.06	8.80E-11	-0.01	0.08	.94
Type 2 diabetes	rs143304587	T	C	-0.24	0.04	4.80E-09	-0.02	0.06	.76
Type 2 diabetes	rs149692182	T	C	0.54	0.09	4.10E-09	-0.04	0.06	.49
Type 2 diabetes	rs17031005	A	G	0.14	0.03	2.40E-08	0.03	0.03	.26
Type 2 diabetes	rs2023681	A	G	-0.14	0.03	2.80E-08	-0.01	0.04	.73
Type 2 diabetes	rs231360	T	C	0.09	0.02	4.80E-09	0.03	0.02	.17
Type 2 diabetes	rs3129768	T	G	0.11	0.02	1.60E-09	-0.02	0.02	.43
Type 2 diabetes	rs35198068	T	C	-0.33	0.02	1.10E-94	0.00	0.02	.88
Type 2 diabetes	rs3821943	T	C	0.10	0.02	2.50E-11	-0.01	0.02	.53
Type 2 diabetes	rs4238013	T	C	-0.13	0.02	4.80E-11	-0.03	0.03	.22

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Type 2 diabetes	rs4686696	A	G	0.15	0.02	7.00E-23	-0.02	0.02	.41
Type 2 diabetes	rs4918791	A	G	-0.11	0.02	1.10E-08	-0.03	0.02	.22
Type 2 diabetes	rs5215	T	C	-0.08	0.02	1.90E-08	0.00	0.02	.80
Type 2 diabetes	rs72832303	A	G	-0.38	0.06	1.60E-11	0.01	0.07	.85
Type 2 diabetes	rs7428936	T	C	0.09	0.02	1.90E-09	0.05	0.02	1.94E-02
Type 2 diabetes	rs7451008	T	C	-0.19	0.02	1.10E-30	0.01	0.02	.49
Type 2 diabetes	rs8056814	A	G	-0.16	0.03	1.30E-08	0.01	0.03	.73
Type 2 diabetes	rs860262	A	C	-0.10	0.02	1.60E-11	0.00	0.02	.90
Type 2 diabetes	rs9410573	T	C	0.09	0.02	1.70E-08	0.04	0.02	4.34E-02
Type 2 diabetes	rs9667947	T	C	0.11	0.02	1.50E-08	0.00	0.03	.88
Fasting glucose	rs10023	A	G	-0.01	0.00	2.81E-08	0.02	0.02	.54
Fasting glucose	rs10181875	T	C	0.02	0.00	1.86E-14	-0.06	0.04	.09
Fasting glucose	rs10305457	T	C	0.02	0.00	1.21E-14	-0.02	0.03	.54
Fasting glucose	rs10811660	A	G	-0.02	0.00	7.94E-25	0.02	0.02	.45
Fasting glucose	rs10830974	T	C	0.02	0.00	7.81E-18	0.02	0.02	.44
Fasting glucose	rs10974438	A	C	-0.02	0.00	9.85E-31	-0.03	0.02	.07
Fasting glucose	rs11020124	T	C	-0.06	0.00	1.00E-200	0.01	0.02	.79
Fasting glucose	rs11020131	A	G	0.06	0.01	7.73E-18	-0.08	0.06	.19
Fasting glucose	rs112508541	T	G	-0.03	0.01	9.79E-10	-0.07	0.07	.29
Fasting glucose	rs115545608	T	G	0.04	0.01	7.66E-09	-0.14	0.09	.12
Fasting glucose	rs115941163	T	C	0.06	0.01	3.51E-16	0.15	0.10	.16
Fasting glucose	rs11598	A	G	-0.03	0.00	3.15E-14	-0.07	0.06	.24
Fasting glucose	rs11603349	T	C	0.02	0.00	3.12E-25	0.00	0.03	.93
Fasting glucose	rs11610045	A	G	0.01	0.00	3.26E-13	0.08	0.02	1.84E-05
Fasting glucose	rs11619319	A	G	-0.02	0.00	3.41E-20	0.04	0.02	.07
Fasting glucose	rs11708067	A	G	0.03	0.00	1.63E-43	-0.02	0.02	.39
Fasting glucose	rs12055786	T	C	0.01	0.00	1.17E-11	0.00	0.02	.85
Fasting glucose	rs1260326	T	C	-0.03	0.00	4.48E-65	-0.01	0.02	.57
Fasting glucose	rs12784552	A	G	0.03	0.00	2.86E-31	-0.01	0.03	.71
Fasting glucose	rs12888855	A	C	-0.01	0.00	6.02E-12	-0.03	0.02	.27
Fasting glucose	rs12898997	T	C	-0.01	0.00	4.64E-09	0.01	0.02	.72
Fasting glucose	rs13389076	A	G	0.06	0.00	1.72E-36	-0.03	0.04	.45
Fasting glucose	rs13431652	T	C	0.07	0.00	1.00E-200	0.00	0.02	.91
Fasting glucose	rs1371614	T	C	0.02	0.00	5.85E-16	0.00	0.02	.90
Fasting glucose	rs138598212	A	G	0.03	0.00	2.94E-12	0.02	0.05	.64
Fasting glucose	rs141621067	A	G	0.07	0.01	8.55E-14	0.02	0.08	.83
Fasting glucose	rs145391098	A	G	-0.03	0.01	3.44E-09	0.01	0.07	.88
Fasting glucose	rs147001976	A	G	-0.04	0.01	9.05E-12	0.06	0.07	.44
Fasting glucose	rs149725176	A	G	-0.02	0.00	1.86E-10	0.01	0.03	.82

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Fasting glucose	rs157512	T	C	0.01	0.00	5.43E-10	0.01	0.02	.55
Fasting glucose	rs1604038	T	C	-0.02	0.00	4.47E-28	0.01	0.02	.47
Fasting glucose	rs1681630	T	C	0.01	0.00	9.67E-10	0.03	0.02	.11
Fasting glucose	rs16823014	A	G	0.03	0.00	1.01E-08	0.07	0.05	.11
Fasting glucose	rs16851397	A	G	0.03	0.00	1.26E-12	0.00	0.05	.94
Fasting glucose	rs16913693	T	G	0.04	0.00	2.82E-16	-0.03	0.06	.55
Fasting glucose	rs17168486	T	C	0.03	0.00	4.17E-36	0.06	0.02	1.64E-02
Fasting glucose	rs17265513	T	C	-0.02	0.00	5.10E-14	-0.04	0.02	.08
Fasting glucose	rs17267869	T	C	0.02	0.00	1.74E-10	0.00	0.03	.93
Fasting glucose	rs17437560	T	C	-0.02	0.00	3.33E-08	-0.01	0.03	.74
Fasting glucose	rs174583	T	C	-0.02	0.00	3.37E-22	0.01	0.02	.53
Fasting glucose	rs1820176	T	C	0.02	0.00	1.91E-34	-0.01	0.02	.70
Fasting glucose	rs194518	A	G	0.01	0.00	8.76E-09	-0.01	0.02	.69
Fasting glucose	rs2075423	T	G	-0.02	0.00	3.18E-21	0.00	0.02	.85
Fasting glucose	rs2108349	A	G	-0.02	0.00	1.25E-15	0.00	0.02	.97
Fasting glucose	rs2126259	T	C	0.02	0.00	4.06E-17	-0.02	0.04	.49
Fasting glucose	rs2168101	A	C	-0.01	0.00	3.09E-08	0.01	0.02	.72
Fasting glucose	rs2216502	A	G	-0.02	0.00	2.53E-09	0.03	0.04	.41
Fasting glucose	rs2268575	T	C	-0.03	0.00	5.05E-55	0.00	0.03	.94
Fasting glucose	rs2268648	T	C	-0.01	0.00	5.30E-09	-0.01	0.02	.59
Fasting glucose	rs2390732	A	G	0.01	0.00	2.38E-15	0.03	0.02	.15
Fasting glucose	rs2657879	A	G	-0.01	0.00	7.33E-09	0.00	0.02	.84
Fasting glucose	rs2839671	A	G	-0.02	0.00	8.38E-14	0.02	0.02	.41
Fasting glucose	rs34730887	A	G	-0.01	0.00	1.98E-09	0.01	0.02	.60
Fasting glucose	rs348330	A	G	-0.01	0.00	3.04E-10	0.01	0.02	.60
Fasting glucose	rs35510946	A	G	0.01	0.00	5.01E-10	-0.01	0.02	.48
Fasting glucose	rs35762680	T	C	0.05	0.01	6.43E-24	0.07	0.05	.16
Fasting glucose	rs35889227	T	G	-0.01	0.00	3.37E-10	0.02	0.02	.30
Fasting glucose	rs3778321	A	G	-0.02	0.00	3.16E-17	-0.06	0.03	3.10E-02
Fasting glucose	rs3829109	A	G	-0.02	0.00	1.09E-15	0.06	0.02	2.01E-02
Fasting glucose	rs3842753	T	G	0.01	0.00	2.84E-09	0.00	0.02	.94
Fasting glucose	rs39713	T	C	-0.02	0.00	1.77E-08	-0.01	0.04	.71
Fasting glucose	rs4388843	A	G	-0.02	0.00	2.14E-11	-0.01	0.03	.74
Fasting glucose	rs4760278	A	C	-0.01	0.00	3.33E-08	-0.02	0.02	.37
Fasting glucose	rs4862423	T	C	0.01	0.00	4.45E-10	-0.03	0.02	.21
Fasting glucose	rs507666	A	G	0.02	0.00	6.99E-17	0.13	0.02	9.10E-09
Fasting glucose	rs56100844	T	G	0.12	0.01	9.82E-35	-0.07	0.08	.40
Fasting glucose	rs576674	A	G	-0.02	0.00	9.70E-13	0.01	0.03	.58
Fasting glucose	rs57911164	A	G	0.02	0.00	4.30E-09	0.01	0.03	.75

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Fasting glucose	rs58234170	A	G	-0.01	0.00	3.13E-08	-0.03	0.02	.21
Fasting glucose	rs58925536	T	C	0.03	0.01	5.82E-09	0.03	0.05	.58
Fasting glucose	rs6113722	A	G	-0.04	0.00	7.66E-25	-0.01	0.04	.74
Fasting glucose	rs6489811	A	G	-0.01	0.00	3.27E-09	-0.02	0.02	.33
Fasting glucose	rs6598541	A	G	0.01	0.00	4.12E-12	-0.01	0.02	.54
Fasting glucose	rs6662924	A	C	0.01	0.00	3.34E-10	-0.04	0.02	.07
Fasting glucose	rs6808574	T	C	-0.01	0.00	7.21E-14	0.03	0.02	.21
Fasting glucose	rs7012637	A	G	-0.02	0.00	9.75E-25	0.04	0.02	3.92E-02
Fasting glucose	rs7095788	T	C	-0.01	0.00	1.98E-09	-0.02	0.02	.32
Fasting glucose	rs7163757	T	C	-0.02	0.00	2.64E-36	0.04	0.02	2.64E-02
Fasting glucose	rs7178572	A	G	-0.01	0.00	7.09E-10	-0.05	0.02	6.70E-03
Fasting glucose	rs7256920	A	G	-0.01	0.00	2.75E-09	-0.05	0.02	2.24E-02
Fasting glucose	rs72884870	T	G	-0.07	0.01	1.29E-29	0.00	0.07	.95
Fasting glucose	rs72966526	T	C	0.03	0.00	9.10E-11	0.07	0.05	.16
Fasting glucose	rs73018724	A	G	-0.05	0.01	1.35E-21	-0.05	0.04	.29
Fasting glucose	rs737383	T	C	-0.01	0.00	2.29E-08	0.00	0.02	.83
Fasting glucose	rs74897641	A	G	0.10	0.01	2.95E-26	-0.24	0.10	1.36E-02
Fasting glucose	rs76031050	A	G	-0.06	0.01	1.49E-24	-0.11	0.07	.10
Fasting glucose	rs76895692	T	C	0.04	0.01	1.74E-11	-0.02	0.07	.79
Fasting glucose	rs7708285	A	G	-0.01	0.00	1.25E-09	0.00	0.02	.83
Fasting glucose	rs7729395	T	C	-0.02	0.00	3.09E-08	-0.03	0.05	.60
Fasting glucose	rs78132593	A	C	-0.01	0.00	2.60E-10	-0.01	0.02	.80
Fasting glucose	rs78265553	A	G	0.06	0.01	1.45E-19	-0.04	0.08	.59
Fasting glucose	rs7903146	T	C	0.03	0.00	2.00E-35	-0.01	0.02	.72
Fasting glucose	rs79582698	A	C	-0.03	0.00	6.81E-10	-0.03	0.05	.59
Fasting glucose	rs853770	T	C	0.03	0.00	6.57E-75	0.00	0.02	.88
Fasting glucose	rs878521	A	G	0.05	0.00	2.65E-174	-0.01	0.02	.49
Fasting glucose	rs896854	T	C	0.01	0.00	5.61E-09	0.01	0.02	.64
Fasting glucose	rs9650069	T	C	-0.03	0.00	8.31E-58	0.01	0.02	.59
Fasting glucose	rs9850375	T	C	0.01	0.00	3.92E-09	-0.01	0.02	.74
Fasting insulin	rs10050393	T	C	0.01	0.00	4.84E-08	0.01	0.02	.42
Fasting insulin	rs10503388	A	G	0.01	0.00	8.28E-09	0.02	0.02	.42
Fasting insulin	rs116141873	T	G	0.04	0.01	1.42E-11	0.02	0.05	.67
Fasting insulin	rs11708067	A	G	-0.01	0.00	1.30E-09	-0.02	0.02	.39
Fasting insulin	rs11727676	T	C	-0.02	0.00	2.90E-08	0.01	0.03	.86
Fasting insulin	rs118164457	T	C	-0.03	0.01	3.86E-10	-0.04	0.07	.55
Fasting insulin	rs1206760	A	G	-0.01	0.00	8.82E-10	-0.01	0.02	.62
Fasting insulin	rs12454712	T	C	0.01	0.00	1.78E-09	0.03	0.02	.09
Fasting insulin	rs1260326	T	C	-0.02	0.00	8.42E-38	-0.01	0.02	.57

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Fasting insulin	rs13258890	T	C	0.01	0.00	2.77E-08	0.04	0.02	.09
Fasting insulin	rs13389219	T	C	-0.02	0.00	5.84E-28	-0.02	0.02	.26
Fasting insulin	rs1351394	T	C	-0.01	0.00	2.71E-09	0.01	0.02	.78
Fasting insulin	rs1474696	A	G	-0.01	0.00	3.02E-16	0.03	0.02	.15
Fasting insulin	rs17331151	T	C	-0.02	0.00	1.52E-08	0.01	0.03	.67
Fasting insulin	rs2108349	A	G	-0.01	0.00	1.13E-08	0.00	0.02	.97
Fasting insulin	rs2780215	A	G	0.04	0.01	1.06E-09	-0.03	0.04	.42
Fasting insulin	rs2845885	T	C	-0.02	0.00	1.18E-08	0.02	0.04	.69
Fasting insulin	rs2943646	A	G	-0.03	0.00	8.47E-39	-0.01	0.02	.72
Fasting insulin	rs308971	A	G	-0.02	0.00	3.91E-13	-0.07	0.03	8.61E-03
Fasting insulin	rs35000407	T	G	0.03	0.00	1.50E-21	-0.03	0.03	.32
Fasting insulin	rs3775380	A	G	-0.01	0.00	1.48E-11	-0.01	0.02	.59
Fasting insulin	rs3936511	A	G	-0.02	0.00	2.81E-14	0.02	0.02	.42
Fasting insulin	rs459193	A	G	-0.02	0.00	1.12E-18	-0.02	0.02	.41
Fasting insulin	rs4865796	A	G	0.02	0.00	7.33E-17	-0.03	0.02	.14
Fasting insulin	rs57400569	A	G	-0.01	0.00	3.28E-09	0.01	0.02	.51
Fasting insulin	rs6487237	A	C	0.02	0.00	4.68E-09	-0.02	0.02	.35
Fasting insulin	rs6601299	T	C	0.02	0.00	2.83E-18	-0.04	0.03	.18
Fasting insulin	rs6674544	A	G	0.02	0.00	6.97E-21	0.01	0.02	.74
Fasting insulin	rs6855363	T	C	0.01	0.00	4.04E-08	0.01	0.02	.72
Fasting insulin	rs7012814	A	G	-0.02	0.00	8.34E-30	0.04	0.02	3.84E-02
Fasting insulin	rs7133378	A	G	-0.01	0.00	6.00E-11	-0.01	0.02	.72
Fasting insulin	rs73013411	A	C	-0.02	0.00	2.08E-08	-0.04	0.03	.19
Fasting insulin	rs75179845	T	C	-0.02	0.00	6.05E-11	-0.01	0.03	.67
Fasting insulin	rs7903146	T	C	-0.01	0.00	1.24E-09	-0.01	0.02	.72
Fasting insulin	rs79663649	A	G	-0.04	0.01	2.11E-08	-0.03	0.07	.72
Fasting insulin	rs860598	A	G	0.02	0.00	6.88E-12	0.00	0.02	.90
Fasting insulin	rs9472135	T	C	0.01	0.00	4.21E-08	0.01	0.02	.79
Fasting insulin	rs972283	A	G	-0.01	0.00	1.09E-08	0.00	0.02	.79
Fasting insulin	rs9884482	T	C	-0.01	0.00	2.88E-11	0.03	0.02	.13
Fasting insulin	rs998584	A	C	0.01	0.00	2.31E-10	0.03	0.02	.15
2-h glucose	rs11670462	T	C	0.05	0.01	1.80E-09	0.01	0.02	.56
2-h glucose	rs11708067	A	G	0.09	0.01	1.98E-22	-0.02	0.02	.39
2-h glucose	rs117643180	A	C	0.23	0.03	7.31E-14	-0.03	0.07	.66
2-h glucose	rs1260326	T	C	0.05	0.01	5.93E-12	-0.01	0.02	.57
2-h glucose	rs12692738	T	C	0.05	0.01	2.72E-08	0.03	0.02	.21
2-h glucose	rs17271305	A	G	-0.06	0.01	2.88E-14	0.00	0.02	.81
2-h glucose	rs2126259	T	C	-0.07	0.01	2.98E-10	-0.02	0.04	.49
2-h glucose	rs2268575	T	C	-0.06	0.01	4.91E-08	0.00	0.03	.94

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
2-h glucose	rs2649999	T	C	0.05	0.01	2.01E-10	0.02	0.02	.30
2-h glucose	rs550057	T	C	0.05	0.01	3.62E-11	0.14	0.02	1.15E-09
2-h glucose	rs7012637	A	G	0.05	0.01	5.40E-10	0.04	0.02	3.92E-02
2-h glucose	rs7903146	T	C	0.09	0.01	2.79E-26	-0.01	0.02	.72
2-h glucose	rs878521	A	G	0.10	0.01	1.25E-28	-0.01	0.02	.49
HbA1c	rs10169706	T	C	0.03	0.00	1.48E-08	0.05	0.04	.19
HbA1c	rs10405535	A	G	0.01	0.00	6.47E-14	0.05	0.02	4.36E-02
HbA1c	rs1044277	T	C	-0.01	0.00	1.46E-12	0.03	0.03	.19
HbA1c	rs10762287	T	C	-0.01	0.00	1.91E-18	0.00	0.02	.91
HbA1c	rs10774624	A	G	0.01	0.00	4.17E-14	0.05	0.02	2.23E-02
HbA1c	rs10811661	T	C	0.01	0.00	1.74E-14	-0.02	0.02	.43
HbA1c	rs10823340	T	C	0.01	0.00	1.46E-12	0.01	0.02	.79
HbA1c	rs10998752	A	G	0.01	0.00	1.32E-14	-0.04	0.02	.11
HbA1c	rs11039154	T	C	-0.01	0.00	3.11E-09	-0.06	0.02	3.03E-03
HbA1c	rs11224302	T	C	-0.02	0.00	4.63E-14	0.03	0.03	.24
HbA1c	rs11248914	T	C	0.01	0.00	1.42E-14	0.01	0.02	.53
HbA1c	rs11257655	T	C	0.01	0.00	1.91E-13	-0.06	0.02	9.84E-03
HbA1c	rs11558471	A	G	0.02	0.00	3.38E-25	-0.02	0.02	.27
HbA1c	rs11643024	A	G	0.01	0.00	7.98E-10	0.06	0.02	2.05E-03
HbA1c	rs11650031	T	C	-0.02	0.00	9.90E-14	-0.05	0.03	.14
HbA1c	rs11656775	A	G	0.01	0.00	2.50E-08	0.01	0.02	.65
HbA1c	rs11719201	T	C	-0.01	0.00	2.43E-18	0.01	0.02	.66
HbA1c	rs11727331	A	G	-0.02	0.00	1.14E-11	0.06	0.04	.18
HbA1c	rs117440287	A	G	-0.02	0.00	3.29E-09	0.03	0.05	.59
HbA1c	rs1175549	A	C	0.01	0.00	7.13E-13	0.02	0.02	.43
HbA1c	rs117872282	T	C	-0.04	0.01	1.53E-12	0.08	0.07	.23
HbA1c	rs12491937	A	G	0.01	0.00	1.42E-13	0.02	0.02	.40
HbA1c	rs12612492	T	C	0.02	0.00	1.88E-26	-0.04	0.03	.14
HbA1c	rs12776509	A	G	0.02	0.00	1.01E-09	0.00	0.04	.96
HbA1c	rs1278769	A	G	-0.01	0.00	5.52E-12	0.09	0.02	3.29E-05
HbA1c	rs13134327	A	G	0.01	0.00	2.81E-26	0.03	0.02	.15
HbA1c	rs13234131	A	G	-0.01	0.00	2.06E-09	0.04	0.03	.22
HbA1c	rs13389076	A	G	0.03	0.00	3.04E-18	-0.03	0.04	.45
HbA1c	rs13419763	T	C	0.01	0.00	5.48E-09	-0.01	0.02	.72
HbA1c	rs1367173	T	C	-0.02	0.00	1.66E-14	-0.02	0.03	.57
HbA1c	rs1535464	A	G	-0.01	0.00	1.11E-08	-0.03	0.02	.15
HbA1c	rs16926246	T	C	-0.07	0.00	1.00E-200	-0.01	0.03	.71
HbA1c	rs17037289	A	G	-0.01	0.00	2.40E-09	-0.03	0.02	.20
HbA1c	rs17256082	T	C	-0.01	0.00	3.19E-08	0.00	0.02	.97

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
HbA1c	rs174559	A	G	-0.01	0.00	3.31E-13	-0.01	0.02	.66
HbA1c	rs17533945	T	C	-0.01	0.00	1.62E-23	0.00	0.02	.99
HbA1c	rs1800562	A	G	-0.04	0.00	2.33E-50	-0.01	0.05	.81
HbA1c	rs1948759	A	G	-0.01	0.00	2.44E-08	0.06	0.03	4.95E-02
HbA1c	rs2073285	T	C	-0.02	0.00	1.72E-14	-0.05	0.03	.07
HbA1c	rs2229498	A	G	0.01	0.00	9.16E-10	0.01	0.02	.63
HbA1c	rs2249407	A	C	0.01	0.00	4.40E-10	0.00	0.02	.87
HbA1c	rs2273475	A	G	-0.01	0.00	1.99E-09	0.04	0.03	.22
HbA1c	rs2375278	A	G	0.01	0.00	1.05E-11	0.00	0.03	.91
HbA1c	rs247833	A	G	0.01	0.00	2.85E-08	0.02	0.03	.46
HbA1c	rs267738	T	G	0.01	0.00	1.14E-11	0.00	0.02	.85
HbA1c	rs2748427	A	G	-0.03	0.00	9.82E-49	-0.02	0.03	.55
HbA1c	rs2908290	A	G	0.02	0.00	6.81E-32	0.00	0.02	.99
HbA1c	rs2971670	T	C	0.03	0.00	5.10E-88	-0.01	0.02	.67
HbA1c	rs3129795	T	G	-0.01	0.00	2.66E-10	-0.01	0.02	.71
HbA1c	rs34664882	A	G	-0.05	0.00	4.82E-37	-0.13	0.06	.05
HbA1c	rs360140	A	C	-0.01	0.00	9.62E-13	0.03	0.02	.14
HbA1c	rs3778321	A	G	-0.01	0.00	4.18E-11	-0.06	0.03	3.10E-02
HbA1c	rs3819410	A	G	-0.01	0.00	1.49E-11	-0.01	0.02	0.57
HbA1c	rs3829109	A	G	-0.01	0.00	2.68E-08	0.06	0.02	2.01E-02
HbA1c	rs3842753	T	G	0.01	0.00	3.93E-08	0.00	0.02	.94
HbA1c	rs452306	T	C	-0.01	0.00	5.51E-13	0.00	0.02	.89
HbA1c	rs4724295	A	G	0.01	0.00	3.11E-09	-0.02	0.02	.48
HbA1c	rs4727979	A	C	0.01	0.00	4.61E-08	0.03	0.03	.33
HbA1c	rs4737009	A	G	0.02	0.00	8.29E-56	0.04	0.02	.08
HbA1c	rs4746841	T	G	-0.03	0.00	4.46E-43	-0.01	0.04	.73
HbA1c	rs4760682	A	C	0.02	0.00	3.20E-20	0.02	0.03	.49
HbA1c	rs477224	T	C	-0.02	0.00	2.64E-34	0.00	0.02	.82
HbA1c	rs4980325	T	G	0.01	0.00	4.70E-14	0.03	0.02	.17
HbA1c	rs55964643	A	G	-0.01	0.00	2.60E-08	0.03	0.02	.13
HbA1c	rs56071183	A	G	-0.05	0.01	6.86E-14	0.02	0.08	.76
HbA1c	rs560887	T	C	-0.03	0.00	5.55E-122	-0.02	0.02	.49
HbA1c	rs59036878	A	G	0.01	0.00	2.48E-09	0.06	0.04	.19
HbA1c	rs608793	T	C	0.01	0.00	4.55E-08	-0.02	0.02	.36
HbA1c	rs61750929	T	C	-0.03	0.00	9.49E-24	-0.01	0.04	.76
HbA1c	rs6445541	T	G	0.01	0.00	1.14E-08	0.02	0.02	.37
HbA1c	rs651007	T	C	0.01	0.00	3.28E-15	0.14	0.02	1.04E-08
HbA1c	rs6804915	A	C	-0.01	0.00	2.76E-16	0.01	0.02	.51
HbA1c	rs6877043	T	C	0.01	0.00	1.99E-10	0.02	0.02	.37

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
HbA1c	rs6929796	A	G	-0.01	0.00	3.26E-08	-0.05	0.02	3.36E-02
HbA1c	rs6931514	A	G	-0.01	0.00	1.18E-13	0.02	0.02	.41
HbA1c	rs6980507	A	G	0.01	0.00	8.15E-20	-0.05	0.02	2.46E-02
HbA1c	rs7042939	A	G	0.01	0.00	1.50E-15	0.03	0.02	.22
HbA1c	rs71351176	T	C	-0.03	0.00	2.80E-12	-0.07	0.06	.20
HbA1c	rs7198799	T	C	0.01	0.00	4.76E-09	0.02	0.02	.20
HbA1c	rs7220522	A	G	-0.01	0.00	2.45E-09	0.01	0.02	.70
HbA1c	rs72812178	T	G	0.02	0.00	8.73E-09	-0.08	0.05	.12
HbA1c	rs72853027	T	C	-0.01	0.00	1.10E-15	0.02	0.03	.43
HbA1c	rs72884870	T	G	-0.04	0.00	8.89E-16	0.00	0.07	.95
HbA1c	rs737092	T	C	-0.01	0.00	7.57E-09	-0.01	0.02	.47
HbA1c	rs74002924	T	C	0.01	0.00	2.60E-14	-0.01	0.03	.58
HbA1c	rs7547793	A	C	-0.01	0.00	6.61E-09	-0.05	0.04	.15
HbA1c	rs76533333	A	G	-0.03	0.00	2.81E-29	-0.02	0.03	.61
HbA1c	rs7762959	T	C	0.01	0.00	3.44E-09	0.00	0.03	.88
HbA1c	rs78574741	A	G	0.02	0.00	1.95E-08	-0.01	0.04	.73
HbA1c	rs7861647	T	C	0.01	0.00	4.50E-14	0.00	0.02	.94
HbA1c	rs7903146	T	C	0.01	0.00	1.04E-22	-0.01	0.02	.72
HbA1c	rs79158370	A	G	0.01	0.00	2.00E-08	0.03	0.04	.47
HbA1c	rs7916281	T	C	-0.03	0.00	1.22E-21	-0.03	0.04	.47
HbA1c	rs79784692	A	G	0.02	0.00	8.16E-15	-0.04	0.04	.33
HbA1c	rs7994900	T	C	0.01	0.00	6.65E-14	0.01	0.02	.74
HbA1c	rs8075623	A	G	-0.02	0.00	4.19E-09	-0.05	0.04	.16
HbA1c	rs8138197	A	G	-0.01	0.00	3.54E-08	-0.02	0.02	.28
HbA1c	rs837763	T	C	0.02	0.00	5.20E-38	-0.02	0.02	.27
HbA1c	rs855791	A	G	0.02	0.00	1.34E-56	0.01	0.02	.63
HbA1c	rs857725	T	G	-0.02	0.00	5.43E-55	0.00	0.02	.89
HbA1c	rs9348686	A	G	0.01	0.00	8.37E-11	-0.02	0.02	.31
HbA1c	rs9376090	T	C	0.02	0.00	1.90E-62	-0.03	0.02	.12
HbA1c	rs9550194	A	G	0.01	0.00	2.27E-08	-0.03	0.02	.22
HbA1c	rs9818758	A	G	0.01	0.00	1.49E-13	0.02	0.02	.44
HbA1c	rs9909940	T	C	0.03	0.00	1.43E-116	0.02	0.02	.28
HbA1c	rs9914988	A	G	0.01	0.00	4.66E-17	0.01	0.02	.56
HOMA-B	rs11558471	A	G	-0.02	0.00	1.94E-09	-0.02	0.02	.27
HOMA-B	rs13273088	A	G	-0.02	0.00	3.92E-10	0.02	0.02	.49
HOMA-B	rs13430620	A	C	-0.09	0.02	4.55E-09	0.07	0.05	.20
HOMA-B	rs174556	T	C	0.02	0.00	2.08E-09	-0.01	0.02	.52
HOMA-B	rs217554	A	G	0.02	0.00	1.39E-09	-0.03	0.02	.23
HOMA-B	rs2943640	A	C	-0.02	0.00	3.88E-10	0.00	0.02	.87

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
HOMA-B	rs35747	A	G	0.02	0.00	1.90E-09	0.00	0.02	.89
HOMA-B	rs3757840	T	G	-0.02	0.00	3.16E-12	-0.01	0.02	.72
HOMA-B	rs477224	T	C	0.02	0.00	7.31E-13	0.00	0.02	.82
HOMA-B	rs557462	T	C	-0.04	0.00	2.45E-42	-0.01	0.02	.59
HOMA-B	rs7903146	T	C	-0.02	0.00	4.26E-11	-0.01	0.02	.72
HOMA-IR	rs12328675	T	C	0.03	0.00	1.87E-11	-0.01	0.03	.85
HOMA-IR	rs1260326	T	C	-0.02	0.00	6.67E-17	-0.01	0.02	.57
HOMA-IR	rs17036328	T	C	0.03	0.00	1.05E-09	-0.04	0.03	.16
HOMA-IR	rs2820237	A	G	0.02	0.00	1.94E-08	-0.01	0.02	.64
HOMA-IR	rs2972144	A	G	-0.02	0.00	1.83E-12	-0.01	0.02	.77
HOMA-IR	rs35755	A	G	-0.02	0.00	2.17E-11	-0.03	0.03	.31
HOMA-IR	rs4240624	A	G	-0.03	0.00	3.13E-08	0.06	0.03	.09
HOMA-IR	rs4691380	T	C	-0.02	0.00	8.31E-09	-0.01	0.02	.72
HOMA-IR	rs9504350	T	C	-0.29	0.05	2.46E-08	-0.10	0.07	.16
Coronary heart disease	rs10840293	A	G	0.05	0.01	1.28E-08	0.03	0.02	.14
Coronary heart disease	rs11065979	C	T	-0.07	0.01	1.93E-10	0.04	0.02	4.60E-02
Coronary heart disease	rs11191416	T	G	0.08	0.01	4.65E-09	0.02	0.03	.37
Coronary heart disease	rs11206510	T	C	0.07	0.01	2.34E-08	0.03	0.02	.24
Coronary heart disease	rs11556924	C	T	0.07	0.01	5.34E-11	0.04	0.02	.06
Coronary heart disease	rs115654617	C	A	-0.14	0.02	3.12E-18	0.02	0.03	.51
Coronary heart disease	rs11838776	G	A	-0.07	0.01	1.83E-10	0.03	0.02	.24
Coronary heart disease	rs1199338	A	C	-0.07	0.01	3.90E-09	0.05	0.02	4.61E-02
Coronary heart disease	rs12202017	A	G	0.07	0.01	1.98E-11	0.02	0.02	.44
Coronary heart disease	rs1412444	C	T	-0.07	0.01	5.15E-12	0.01	0.02	.72
Coronary heart disease	rs16986953	G	A	-0.09	0.02	1.45E-08	0.06	0.03	.07
Coronary heart disease	rs17087335	G	T	-0.06	0.01	4.59E-08	-0.02	0.02	.48
Coronary heart disease	rs1746050	C	A	0.09	0.01	6.28E-13	-0.01	0.02	.74
Coronary heart disease	rs17678683	T	G	-0.10	0.02	3.00E-09	-0.02	0.03	.50
Coronary heart disease	rs186696265	C	T	-0.55	0.05	3.35E-30	-0.15	0.09	.09
Coronary heart disease	rs1870634	G	T	0.08	0.01	5.55E-15	-0.02	0.02	.24
Coronary heart disease	rs2107595	G	A	-0.07	0.01	8.05E-11	0.01	0.03	.83
Coronary heart disease	rs2128739	C	A	-0.07	0.01	7.05E-11	0.05	0.02	1.19E-02
Coronary heart disease	rs2487928	G	A	-0.06	0.01	4.41E-11	0.01	0.02	.81
Coronary heart disease	rs2519093	C	T	-0.08	0.01	1.19E-11	-0.14	0.03	1.74E-08
Coronary heart disease	rs2681472	A	G	-0.07	0.01	6.17E-11	-0.01	0.02	.53
Coronary heart disease	rs28451064	G	A	-0.13	0.02	1.33E-15	0.06	0.04	.09
Coronary heart disease	rs2891168	A	G	-0.19	0.01	2.29E-98	0.00	0.02	.89
Coronary heart disease	rs3731249	C	T	-0.17	0.03	1.44E-08	-0.03	0.05	.61
Coronary heart disease	rs3918226	C	T	-0.13	0.02	1.69E-09	0.02	0.04	.64

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Coronary heart disease	rs4420638	A	G	-0.09	0.01	7.07E-11	-0.01	0.02	.56
Coronary heart disease	rs4468572	C	T	0.08	0.01	4.44E-16	-0.02	0.02	.31
Coronary heart disease	rs515135	C	T	0.07	0.01	3.09E-08	0.01	0.03	.59
Coronary heart disease	rs55730499	C	T	-0.32	0.02	5.39E-39	0.05	0.04	.21
Coronary heart disease	rs56062135	C	T	0.07	0.01	4.52E-09	0.01	0.02	.58
Coronary heart disease	rs56289821	G	A	0.13	0.02	4.44E-15	-0.05	0.03	.08
Coronary heart disease	rs56336142	T	C	0.07	0.01	1.85E-08	0.03	0.03	.23
Coronary heart disease	rs624249	C	A	0.06	0.01	6.82E-09	0.03	0.02	.19
Coronary heart disease	rs663129	G	A	-0.06	0.01	3.20E-08	-0.03	0.02	.21
Coronary heart disease	rs6689306	G	A	-0.06	0.01	2.60E-09	-0.02	0.02	.29
Coronary heart disease	rs67180937	G	T	0.08	0.01	1.01E-12	0.01	0.02	.74
Coronary heart disease	rs6905073	G	T	0.06	0.01	1.91E-09	-0.02	0.02	.27
Coronary heart disease	rs72689147	G	T	0.07	0.01	6.07E-09	-0.02	0.02	.29
Coronary heart disease	rs7412	C	T	0.14	0.02	8.17E-11	-0.04	0.03	.26
Coronary heart disease	rs7528419	A	G	0.11	0.01	1.97E-23	-0.01	0.02	.68
Coronary heart disease	rs8042271	A	G	-0.10	0.02	3.68E-08	0.07	0.04	.08
Coronary heart disease	rs9349379	A	G	-0.13	0.01	1.81E-42	0.00	0.02	.94
Coronary heart disease	rs9970807	C	T	0.13	0.02	5.00E-14	0.02	0.03	.43
Serum total cholesterol	rs10449300	G	A	-0.06	0.01	3.03E-08	0.02	0.02	.45
Serum total cholesterol	rs111617668	T	C	-0.11	0.02	1.24E-08	-0.03	0.04	.47
Serum total cholesterol	rs1168041	C	T	0.06	0.01	1.84E-08	-0.02	0.02	.30
Serum total cholesterol	rs11881756	C	T	-0.13	0.02	2.42E-12	0.04	0.04	.28
Serum total cholesterol	rs12043403	C	T	-0.12	0.02	6.04E-11	0.03	0.04	.52
Serum total cholesterol	rs1260326	C	T	-0.07	0.01	4.44E-11	0.01	0.02	.57
Serum total cholesterol	rs138270540	C	A	0.22	0.04	1.48E-09	-0.11	0.08	.17
Serum total cholesterol	rs144064722	G	A	0.26	0.03	7.23E-14	0.04	0.06	.47
Serum total cholesterol	rs144545816	A	G	0.08	0.01	4.78E-12	-0.01	0.03	.61
Serum total cholesterol	rs1532085	G	A	-0.08	0.01	2.69E-14	0.02	0.02	.30
Serum total cholesterol	rs17699030	G	A	-0.15	0.03	1.01E-08	-0.05	0.04	.20
Serum total cholesterol	rs185415345	A	G	-0.15	0.03	2.94E-08	-0.02	0.09	.84
Serum total cholesterol	rs2207132	A	G	0.14	0.02	4.42E-08	-0.06	0.05	.27
Serum total cholesterol	rs2746683	C	A	0.11	0.02	5.55E-10	0.03	0.03	.29
Serum total cholesterol	rs2967668	G	A	-0.14	0.02	3.18E-15	-0.01	0.03	.83
Serum total cholesterol	rs2980853	C	A	-0.06	0.01	3.27E-10	-0.02	0.02	.17
Serum total cholesterol	rs3005923	A	G	-0.31	0.04	4.02E-17	-0.02	0.08	.81
Serum total cholesterol	rs3741298	T	C	-0.09	0.01	1.33E-14	-0.02	0.02	.33
Serum total cholesterol	rs429358	C	T	0.18	0.01	2.88E-40	-0.01	0.03	.68
Serum total cholesterol	rs4803748	T	C	-0.06	0.01	1.02E-08	0.01	0.02	.60
Serum total cholesterol	rs4927207	A	G	-0.07	0.01	2.71E-09	0.02	0.02	.31

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Serum total cholesterol	rs629301	T	G	0.10	0.01	3.34E-17	-0.01	0.02	.61
Serum total cholesterol	rs6662286	C	T	0.15	0.02	4.96E-19	0.01	0.04	.72
Serum total cholesterol	rs72999033	T	C	-0.13	0.02	2.96E-09	-0.04	0.04	.33
Serum total cholesterol	rs7412	T	C	-0.41	0.03	1.94E-58	0.04	0.03	.26
Serum total cholesterol	rs74604756	T	G	-0.15	0.02	6.71E-15	0.04	0.06	.51
Serum total cholesterol	rs7604788	T	C	-0.16	0.02	3.77E-13	-0.09	0.06	.15
Serum total cholesterol	rs79225634	T	C	0.08	0.01	3.34E-15	-0.03	0.02	.15
Serum total cholesterol	rs952275	G	T	0.09	0.01	5.29E-19	0.00	0.02	.98
Serum total triglycerides	rs115849089	A	G	-0.16	0.02	6.90E-22	0.02	0.03	.43
Serum total triglycerides	rs1168041	C	T	0.10	0.01	3.40E-17	-0.02	0.02	.30
Serum total triglycerides	rs1260326	C	T	-0.11	0.01	1.00E-24	0.01	0.02	.57
Serum total triglycerides	rs2980853	C	A	-0.07	0.01	7.07E-14	-0.02	0.02	.17
Serum total triglycerides	rs34346326	C	T	-0.10	0.01	7.08E-14	-0.04	0.03	.12
Serum total triglycerides	rs429358	C	T	0.12	0.01	5.87E-18	-0.01	0.03	.68
Serum total triglycerides	rs4296389	T	C	-0.09	0.01	9.41E-18	-0.01	0.02	.73
Serum total triglycerides	rs5167	G	T	0.06	0.01	3.39E-09	0.00	0.02	.96
Serum total triglycerides	rs72999033	T	C	-0.17	0.02	1.91E-15	-0.04	0.04	.33
Serum total triglycerides	rs7575840	T	G	0.06	0.01	1.95E-08	0.01	0.02	.55
Serum total triglycerides	rs9472125	T	C	-0.09	0.02	6.64E-09	-0.01	0.04	.88
Total cholesterol in LDL	rs10056811	A	G	0.09	0.01	4.74E-17	-0.03	0.02	.15
Total cholesterol in LDL	rs112635299	T	G	0.23	0.04	8.66E-09	0.10	0.08	.21
Total cholesterol in LDL	rs113105517	G	A	-0.20	0.02	2.50E-18	0.00	0.08	.97
Total cholesterol in LDL	rs11587071	T	C	-0.09	0.01	4.02E-11	-0.02	0.03	.49
Total cholesterol in LDL	rs11878174	C	T	0.08	0.01	2.42E-10	0.02	0.02	.37
Total cholesterol in LDL	rs11881756	C	T	-0.17	0.02	4.69E-19	0.04	0.04	.28
Total cholesterol in LDL	rs12043403	C	T	-0.14	0.02	2.37E-14	0.03	0.04	.52
Total cholesterol in LDL	rs138270540	C	A	0.22	0.04	1.35E-09	-0.11	0.08	.17
Total cholesterol in LDL	rs142130958	A	G	-0.23	0.02	6.16E-44	0.05	0.03	.11
Total cholesterol in LDL	rs144064722	G	A	0.24	0.03	2.82E-12	0.04	0.06	.47
Total cholesterol in LDL	rs146390218	G	A	-0.28	0.05	3.27E-09	0.10	0.07	.13
Total cholesterol in LDL	rs185415345	A	G	-0.17	0.03	1.33E-09	-0.02	0.09	.84
Total cholesterol in LDL	rs193084249	G	A	0.18	0.03	1.42E-08	0.06	0.07	.37
Total cholesterol in LDL	rs1962352	G	A	0.07	0.01	8.07E-11	-0.03	0.02	.13
Total cholesterol in LDL	rs207122	C	T	0.13	0.02	1.79E-12	0.02	0.03	.57
Total cholesterol in LDL	rs2129944	G	T	-0.06	0.01	4.65E-08	0.06	0.03	1.01E-02
Total cholesterol in LDL	rs2207132	A	G	0.14	0.02	2.08E-08	-0.06	0.05	.27
Total cholesterol in LDL	rs2479409	A	G	-0.07	0.01	1.14E-08	-0.01	0.02	.63
Total cholesterol in LDL	rs28399637	A	G	0.07	0.01	1.05E-08	-0.02	0.02	.34
Total cholesterol in LDL	rs2927436	G	A	-0.09	0.01	1.26E-16	0.02	0.02	.45

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Total cholesterol in LDL	rs2965149	C	T	-0.07	0.01	1.09E-10	0.00	0.02	.86
Total cholesterol in LDL	rs2967668	G	A	-0.18	0.02	4.76E-26	-0.01	0.03	.83
Total cholesterol in LDL	rs2972558	T	C	0.09	0.01	3.00E-14	0.03	0.02	.22
Total cholesterol in LDL	rs3005923	A	G	-0.33	0.04	3.54E-19	-0.02	0.08	.81
Total cholesterol in LDL	rs3760647	G	A	0.07	0.01	5.80E-09	-0.03	0.02	.18
Total cholesterol in LDL	rs429358	C	T	0.23	0.01	2.64E-62	-0.01	0.03	.68
Total cholesterol in LDL	rs4927207	A	G	-0.08	0.01	4.99E-11	0.02	0.02	.31
Total cholesterol in LDL	rs614303	A	G	0.09	0.01	1.12E-14	-0.01	0.02	.72
Total cholesterol in LDL	rs62119327	T	G	-0.31	0.04	1.29E-12	0.10	0.07	.15
Total cholesterol in LDL	rs629301	T	G	0.13	0.01	6.81E-26	-0.01	0.02	.61
Total cholesterol in LDL	rs635634	T	C	0.07	0.01	2.99E-08	0.15	0.03	1.02E-08
Total cholesterol in LDL	rs6662286	C	T	0.15	0.02	1.48E-20	0.01	0.04	.72
Total cholesterol in LDL	rs6756629	A	G	-0.14	0.02	1.22E-14	-0.01	0.04	.71
Total cholesterol in LDL	rs73066442	G	A	0.07	0.01	9.71E-10	0.02	0.03	.45
Total cholesterol in LDL	rs73107473	A	G	0.08	0.01	1.63E-08	0.03	0.03	.28
Total cholesterol in LDL	rs7412	T	C	-0.59	0.03	1.75E-119	0.04	0.03	.26
Total cholesterol in LDL	rs7604788	T	C	-0.18	0.02	7.22E-16	-0.09	0.06	.15
Total cholesterol in LDL	rs78098253	A	C	0.18	0.03	1.83E-08	0.04	0.07	.55
Total cholesterol in LDL	rs934197	A	G	0.12	0.01	5.14E-27	0.02	0.02	.44
Total cholesterol in HDL	rs111894427	T	C	0.13	0.02	1.83E-09	0.00	0.05	.99
Total cholesterol in HDL	rs117427818	T	C	-0.25	0.03	5.06E-14	-0.06	0.05	.20
Total cholesterol in HDL	rs11865000	A	G	-0.09	0.02	2.41E-08	0.00	0.03	.96
Total cholesterol in HDL	rs1461729	G	A	0.09	0.01	1.32E-10	0.04	0.03	.20
Total cholesterol in HDL	rs16940810	T	C	0.19	0.03	5.67E-10	-0.05	0.05	.34
Total cholesterol in HDL	rs174594	A	C	0.07	0.01	3.35E-11	-0.01	0.02	.62
Total cholesterol in HDL	rs17821298	A	C	0.07	0.01	7.23E-10	0.01	0.02	.61
Total cholesterol in HDL	rs1800961	T	C	-0.16	0.03	4.67E-09	0.01	0.06	.92
Total cholesterol in HDL	rs1883025	T	C	-0.08	0.01	1.50E-09	0.02	0.02	.42
Total cholesterol in HDL	rs2070895	A	G	0.13	0.01	7.97E-29	0.02	0.02	.41
Total cholesterol in HDL	rs247617	A	C	0.23	0.01	5.76E-97	0.03	0.02	.20
Total cholesterol in HDL	rs261291	C	T	0.13	0.01	6.80E-36	-0.02	0.02	.21
Total cholesterol in HDL	rs289743	A	G	-0.09	0.01	9.14E-17	-0.02	0.02	.32
Total cholesterol in HDL	rs291	C	T	0.10	0.01	2.90E-16	0.02	0.02	.35
Total cholesterol in HDL	rs4149307	T	C	0.10	0.02	3.08E-08	-0.02	0.03	.53
Total cholesterol in HDL	rs55995508	A	G	0.16	0.03	2.61E-10	0.14	0.06	3.00E-02
Total cholesterol in HDL	rs6065904	A	G	-0.07	0.01	2.03E-08	0.03	0.02	.21
Total cholesterol in HDL	rs6507939	C	A	0.09	0.01	9.48E-12	-0.04	0.03	.13
Apolipoprotein B	rs10056811	A	G	0.09	0.01	1.35E-15	-0.03	0.02	.15
Apolipoprotein B	rs113105517	G	A	-0.18	0.02	1.36E-13	0.00	0.08	.97

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Apolipoprotein B	rs115849089	A	G	-0.10	0.02	1.04E-08	0.02	0.03	.43
Apolipoprotein B	rs1168041	C	T	0.07	0.01	1.06E-09	-0.02	0.02	.30
Apolipoprotein B	rs11881756	C	T	-0.13	0.02	4.38E-11	0.04	0.04	.28
Apolipoprotein B	rs12043403	C	T	-0.11	0.02	1.10E-09	0.03	0.04	.52
Apolipoprotein B	rs1260326	C	T	-0.07	0.01	2.51E-10	0.01	0.02	.57
Apolipoprotein B	rs1367117	A	G	0.11	0.01	9.99E-22	0.02	0.02	.40
Apolipoprotein B	rs142130958	A	G	-0.20	0.02	7.78E-32	0.05	0.03	.11
Apolipoprotein B	rs144064722	G	A	0.20	0.04	2.29E-08	0.04	0.06	.47
Apolipoprotein B	rs2927436	G	A	-0.08	0.01	2.08E-12	0.02	0.02	.45
Apolipoprotein B	rs2967668	G	A	-0.10	0.02	3.73E-09	-0.01	0.03	.83
Apolipoprotein B	rs2980875	G	A	-0.07	0.01	6.68E-12	-0.03	0.02	.13
Apolipoprotein B	rs3005923	A	G	-0.28	0.04	4.73E-14	-0.02	0.08	.81
Apolipoprotein B	rs429358	C	T	0.19	0.01	2.77E-43	-0.01	0.03	.68
Apolipoprotein B	rs4803762	A	G	0.06	0.01	1.02E-08	0.00	0.02	.95
Apolipoprotein B	rs4926673	A	G	-0.09	0.01	7.65E-10	0.03	0.03	.33
Apolipoprotein B	rs533617	C	T	-0.18	0.02	7.50E-16	-0.07	0.05	.20
Apolipoprotein B	rs614303	A	G	0.08	0.01	1.71E-11	-0.01	0.02	.72
Apolipoprotein B	rs629301	T	G	0.09	0.01	3.56E-13	-0.01	0.02	.61
Apolipoprotein B	rs6756629	A	G	-0.11	0.02	1.90E-09	-0.01	0.04	.71
Apolipoprotein B	rs72999033	T	C	-0.14	0.02	5.68E-10	-0.04	0.04	.33
Apolipoprotein B	rs7412	T	C	-0.43	0.03	4.39E-59	0.04	0.03	.26
Diastolic blood pressure	rs1000423	T	C	0.19	0.02	9.54E-22	-0.03	0.03	.26
Diastolic blood pressure	rs10042590	A	G	-0.23	0.03	6.60E-13	-0.04	0.05	.42
Diastolic blood pressure	rs10048404	T	C	-0.11	0.02	2.01E-09	0.00	0.04	.99
Diastolic blood pressure	rs10053638	T	C	-0.21	0.03	1.65E-13	0.00	0.04	.95
Diastolic blood pressure	rs10054208	T	C	0.12	0.02	1.49E-10	0.03	0.04	.48
Diastolic blood pressure	rs1006545	T	G	0.36	0.03	7.96E-40	-0.05	0.06	.39
Diastolic blood pressure	rs10069690	T	C	0.16	0.02	1.42E-14	-0.02	0.03	.54
Diastolic blood pressure	rs10164193	T	G	-0.22	0.03	1.87E-11	-0.01	0.04	.89
Diastolic blood pressure	rs10170324	T	C	-0.15	0.03	4.05E-08	0.04	0.04	.36
Diastolic blood pressure	rs10170954	A	C	-0.10	0.02	6.90E-09	-0.01	0.03	.73
Diastolic blood pressure	rs10195252	T	C	0.13	0.02	3.88E-14	0.00	0.03	.92
Diastolic blood pressure	rs10213478	T	C	-0.15	0.03	3.81E-08	0.01	0.04	.80
Diastolic blood pressure	rs10245801	A	G	-0.14	0.02	1.77E-11	0.00	0.04	.96
Diastolic blood pressure	rs1025655	A	G	-0.11	0.02	1.32E-09	0.03	0.03	.24
Diastolic blood pressure	rs1035272	T	G	0.17	0.03	3.03E-09	0.01	0.04	.85
Diastolic blood pressure	rs1035514	A	G	0.16	0.03	8.25E-10	0.04	0.04	.33
Diastolic blood pressure	rs1035673	T	C	0.16	0.02	3.00E-20	0.00	0.03	.90
Diastolic blood pressure	rs10401771	A	G	0.12	0.02	3.50E-11	-0.03	0.03	.20

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs10421783	A	C	0.10	0.02	2.37E-08	0.00	0.04	.92
Diastolic blood pressure	rs10434099	A	C	0.10	0.02	4.42E-09	0.05	0.03	.15
Diastolic blood pressure	rs1044822	T	C	-0.13	0.02	4.14E-08	0.05	0.04	.14
Diastolic blood pressure	rs10467770	T	C	0.11	0.02	2.10E-08	0.01	0.03	.72
Diastolic blood pressure	rs10468291	A	C	-0.12	0.02	3.70E-11	0.02	0.03	.50
Diastolic blood pressure	rs1047891	A	C	-0.14	0.02	8.19E-14	0.00	0.03	.89
Diastolic blood pressure	rs10489290	A	C	0.14	0.02	4.07E-11	0.03	0.03	.39
Diastolic blood pressure	rs10490923	A	G	0.15	0.03	5.02E-09	-0.07	0.04	.08
Diastolic blood pressure	rs10493408	A	C	0.16	0.03	5.09E-10	-0.04	0.04	.32
Diastolic blood pressure	rs1049376	T	C	-0.11	0.02	1.21E-08	-0.01	0.04	.86
Diastolic blood pressure	rs10495928	A	G	0.12	0.02	7.69E-12	-0.04	0.03	.11
Diastolic blood pressure	rs10509174	A	G	0.19	0.03	3.29E-08	0.07	0.05	.15
Diastolic blood pressure	rs10740993	T	C	0.22	0.02	3.83E-36	0.02	0.03	.41
Diastolic blood pressure	rs10741083	T	C	-0.13	0.02	1.17E-12	-0.05	0.03	.07
Diastolic blood pressure	rs10761530	T	C	0.12	0.02	1.14E-11	-0.02	0.03	.53
Diastolic blood pressure	rs1077393	A	G	-0.25	0.02	2.32E-43	0.05	0.03	4.45E-02
Diastolic blood pressure	rs10776752	T	G	0.46	0.03	1.25E-43	0.04	0.05	.36
Diastolic blood pressure	rs10777212	T	G	-0.13	0.02	1.15E-11	-0.04	0.03	.23
Diastolic blood pressure	rs1077795	A	G	0.20	0.02	1.62E-23	0.01	0.03	.71
Diastolic blood pressure	rs10804330	T	C	0.13	0.02	4.60E-14	0.01	0.03	.72
Diastolic blood pressure	rs10828542	A	G	0.10	0.02	2.34E-08	-0.03	0.03	.28
Diastolic blood pressure	rs10832013	T	G	0.15	0.02	4.51E-16	0.00	0.03	.93
Diastolic blood pressure	rs10835161	T	G	-0.14	0.02	1.01E-14	0.00	0.03	.90
Diastolic blood pressure	rs10840378	T	C	0.28	0.02	3.33E-36	0.03	0.03	.27
Diastolic blood pressure	rs10846495	T	G	0.21	0.04	1.35E-08	0.04	0.07	.62
Diastolic blood pressure	rs10849908	T	C	0.13	0.02	1.26E-13	-0.04	0.03	.14
Diastolic blood pressure	rs10850526	A	G	-0.20	0.02	1.61E-26	0.01	0.04	.83
Diastolic blood pressure	rs10873612	T	C	-0.11	0.02	9.51E-10	-0.02	0.03	.59
Diastolic blood pressure	rs10895022	T	C	-0.12	0.02	1.54E-09	-0.03	0.03	.34
Diastolic blood pressure	rs10906391	T	C	0.13	0.02	7.57E-12	-0.02	0.03	.52
Diastolic blood pressure	rs10934116	T	C	-0.13	0.02	1.54E-08	-0.04	0.03	.25
Diastolic blood pressure	rs10980408	T	C	-0.37	0.05	4.17E-15	0.05	0.06	.42
Diastolic blood pressure	rs11026586	A	G	0.29	0.03	2.68E-17	0.06	0.05	.22
Diastolic blood pressure	rs11059094	T	C	-0.15	0.02	6.16E-18	0.01	0.03	.76
Diastolic blood pressure	rs11070245	T	G	-0.13	0.02	1.57E-13	0.03	0.03	.26
Diastolic blood pressure	rs11084240	T	C	0.22	0.03	1.28E-11	0.00	0.06	.99
Diastolic blood pressure	rs11097755	T	C	0.12	0.02	1.72E-11	-0.04	0.03	.15
Diastolic blood pressure	rs11108209	T	C	-0.19	0.03	2.40E-10	-0.03	0.05	.48
Diastolic blood pressure	rs11112529	T	C	-0.10	0.02	1.17E-08	-0.02	0.03	.44

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs11130567	T	C	0.11	0.02	5.37E-09	-0.05	0.04	.13
Diastolic blood pressure	rs111384899	T	C	-0.14	0.02	4.62E-10	0.06	0.04	.13
Diastolic blood pressure	rs11141731	T	C	-0.13	0.02	1.31E-09	0.04	0.03	.21
Diastolic blood pressure	rs1114344	A	G	0.21	0.02	1.83E-33	0.02	0.03	.43
Diastolic blood pressure	rs1114347	A	G	-0.18	0.02	3.32E-25	-0.01	0.03	.79
Diastolic blood pressure	rs11145807	A	G	0.16	0.02	4.10E-17	-0.03	0.04	.45
Diastolic blood pressure	rs11153730	T	C	0.16	0.02	2.57E-19	-0.03	0.03	.20
Diastolic blood pressure	rs11158678	T	C	0.10	0.02	1.24E-08	-0.06	0.03	.07
Diastolic blood pressure	rs11167039	A	G	-0.18	0.03	3.60E-09	-0.04	0.06	.52
Diastolic blood pressure	rs11168254	T	G	0.22	0.04	4.07E-08	0.17	0.07	1.78E-02
Diastolic blood pressure	rs11177683	A	G	-0.12	0.02	6.47E-10	0.04	0.04	.21
Diastolic blood pressure	rs111777102	T	C	0.21	0.04	1.56E-09	-0.09	0.05	.06
Diastolic blood pressure	rs11196549	A	G	0.45	0.04	2.94E-23	0.05	0.06	.44
Diastolic blood pressure	rs11196627	T	C	-0.12	0.02	1.07E-11	0.05	0.04	.13
Diastolic blood pressure	rs112372061	A	G	0.27	0.05	9.62E-09	0.00	0.06	.97
Diastolic blood pressure	rs11252324	T	G	-0.23	0.03	1.03E-12	0.08	0.05	.07
Diastolic blood pressure	rs11259905	A	C	0.13	0.02	1.29E-09	-0.05	0.04	.27
Diastolic blood pressure	rs113134141	A	G	-0.16	0.03	2.50E-08	0.01	0.04	.87
Diastolic blood pressure	rs1133400	A	G	-0.13	0.02	8.30E-10	0.01	0.03	.66
Diastolic blood pressure	rs113352426	T	C	0.40	0.04	4.67E-20	0.08	0.06	.19
Diastolic blood pressure	rs113499824	T	G	0.41	0.05	4.11E-18	-0.01	0.08	.93
Diastolic blood pressure	rs113783450	A	G	-0.13	0.02	4.75E-11	0.04	0.04	.30
Diastolic blood pressure	rs114503346	T	C	-0.27	0.04	3.10E-10	0.11	0.09	.24
Diastolic blood pressure	rs114654100	A	G	0.19	0.04	3.16E-08	-0.16	0.08	2.86E-02
Diastolic blood pressure	rs115245297	T	C	-0.31	0.04	1.06E-12	-0.07	0.08	.33
Diastolic blood pressure	rs11543651	T	C	-0.12	0.02	6.64E-10	0.01	0.04	.79
Diastolic blood pressure	rs115521166	A	G	0.39	0.05	1.57E-14	-0.09	0.09	.30
Diastolic blood pressure	rs11578696	A	G	0.15	0.03	1.65E-08	-0.13	0.06	3.79E-02
Diastolic blood pressure	rs11592107	A	G	0.12	0.02	1.23E-10	-0.01	0.03	.82
Diastolic blood pressure	rs11593126	A	G	-0.22	0.03	1.21E-10	-0.06	0.08	.48
Diastolic blood pressure	rs11608122	T	C	0.12	0.02	2.97E-10	0.07	0.04	.07
Diastolic blood pressure	rs11609944	A	G	0.14	0.02	3.37E-14	0.03	0.03	.44
Diastolic blood pressure	rs116234817	A	G	0.32	0.04	2.73E-14	-0.02	0.06	.81
Diastolic blood pressure	rs11636952	T	C	0.40	0.02	5.21E-99	0.00	0.03	.91
Diastolic blood pressure	rs11661473	A	G	0.20	0.02	1.54E-24	0.05	0.04	.24
Diastolic blood pressure	rs11664781	T	C	0.11	0.02	2.60E-08	0.08	0.04	4.33E-02
Diastolic blood pressure	rs11681462	A	C	-0.13	0.02	5.96E-10	-0.07	0.05	.12
Diastolic blood pressure	rs116917543	A	C	-0.37	0.05	6.94E-14	-0.06	0.07	.43
Diastolic blood pressure	rs11721984	T	C	-0.14	0.02	1.89E-15	0.01	0.03	.88

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs117455294	A	C	0.23	0.04	3.36E-08	0.10	0.07	.11
Diastolic blood pressure	rs11778153	T	C	0.12	0.02	5.84E-11	-0.02	0.04	.51
Diastolic blood pressure	rs11781001	A	G	0.15	0.02	1.11E-10	-0.03	0.05	.49
Diastolic blood pressure	rs117844477	T	C	-0.38	0.06	4.33E-12	-0.01	0.09	.89
Diastolic blood pressure	rs1178979	T	C	0.15	0.02	9.96E-12	0.07	0.04	.11
Diastolic blood pressure	rs11832104	T	C	0.24	0.02	5.84E-25	-0.05	0.03	.10
Diastolic blood pressure	rs11837982	A	C	0.15	0.02	2.14E-16	0.01	0.04	.81
Diastolic blood pressure	rs11853359	A	G	-0.17	0.02	1.30E-19	0.01	0.03	.82
Diastolic blood pressure	rs11859505	A	G	-0.10	0.02	9.76E-09	0.00	0.03	.96
Diastolic blood pressure	rs11890632	T	G	-0.17	0.03	9.96E-10	-0.05	0.05	.34
Diastolic blood pressure	rs11923343	A	G	-0.11	0.02	3.10E-10	0.01	0.03	.74
Diastolic blood pressure	rs11945489	T	C	-0.14	0.02	3.99E-13	-0.02	0.04	.56
Diastolic blood pressure	rs11961593	T	C	-0.32	0.03	1.49E-19	-0.01	0.06	.80
Diastolic blood pressure	rs11966966	T	C	0.25	0.02	3.10E-36	0.01	0.03	.78
Diastolic blood pressure	rs11974176	T	C	0.13	0.02	2.94E-12	-0.04	0.03	.09
Diastolic blood pressure	rs12052761	A	G	-0.12	0.02	4.22E-12	0.01	0.03	.73
Diastolic blood pressure	rs12142296	T	G	-0.16	0.03	8.89E-11	0.04	0.04	.36
Diastolic blood pressure	rs12143164	T	C	-0.10	0.02	4.62E-08	0.00	0.04	.95
Diastolic blood pressure	rs12192720	A	G	-0.11	0.02	1.18E-08	-0.01	0.03	.67
Diastolic blood pressure	rs12216886	T	G	0.13	0.02	4.76E-09	-0.08	0.04	4.66E-02
Diastolic blood pressure	rs12247028	A	G	-0.14	0.02	1.18E-13	-0.07	0.04	.07
Diastolic blood pressure	rs12280469	A	G	0.24	0.03	3.37E-20	-0.02	0.04	.53
Diastolic blood pressure	rs12323265	A	G	-0.12	0.02	1.00E-10	-0.08	0.03	2.20E-02
Diastolic blood pressure	rs1232482	T	C	-0.12	0.02	6.10E-12	-0.06	0.03	1.57E-02
Diastolic blood pressure	rs12337056	T	C	0.14	0.02	2.18E-09	0.02	0.05	.71
Diastolic blood pressure	rs12411044	A	G	-0.22	0.02	5.18E-25	0.00	0.04	.99
Diastolic blood pressure	rs12446456	T	C	-0.18	0.02	3.99E-25	0.04	0.03	.15
Diastolic blood pressure	rs12484046	A	G	0.10	0.02	3.69E-08	0.02	0.03	.63
Diastolic blood pressure	rs12495847	A	G	0.13	0.02	3.44E-12	0.01	0.04	.86
Diastolic blood pressure	rs12509595	T	C	-0.50	0.02	1.58E-148	-0.01	0.03	.78
Diastolic blood pressure	rs12515541	T	G	0.12	0.02	6.23E-11	-0.03	0.03	.27
Diastolic blood pressure	rs12536606	T	C	-0.12	0.02	3.18E-10	-0.02	0.04	.56
Diastolic blood pressure	rs12549801	A	G	-0.12	0.02	1.44E-08	0.01	0.04	.72
Diastolic blood pressure	rs12574332	T	C	0.21	0.03	6.14E-15	-0.01	0.04	.87
Diastolic blood pressure	rs12609484	T	G	-0.14	0.02	1.16E-13	-0.01	0.04	.84
Diastolic blood pressure	rs12630496	T	C	-0.12	0.02	1.81E-10	0.01	0.03	.82
Diastolic blood pressure	rs1263671	T	C	-0.14	0.02	4.69E-09	-0.02	0.04	.67
Diastolic blood pressure	rs1265842	T	C	0.11	0.02	1.70E-10	0.00	0.03	.92
Diastolic blood pressure	rs12665161	A	G	0.12	0.02	1.63E-11	0.01	0.03	.80

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs12675715	T	G	0.10	0.02	2.31E-08	0.02	0.03	.33
Diastolic blood pressure	rs12703989	A	G	0.10	0.02	4.35E-09	-0.07	0.03	3.25E-02
Diastolic blood pressure	rs12728150	A	G	-0.20	0.03	1.28E-10	-0.05	0.05	.33
Diastolic blood pressure	rs12730750	A	G	0.11	0.02	1.95E-09	-0.02	0.04	.69
Diastolic blood pressure	rs1275988	T	C	-0.29	0.02	1.92E-62	-0.03	0.04	.40
Diastolic blood pressure	rs12790943	T	C	-0.10	0.02	1.14E-08	0.01	0.03	.66
Diastolic blood pressure	rs12806952	T	C	-0.11	0.02	1.07E-09	0.04	0.03	.24
Diastolic blood pressure	rs12866098	A	G	0.10	0.02	2.73E-08	-0.02	0.04	.70
Diastolic blood pressure	rs12906962	T	C	-0.24	0.02	8.73E-37	0.02	0.03	.62
Diastolic blood pressure	rs12919839	T	C	-0.11	0.02	1.04E-08	0.05	0.03	.09
Diastolic blood pressure	rs12926550	A	G	-0.15	0.02	4.44E-16	0.00	0.04	.93
Diastolic blood pressure	rs12929303	A	G	0.16	0.02	1.58E-19	0.00	0.03	.94
Diastolic blood pressure	rs12949655	A	G	0.20	0.03	8.91E-10	0.01	0.07	.86
Diastolic blood pressure	rs12983471	A	G	0.10	0.02	1.15E-08	0.01	0.03	.76
Diastolic blood pressure	rs12990959	T	C	-0.13	0.02	1.11E-11	-0.02	0.03	.44
Diastolic blood pressure	rs13001283	A	G	0.15	0.02	1.92E-10	0.11	0.05	2.11E-02
Diastolic blood pressure	rs13014371	T	C	-0.12	0.02	1.68E-11	0.00	0.03	.89
Diastolic blood pressure	rs13020482	T	C	-0.26	0.04	1.70E-09	-0.06	0.06	.36
Diastolic blood pressure	rs13026308	A	C	-0.14	0.03	2.67E-08	-0.11	0.04	4.37E-03
Diastolic blood pressure	rs13044147	T	G	-0.23	0.04	5.88E-09	0.06	0.06	.27
Diastolic blood pressure	rs13094525	A	G	0.09	0.02	4.93E-08	-0.01	0.03	.68
Diastolic blood pressure	rs13139571	A	C	-0.24	0.02	2.29E-32	0.00	0.03	.91
Diastolic blood pressure	rs13179413	T	C	0.13	0.02	3.04E-10	-0.04	0.04	.29
Diastolic blood pressure	rs13195550	T	C	0.13	0.02	1.69E-12	0.00	0.04	.97
Diastolic blood pressure	rs13206164	T	C	0.27	0.05	8.24E-09	-0.02	0.08	.76
Diastolic blood pressure	rs1322639	A	G	-0.16	0.02	3.87E-14	-0.05	0.03	.07
Diastolic blood pressure	rs13240040	A	G	0.12	0.02	3.98E-10	0.00	0.04	1.00
Diastolic blood pressure	rs13240528	A	C	-0.13	0.02	3.27E-14	-0.01	0.03	.77
Diastolic blood pressure	rs13270541	A	G	0.12	0.02	1.33E-08	-0.04	0.03	.13
Diastolic blood pressure	rs1327235	A	G	-0.30	0.02	4.76E-68	0.05	0.03	4.89E-02
Diastolic blood pressure	rs134041	T	C	0.12	0.02	3.05E-12	0.05	0.03	.11
Diastolic blood pressure	rs137920360	T	C	-0.25	0.05	1.93E-08	-0.01	0.06	.87
Diastolic blood pressure	rs141212865	A	C	0.15	0.02	2.53E-11	-0.01	0.04	.70
Diastolic blood pressure	rs1422278	T	G	0.23	0.03	2.28E-20	-0.01	0.04	.84
Diastolic blood pressure	rs142449193	T	C	-0.26	0.04	1.51E-09	0.00	0.06	.96
Diastolic blood pressure	rs1425152	A	C	0.11	0.02	2.92E-10	-0.06	0.03	.09
Diastolic blood pressure	rs1425486	T	C	-0.13	0.02	1.11E-12	-0.02	0.03	.37
Diastolic blood pressure	rs1436138	A	G	0.20	0.02	7.33E-28	0.04	0.03	.25
Diastolic blood pressure	rs143854972	A	G	0.29	0.04	1.15E-14	0.10	0.06	.11

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs144282473	T	C	0.38	0.05	1.05E-14	0.00	0.08	.99
Diastolic blood pressure	rs145422110	T	C	0.54	0.07	6.41E-13	0.09	0.10	.37
Diastolic blood pressure	rs1465249	T	C	0.10	0.02	3.56E-08	-0.07	0.03	.05
Diastolic blood pressure	rs1480380	T	C	-0.33	0.03	8.88E-29	-0.04	0.05	.38
Diastolic blood pressure	rs1494649	T	C	0.13	0.02	4.25E-11	-0.04	0.04	.24
Diastolic blood pressure	rs1498768	A	G	0.21	0.03	8.12E-10	-0.02	0.06	.75
Diastolic blood pressure	rs1502358	A	G	-0.11	0.02	1.13E-09	0.06	0.04	.09
Diastolic blood pressure	rs150816167	T	C	-0.29	0.04	1.17E-10	-0.11	0.07	.09
Diastolic blood pressure	rs151356	A	G	-0.19	0.02	2.12E-18	-0.04	0.03	.25
Diastolic blood pressure	rs151378	A	G	-0.11	0.02	2.61E-09	0.05	0.03	.16
Diastolic blood pressure	rs152130	A	G	-0.12	0.02	9.70E-10	-0.06	0.04	.10
Diastolic blood pressure	rs1527351	T	C	0.17	0.02	2.07E-19	-0.03	0.03	.22
Diastolic blood pressure	rs1535271	A	G	-0.16	0.02	3.49E-13	0.04	0.04	.36
Diastolic blood pressure	rs1536608	T	G	0.11	0.02	1.70E-09	-0.03	0.03	.42
Diastolic blood pressure	rs1543310	T	C	-0.14	0.02	7.31E-15	-0.05	0.04	.21
Diastolic blood pressure	rs1565716	A	G	0.21	0.03	3.45E-10	0.13	0.05	8.29E-03
Diastolic blood pressure	rs1571737	T	C	0.13	0.02	1.45E-08	0.02	0.03	.54
Diastolic blood pressure	rs1650554	A	G	0.13	0.02	5.13E-13	0.04	0.03	.12
Diastolic blood pressure	rs16849203	T	C	-0.27	0.05	2.75E-08	0.03	0.08	.71
Diastolic blood pressure	rs16852778	T	C	0.16	0.02	4.03E-11	-0.04	0.04	.42
Diastolic blood pressure	rs16853084	T	C	-0.27	0.05	2.57E-08	0.01	0.07	.88
Diastolic blood pressure	rs1687295	T	C	0.21	0.02	2.99E-26	0.03	0.03	.36
Diastolic blood pressure	rs16891474	T	G	-0.17	0.02	7.47E-12	-0.03	0.03	.32
Diastolic blood pressure	rs1689468	A	G	0.12	0.02	1.05E-11	0.01	0.03	.66
Diastolic blood pressure	rs16916914	T	C	-0.36	0.05	8.04E-15	-0.02	0.07	.76
Diastolic blood pressure	rs17137303	T	G	-0.23	0.04	1.16E-09	0.02	0.05	.73
Diastolic blood pressure	rs17244049	T	C	0.21	0.04	2.30E-08	0.02	0.09	.80
Diastolic blood pressure	rs17249006	T	C	-0.20	0.03	8.62E-12	0.00	0.04	.94
Diastolic blood pressure	rs1725074	T	C	0.14	0.03	3.88E-08	-0.08	0.03	2.81E-02
Diastolic blood pressure	rs1727311	T	G	-0.20	0.02	3.96E-20	-0.01	0.04	.76
Diastolic blood pressure	rs17321041	T	C	0.23	0.04	1.78E-10	0.05	0.08	.51
Diastolic blood pressure	rs17353559	A	G	0.11	0.02	7.23E-10	-0.01	0.04	.69
Diastolic blood pressure	rs17361679	T	C	0.16	0.03	1.52E-08	-0.03	0.05	.55
Diastolic blood pressure	rs17396055	A	G	-0.12	0.02	4.13E-10	0.00	0.03	.89
Diastolic blood pressure	rs17422386	A	G	0.26	0.04	3.13E-09	0.09	0.07	.18
Diastolic blood pressure	rs17473424	A	G	0.27	0.03	1.23E-21	-0.01	0.04	.90
Diastolic blood pressure	rs17627481	A	G	-0.37	0.04	1.67E-19	-0.03	0.06	.63
Diastolic blood pressure	rs17669452	A	G	0.14	0.02	3.47E-09	0.05	0.04	.15
Diastolic blood pressure	rs17735275	A	G	0.30	0.05	2.61E-10	-0.01	0.08	.95

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs1779246	A	G	-0.15	0.02	2.67E-12	-0.01	0.04	.76
Diastolic blood pressure	rs17861118	A	G	0.20	0.03	2.77E-09	-0.06	0.06	.35
Diastolic blood pressure	rs17875473	T	C	0.25	0.03	8.64E-15	-0.12	0.08	.11
Diastolic blood pressure	rs1800562	A	G	0.38	0.03	8.53E-29	0.00	0.06	.94
Diastolic blood pressure	rs1819663	A	G	0.11	0.02	4.63E-11	0.00	0.03	.98
Diastolic blood pressure	rs1821295	T	C	-0.14	0.02	3.13E-13	-0.03	0.04	.49
Diastolic blood pressure	rs1842646	A	C	0.10	0.02	2.65E-08	-0.05	0.03	.06
Diastolic blood pressure	rs1848510	A	G	0.13	0.02	4.10E-12	-0.01	0.03	.62
Diastolic blood pressure	rs1863798	A	G	-0.10	0.02	3.26E-08	-0.11	0.03	8.19E-04
Diastolic blood pressure	rs1867624	T	C	0.14	0.02	2.08E-15	0.04	0.04	.31
Diastolic blood pressure	rs1867852	T	C	0.18	0.02	6.23E-22	-0.05	0.04	.18
Diastolic blood pressure	rs1871190	T	G	0.11	0.02	6.63E-09	0.00	0.04	.91
Diastolic blood pressure	rs1876490	A	G	0.14	0.02	1.16E-12	0.04	0.04	.28
Diastolic blood pressure	rs1879056	T	C	-0.22	0.02	6.19E-23	0.03	0.03	.26
Diastolic blood pressure	rs1885018	A	C	0.13	0.02	1.76E-08	0.04	0.04	.37
Diastolic blood pressure	rs188542	T	C	-0.14	0.02	2.54E-16	-0.10	0.03	3.26E-03
Diastolic blood pressure	rs189556314	T	C	-0.27	0.05	2.92E-08	0.05	0.07	.49
Diastolic blood pressure	rs1906672	A	G	0.14	0.02	8.48E-12	-0.04	0.03	.25
Diastolic blood pressure	rs1950500	T	C	0.14	0.02	2.20E-13	-0.08	0.04	1.75E-02
Diastolic blood pressure	rs1980607	A	G	0.12	0.02	1.51E-10	0.01	0.03	.85
Diastolic blood pressure	rs1984195	A	G	0.17	0.02	1.43E-23	0.03	0.03	.31
Diastolic blood pressure	rs1996992	T	G	-0.30	0.04	4.71E-14	0.05	0.06	.35
Diastolic blood pressure	rs2060664	T	C	0.11	0.02	4.65E-08	0.02	0.03	.56
Diastolic blood pressure	rs2065498	T	G	-0.15	0.02	4.19E-10	-0.02	0.03	.47
Diastolic blood pressure	rs2085600	A	G	-0.13	0.02	7.00E-09	0.05	0.03	.11
Diastolic blood pressure	rs2118370	A	G	0.13	0.02	1.38E-08	0.03	0.04	.56
Diastolic blood pressure	rs2146315	T	C	-0.12	0.02	5.03E-09	0.00	0.03	.98
Diastolic blood pressure	rs2171690	T	C	0.12	0.02	1.19E-11	0.01	0.03	.76
Diastolic blood pressure	rs2173957	A	G	0.11	0.02	2.09E-09	-0.02	0.03	.51
Diastolic blood pressure	rs2178152	A	G	-0.13	0.02	1.89E-10	0.02	0.03	.60
Diastolic blood pressure	rs2217171	T	C	-0.18	0.02	1.35E-23	0.00	0.03	.87
Diastolic blood pressure	rs2239268	A	G	0.11	0.02	7.40E-09	0.03	0.03	.32
Diastolic blood pressure	rs2242338	A	C	0.35	0.03	1.25E-25	0.02	0.04	.70
Diastolic blood pressure	rs2246954	A	G	-0.20	0.02	4.10E-26	0.01	0.03	.76
Diastolic blood pressure	rs2252865	T	C	0.12	0.02	5.51E-11	0.03	0.03	.30
Diastolic blood pressure	rs2269579	A	G	-0.18	0.03	1.09E-09	0.04	0.05	.35
Diastolic blood pressure	rs2282823	T	C	0.14	0.02	3.03E-08	0.03	0.04	.38
Diastolic blood pressure	rs2288464	A	C	-0.17	0.03	1.04E-08	0.02	0.04	.70
Diastolic blood pressure	rs2291516	A	G	0.24	0.03	9.88E-17	-0.12	0.04	3.42E-03

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs2298807	T	C	0.12	0.02	4.89E-09	-0.06	0.04	.12
Diastolic blood pressure	rs2306363	T	G	-0.26	0.02	1.63E-34	0.04	0.03	.21
Diastolic blood pressure	rs2328887	T	C	-0.21	0.03	7.55E-13	-0.04	0.07	.56
Diastolic blood pressure	rs234623	A	G	-0.12	0.02	8.56E-12	0.03	0.03	.46
Diastolic blood pressure	rs2348211	T	C	0.14	0.02	2.74E-14	0.01	0.04	.78
Diastolic blood pressure	rs2357786	T	C	0.11	0.02	3.58E-10	-0.05	0.03	.17
Diastolic blood pressure	rs2374479	A	G	0.11	0.02	2.46E-09	0.03	0.04	.47
Diastolic blood pressure	rs237485	A	G	0.11	0.02	3.63E-09	-0.02	0.04	.66
Diastolic blood pressure	rs2384061	A	G	-0.17	0.02	2.25E-23	-0.03	0.03	.20
Diastolic blood pressure	rs2384606	T	C	0.11	0.02	7.35E-10	0.02	0.03	.63
Diastolic blood pressure	rs2408046	T	C	-0.28	0.02	6.20E-35	-0.03	0.03	.40
Diastolic blood pressure	rs2421651	A	G	0.15	0.02	7.61E-17	0.02	0.03	.50
Diastolic blood pressure	rs2427574	A	C	0.12	0.02	1.27E-10	-0.03	0.04	.44
Diastolic blood pressure	rs2439371	A	C	0.13	0.02	1.30E-08	-0.06	0.04	.14
Diastolic blood pressure	rs2450128	A	G	-0.15	0.02	3.53E-10	-0.03	0.04	.45
Diastolic blood pressure	rs2469100	T	G	-0.15	0.03	2.15E-08	0.07	0.05	.14
Diastolic blood pressure	rs2484294	A	G	0.32	0.02	1.17E-58	-0.03	0.04	.34
Diastolic blood pressure	rs2493288	A	G	0.25	0.03	1.97E-23	-0.02	0.04	.63
Diastolic blood pressure	rs2546963	T	C	0.10	0.02	3.66E-08	-0.05	0.03	.08
Diastolic blood pressure	rs2569882	T	C	0.12	0.02	4.28E-11	-0.06	0.03	.09
Diastolic blood pressure	rs2586970	A	G	-0.15	0.02	1.56E-17	-0.05	0.03	.06
Diastolic blood pressure	rs2615000	T	C	-0.13	0.02	2.94E-08	-0.01	0.04	.76
Diastolic blood pressure	rs2616551	A	G	0.13	0.02	3.12E-09	0.05	0.04	.19
Diastolic blood pressure	rs2618647	A	G	-0.12	0.02	2.70E-12	0.03	0.03	.32
Diastolic blood pressure	rs2627316	A	G	-0.15	0.02	7.37E-19	0.03	0.03	.25
Diastolic blood pressure	rs2629665	A	C	-0.12	0.02	1.52E-11	-0.04	0.03	.18
Diastolic blood pressure	rs2639453	T	C	0.14	0.02	6.11E-11	-0.05	0.04	.16
Diastolic blood pressure	rs2643826	T	C	0.19	0.02	2.83E-26	-0.01	0.03	.71
Diastolic blood pressure	rs26492	A	G	0.14	0.02	4.50E-09	0.05	0.03	.15
Diastolic blood pressure	rs2680663	A	G	-0.18	0.02	7.33E-22	0.02	0.04	.53
Diastolic blood pressure	rs2694975	A	G	0.13	0.02	9.57E-10	0.00	0.03	.97
Diastolic blood pressure	rs2695258	T	C	0.12	0.02	4.35E-08	0.02	0.03	.62
Diastolic blood pressure	rs28362590	T	G	0.12	0.02	8.70E-10	-0.01	0.03	.86
Diastolic blood pressure	rs2836489	T	C	0.10	0.02	2.15E-08	0.07	0.03	2.62E-02
Diastolic blood pressure	rs28377357	A	G	-0.12	0.02	6.03E-11	-0.02	0.03	.58
Diastolic blood pressure	rs28429256	A	G	0.16	0.02	2.83E-18	-0.02	0.04	.67
Diastolic blood pressure	rs28444248	T	C	0.16	0.02	1.02E-10	0.09	0.05	.07
Diastolic blood pressure	rs2851336	T	C	-0.12	0.02	1.21E-11	0.04	0.03	.11
Diastolic blood pressure	rs28625968	T	C	0.16	0.02	4.84E-18	-0.03	0.03	.31

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs28661492	T	C	-0.14	0.02	9.56E-10	0.12	0.04	1.46E-03
Diastolic blood pressure	rs28675079	A	G	-0.14	0.02	8.34E-11	-0.04	0.03	.16
Diastolic blood pressure	rs2906152	A	G	-0.19	0.02	5.55E-25	0.01	0.03	.74
Diastolic blood pressure	rs2921604	T	C	-0.10	0.02	4.46E-08	-0.03	0.03	.41
Diastolic blood pressure	rs2925345	T	C	0.19	0.02	1.60E-27	0.03	0.03	.28
Diastolic blood pressure	rs2927071	T	C	-0.14	0.02	6.43E-13	0.02	0.03	.51
Diastolic blood pressure	rs2940928	A	G	-0.13	0.02	7.56E-09	0.01	0.04	.86
Diastolic blood pressure	rs2957468	A	G	0.14	0.02	8.43E-14	0.00	0.03	.96
Diastolic blood pressure	rs2959010	A	G	0.18	0.03	8.67E-13	-0.03	0.04	.52
Diastolic blood pressure	rs297690	T	G	-0.13	0.02	5.54E-11	-0.01	0.04	.75
Diastolic blood pressure	rs2979470	T	C	0.10	0.02	4.61E-09	0.01	0.03	.70
Diastolic blood pressure	rs2994648	T	C	0.13	0.02	3.33E-09	-0.02	0.04	.68
Diastolic blood pressure	rs303217	T	C	-0.10	0.02	4.06E-08	0.03	0.03	.19
Diastolic blood pressure	rs3104419	T	C	0.15	0.02	3.44E-16	-0.01	0.03	.76
Diastolic blood pressure	rs3107147	A	G	0.11	0.02	3.26E-09	0.04	0.03	.28
Diastolic blood pressure	rs311564	A	G	-0.13	0.02	4.23E-13	0.04	0.03	.22
Diastolic blood pressure	rs3118904	A	G	0.12	0.02	1.75E-10	0.03	0.04	.34
Diastolic blood pressure	rs314376	A	G	-0.14	0.02	3.79E-15	0.01	0.03	.74
Diastolic blood pressure	rs3213545	A	G	0.11	0.02	1.06E-08	0.03	0.04	.36
Diastolic blood pressure	rs34029821	A	G	-0.17	0.02	6.97E-18	0.03	0.04	.44
Diastolic blood pressure	rs34163044	A	C	0.15	0.02	9.63E-17	-0.01	0.03	.80
Diastolic blood pressure	rs34196696	T	C	0.13	0.02	1.86E-10	0.07	0.04	.05
Diastolic blood pressure	rs342130	A	G	0.11	0.02	6.17E-10	-0.04	0.03	.24
Diastolic blood pressure	rs34297584	A	G	0.49	0.06	2.78E-14	-0.06	0.11	.59
Diastolic blood pressure	rs342989	A	G	0.16	0.02	3.05E-15	0.05	0.04	.26
Diastolic blood pressure	rs34517439	A	C	-0.25	0.03	2.02E-19	0.09	0.07	.20
Diastolic blood pressure	rs34538877	T	C	-0.12	0.02	2.13E-12	0.02	0.03	.49
Diastolic blood pressure	rs34587285	T	C	0.10	0.02	3.28E-08	0.03	0.03	.38
Diastolic blood pressure	rs34605102	A	G	-0.12	0.02	2.40E-11	0.05	0.03	.05
Diastolic blood pressure	rs34645159	A	G	-0.13	0.02	2.07E-14	0.02	0.03	.50
Diastolic blood pressure	rs34688434	A	C	-0.24	0.03	5.08E-13	-0.01	0.07	.82
Diastolic blood pressure	rs347585	T	C	0.15	0.02	1.57E-15	0.00	0.03	.91
Diastolic blood pressure	rs34846921	T	C	-0.12	0.02	4.19E-09	-0.02	0.04	.58
Diastolic blood pressure	rs351157	A	C	-0.12	0.02	1.49E-08	-0.02	0.04	.58
Diastolic blood pressure	rs35213536	T	G	0.20	0.02	2.54E-23	0.02	0.03	.55
Diastolic blood pressure	rs35241484	T	G	0.13	0.02	5.07E-10	0.01	0.04	.79
Diastolic blood pressure	rs35261542	A	C	0.12	0.02	9.29E-10	0.00	0.03	.89
Diastolic blood pressure	rs35274227	T	C	-0.22	0.03	3.69E-10	-0.20	0.08	7.42E-03
Diastolic blood pressure	rs35287509	T	C	-0.11	0.02	4.17E-09	0.03	0.03	.32

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs35413927	A	G	-0.13	0.02	1.77E-11	0.03	0.04	.42
Diastolic blood pressure	rs35497	A	G	-0.16	0.03	1.08E-09	0.02	0.04	.58
Diastolic blood pressure	rs35552228	T	G	-0.12	0.02	3.09E-08	-0.06	0.04	.19
Diastolic blood pressure	rs35781150	A	G	-0.12	0.02	4.19E-09	-0.01	0.03	.79
Diastolic blood pressure	rs35783704	A	G	-0.21	0.03	2.28E-13	-0.08	0.07	.23
Diastolic blood pressure	rs35927325	T	C	0.22	0.04	1.01E-09	0.01	0.05	.83
Diastolic blood pressure	rs35991606	T	C	-0.16	0.03	1.22E-08	-0.06	0.04	.18
Diastolic blood pressure	rs36022378	T	C	-0.18	0.02	8.60E-16	-0.05	0.05	.29
Diastolic blood pressure	rs3735318	A	G	-0.10	0.02	4.72E-09	0.06	0.03	.09
Diastolic blood pressure	rs3735533	T	C	-0.49	0.03	6.32E-49	-0.06	0.06	.38
Diastolic blood pressure	rs3737136	A	G	-0.27	0.02	4.06E-36	0.03	0.03	.40
Diastolic blood pressure	rs3744010	A	G	-0.14	0.02	2.01E-12	0.04	0.03	.13
Diastolic blood pressure	rs3745318	T	C	0.14	0.02	1.30E-11	-0.03	0.04	.51
Diastolic blood pressure	rs3766694	T	C	0.11	0.02	4.07E-10	0.02	0.03	.55
Diastolic blood pressure	rs3774702	A	G	0.15	0.02	1.18E-10	0.02	0.03	.52
Diastolic blood pressure	rs3779456	T	C	-0.11	0.02	2.14E-10	0.00	0.03	.95
Diastolic blood pressure	rs3782480	T	G	0.15	0.03	3.35E-08	0.06	0.05	.30
Diastolic blood pressure	rs3783412	A	G	0.11	0.02	9.04E-10	0.06	0.03	.08
Diastolic blood pressure	rs378459	T	C	0.16	0.02	8.31E-15	0.00	0.04	.92
Diastolic blood pressure	rs3789368	T	C	-0.11	0.02	1.29E-10	0.02	0.04	.65
Diastolic blood pressure	rs3798293	A	G	-0.13	0.02	2.70E-10	-0.01	0.03	.67
Diastolic blood pressure	rs3802230	A	C	-0.16	0.02	2.75E-20	-0.06	0.03	2.42E-02
Diastolic blood pressure	rs3807101	T	C	-0.17	0.03	4.57E-11	0.06	0.05	.24
Diastolic blood pressure	rs3821843	A	G	0.17	0.02	5.39E-19	0.03	0.04	.40
Diastolic blood pressure	rs3861113	A	C	0.21	0.03	3.95E-11	0.04	0.05	.41
Diastolic blood pressure	rs3898618	T	C	-0.27	0.04	2.49E-12	0.07	0.06	.25
Diastolic blood pressure	rs3918226	T	C	0.61	0.03	5.31E-77	-0.04	0.06	.49
Diastolic blood pressure	rs39281	A	G	0.13	0.02	3.97E-13	0.07	0.03	3.99E-02
Diastolic blood pressure	rs3943093	T	C	0.25	0.02	3.95E-41	0.02	0.03	.42
Diastolic blood pressure	rs3996330	A	C	-0.13	0.02	4.00E-13	-0.04	0.03	.19
Diastolic blood pressure	rs4074812	A	G	-0.13	0.02	2.07E-14	-0.02	0.03	.63
Diastolic blood pressure	rs4077158	T	C	-0.18	0.02	3.09E-26	0.02	0.03	.41
Diastolic blood pressure	rs4141663	T	C	-0.15	0.02	1.41E-17	-0.05	0.03	.12
Diastolic blood pressure	rs41475048	A	G	-0.12	0.02	9.93E-10	0.08	0.04	3.51E-02
Diastolic blood pressure	rs4243951	A	G	-0.19	0.02	2.42E-21	0.02	0.04	.66
Diastolic blood pressure	rs4315061	T	C	0.12	0.02	2.24E-12	-0.02	0.03	.63
Diastolic blood pressure	rs4347951	T	C	0.11	0.02	2.80E-08	-0.01	0.04	.85
Diastolic blood pressure	rs4393303	A	G	0.16	0.02	4.57E-14	0.00	0.03	.96
Diastolic blood pressure	rs4420291	A	G	0.10	0.02	2.17E-08	0.02	0.03	.57

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs4421757	A	G	0.10	0.02	1.63E-08	0.03	0.03	.35
Diastolic blood pressure	rs443198	A	G	0.11	0.02	7.82E-09	0.06	0.03	2.13E-02
Diastolic blood pressure	rs4451700	T	C	0.15	0.02	7.94E-12	-0.02	0.03	.62
Diastolic blood pressure	rs4489092	T	G	-0.10	0.02	1.05E-08	-0.05	0.03	.15
Diastolic blood pressure	rs4507125	A	C	-0.12	0.02	3.60E-09	0.04	0.03	.25
Diastolic blood pressure	rs45474499	T	C	0.36	0.04	8.50E-18	-0.04	0.06	.52
Diastolic blood pressure	rs4615669	A	G	-0.11	0.02	6.10E-11	0.02	0.03	.54
Diastolic blood pressure	rs4630220	A	G	-0.13	0.02	2.75E-11	0.01	0.04	.83
Diastolic blood pressure	rs4634143	T	C	0.12	0.02	7.89E-10	0.04	0.04	.33
Diastolic blood pressure	rs4651224	T	C	0.11	0.02	3.39E-10	-0.04	0.03	.23
Diastolic blood pressure	rs4704514	T	C	0.11	0.02	1.71E-08	-0.07	0.04	.06
Diastolic blood pressure	rs4709746	T	C	-0.14	0.03	2.21E-08	0.02	0.05	.73
Diastolic blood pressure	rs4712955	A	G	-0.17	0.02	1.37E-22	0.02	0.04	.58
Diastolic blood pressure	rs4713650	T	C	-0.12	0.02	2.23E-11	0.00	0.03	.87
Diastolic blood pressure	rs4743021	T	C	-0.11	0.02	2.41E-08	0.05	0.04	.12
Diastolic blood pressure	rs4761524	A	G	0.10	0.02	2.77E-08	0.04	0.03	.24
Diastolic blood pressure	rs4766994	T	C	0.14	0.02	2.08E-11	0.00	0.03	.88
Diastolic blood pressure	rs4773140	A	G	-0.14	0.02	2.90E-11	0.05	0.04	.22
Diastolic blood pressure	rs4809361	T	C	0.15	0.02	5.08E-11	-0.01	0.04	.78
Diastolic blood pressure	rs481795	T	C	0.17	0.02	1.81E-12	0.04	0.04	.34
Diastolic blood pressure	rs4834735	T	C	0.15	0.03	2.64E-09	-0.02	0.05	.75
Diastolic blood pressure	rs4841637	T	C	-0.13	0.02	3.62E-08	-0.02	0.05	.66
Diastolic blood pressure	rs4873492	T	C	0.14	0.02	1.28E-09	-0.05	0.04	.21
Diastolic blood pressure	rs4891258	A	G	-0.12	0.02	5.72E-10	0.00	0.03	.90
Diastolic blood pressure	rs4903064	T	C	0.15	0.02	7.84E-14	0.00	0.03	.99
Diastolic blood pressure	rs4907238	A	G	0.12	0.02	7.03E-10	-0.03	0.03	.33
Diastolic blood pressure	rs4908678	T	C	-0.11	0.02	4.59E-10	0.01	0.03	.75
Diastolic blood pressure	rs4924570	T	C	-0.17	0.02	9.62E-21	-0.06	0.04	.08
Diastolic blood pressure	rs4926923	T	C	0.19	0.03	4.75E-10	0.02	0.05	.60
Diastolic blood pressure	rs4932373	A	C	-0.37	0.02	7.71E-84	0.06	0.04	.14
Diastolic blood pressure	rs4936099	A	C	0.17	0.02	1.16E-22	0.04	0.04	.21
Diastolic blood pressure	rs4948550	T	C	-0.11	0.02	1.00E-08	-0.02	0.03	.44
Diastolic blood pressure	rs4948643	T	C	0.16	0.02	2.26E-16	-0.05	0.04	.19
Diastolic blood pressure	rs4952660	A	C	0.12	0.02	1.48E-10	0.03	0.04	.42
Diastolic blood pressure	rs4952668	A	G	-0.19	0.02	1.13E-26	-0.05	0.04	.16
Diastolic blood pressure	rs4954192	T	C	-0.12	0.02	8.15E-12	0.08	0.04	2.30E-02
Diastolic blood pressure	rs4974072	A	G	0.10	0.02	1.63E-09	0.00	0.03	.91
Diastolic blood pressure	rs4984496	T	G	0.18	0.02	4.93E-21	0.04	0.04	.27
Diastolic blood pressure	rs5021139	T	C	0.11	0.02	2.59E-09	-0.02	0.03	.56

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs504217	T	C	0.27	0.03	2.51E-16	0.02	0.04	.57
Diastolic blood pressure	rs504691	A	C	-0.12	0.02	3.14E-11	-0.03	0.03	.34
Diastolic blood pressure	rs509564	T	C	0.15	0.02	1.40E-12	-0.05	0.04	.20
Diastolic blood pressure	rs55641580	T	C	0.17	0.03	4.79E-11	0.01	0.04	.80
Diastolic blood pressure	rs55684003	A	G	0.12	0.02	1.01E-10	0.00	0.04	1.00
Diastolic blood pressure	rs55706574	A	G	-0.11	0.02	3.20E-09	0.01	0.03	.78
Diastolic blood pressure	rs55710016	A	G	0.12	0.02	2.72E-11	0.00	0.03	.92
Diastolic blood pressure	rs55747751	A	G	-0.22	0.03	1.39E-11	0.07	0.08	.39
Diastolic blood pressure	rs55830103	T	G	-0.20	0.02	9.02E-18	0.05	0.05	.35
Diastolic blood pressure	rs55935819	A	G	0.13	0.02	1.96E-12	-0.02	0.03	.47
Diastolic blood pressure	rs55944332	A	G	-0.24	0.02	3.27E-31	0.04	0.04	.36
Diastolic blood pressure	rs55964643	A	G	0.18	0.02	2.00E-22	0.04	0.03	.28
Diastolic blood pressure	rs55990632	A	G	-0.30	0.05	1.70E-09	0.00	0.08	.99
Diastolic blood pressure	rs55993676	T	G	-0.21	0.02	3.82E-28	-0.01	0.03	.72
Diastolic blood pressure	rs56014530	A	G	0.22	0.02	1.64E-31	0.00	0.04	.97
Diastolic blood pressure	rs56233017	A	G	-0.27	0.04	4.37E-10	0.02	0.10	.83
Diastolic blood pressure	rs56240052	A	G	-0.35	0.05	3.19E-12	0.12	0.09	.16
Diastolic blood pressure	rs56254331	A	C	-0.14	0.02	3.43E-09	0.02	0.06	.73
Diastolic blood pressure	rs56256111	A	G	0.19	0.03	2.60E-13	0.04	0.06	.49
Diastolic blood pressure	rs56335308	A	G	0.36	0.06	6.31E-10	0.09	0.09	.29
Diastolic blood pressure	rs56345595	A	G	0.13	0.02	5.20E-14	-0.06	0.03	.05
Diastolic blood pressure	rs56370893	A	G	-0.21	0.04	5.25E-09	-0.02	0.07	.81
Diastolic blood pressure	rs56405868	T	G	-0.12	0.02	9.61E-09	0.01	0.03	.66
Diastolic blood pressure	rs568032	A	G	-0.27	0.04	6.28E-12	0.01	0.06	.87
Diastolic blood pressure	rs56810307	T	C	-0.16	0.03	1.29E-08	0.00	0.05	.99
Diastolic blood pressure	rs569550	T	G	-0.27	0.02	1.23E-49	-0.04	0.03	.28
Diastolic blood pressure	rs57091267	A	G	-0.18	0.02	2.72E-16	-0.07	0.04	.09
Diastolic blood pressure	rs57361399	T	C	-0.17	0.02	1.20E-15	0.00	0.03	1.00
Diastolic blood pressure	rs57490543	A	C	0.17	0.03	1.22E-08	-0.09	0.05	.05
Diastolic blood pressure	rs57786342	A	G	0.14	0.02	4.37E-11	-0.01	0.03	.85
Diastolic blood pressure	rs57885458	T	C	-0.15	0.02	7.48E-14	0.02	0.03	.61
Diastolic blood pressure	rs58609847	T	C	-0.10	0.02	4.57E-08	0.04	0.04	.22
Diastolic blood pressure	rs58693652	A	G	0.11	0.02	3.69E-10	0.04	0.03	.26
Diastolic blood pressure	rs588273	A	G	-0.11	0.02	7.85E-11	0.02	0.03	.55
Diastolic blood pressure	rs5992929	T	C	0.17	0.02	3.07E-18	-0.03	0.03	.29
Diastolic blood pressure	rs6011210	A	G	-0.15	0.02	1.64E-17	-0.02	0.03	.59
Diastolic blood pressure	rs6021247	A	G	0.13	0.02	8.21E-14	-0.02	0.03	.53
Diastolic blood pressure	rs6031431	A	G	-0.12	0.02	4.94E-11	0.01	0.03	.87
Diastolic blood pressure	rs603424	A	G	0.18	0.02	1.24E-14	-0.04	0.04	.27

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs6039211	A	G	0.18	0.02	6.82E-23	0.02	0.03	.36
Diastolic blood pressure	rs6040421	A	G	0.10	0.02	4.17E-08	0.03	0.03	.32
Diastolic blood pressure	rs6046137	A	G	0.12	0.02	5.45E-09	-0.05	0.04	.20
Diastolic blood pressure	rs604723	T	C	-0.38	0.02	2.32E-87	0.04	0.04	.24
Diastolic blood pressure	rs6062295	A	G	-0.12	0.02	1.17E-11	-0.02	0.03	.51
Diastolic blood pressure	rs61278674	A	G	-0.22	0.03	1.19E-12	-0.03	0.06	.61
Diastolic blood pressure	rs61310799	T	C	-0.18	0.03	3.09E-08	-0.01	0.05	.81
Diastolic blood pressure	rs61408836	T	C	-0.13	0.02	5.69E-09	0.00	0.03	.99
Diastolic blood pressure	rs61447364	A	G	-0.14	0.02	1.03E-08	0.01	0.05	.81
Diastolic blood pressure	rs61736014	A	G	-0.22	0.04	2.27E-08	-0.01	0.06	.90
Diastolic blood pressure	rs61772592	A	G	-0.15	0.03	7.42E-09	0.01	0.04	.90
Diastolic blood pressure	rs61776678	A	G	-0.10	0.02	2.69E-08	-0.04	0.04	.21
Diastolic blood pressure	rs61789369	A	G	-0.30	0.04	3.07E-12	0.05	0.06	.41
Diastolic blood pressure	rs61861138	A	G	-0.12	0.02	1.45E-09	0.00	0.03	.97
Diastolic blood pressure	rs61917655	T	C	0.22	0.03	3.72E-14	0.08	0.05	.13
Diastolic blood pressure	rs61926181	A	G	-0.48	0.05	2.76E-23	0.04	0.08	.61
Diastolic blood pressure	rs62004794	A	G	-0.10	0.02	3.38E-08	0.05	0.03	.17
Diastolic blood pressure	rs62046623	A	G	0.15	0.02	1.04E-12	0.03	0.04	.41
Diastolic blood pressure	rs62055084	T	C	0.12	0.02	1.29E-08	-0.07	0.04	.07
Diastolic blood pressure	rs62059693	T	C	0.14	0.02	2.03E-08	-0.17	0.05	1.01E-03
Diastolic blood pressure	rs62158170	A	G	0.16	0.02	6.63E-15	-0.03	0.04	.52
Diastolic blood pressure	rs62169544	A	G	-0.12	0.02	4.96E-12	0.03	0.03	.32
Diastolic blood pressure	rs62250937	T	C	0.19	0.03	6.35E-09	-0.03	0.06	.58
Diastolic blood pressure	rs62260779	T	C	0.18	0.03	3.82E-09	0.00	0.07	.98
Diastolic blood pressure	rs62301873	A	G	-0.17	0.03	1.06E-09	-0.01	0.04	.75
Diastolic blood pressure	rs62380354	A	C	0.18	0.03	3.68E-10	-0.12	0.07	.08
Diastolic blood pressure	rs62386482	T	C	0.29	0.03	5.17E-18	0.25	0.08	1.31E-03
Diastolic blood pressure	rs62413470	A	G	-0.17	0.02	9.07E-12	-0.02	0.03	.62
Diastolic blood pressure	rs62434124	T	C	-0.49	0.03	7.83E-47	-0.04	0.05	.41
Diastolic blood pressure	rs62491544	A	G	0.14	0.02	1.77E-10	-0.01	0.04	.72
Diastolic blood pressure	rs62503324	T	C	0.20	0.02	2.11E-23	0.02	0.03	.59
Diastolic blood pressure	rs631089	A	C	0.13	0.02	3.90E-09	-0.04	0.03	.26
Diastolic blood pressure	rs6442608	T	C	-0.13	0.02	7.49E-09	-0.05	0.04	.17
Diastolic blood pressure	rs6456739	T	C	0.13	0.02	3.24E-14	0.00	0.03	.94
Diastolic blood pressure	rs6458374	T	C	0.15	0.02	2.33E-12	0.02	0.04	.62
Diastolic blood pressure	rs6464165	T	C	-0.22	0.02	7.34E-29	-0.05	0.04	.20
Diastolic blood pressure	rs6487076	A	G	0.17	0.02	8.69E-17	-0.01	0.03	.87
Diastolic blood pressure	rs6504163	T	C	-0.18	0.02	6.30E-24	0.00	0.03	.92
Diastolic blood pressure	rs650724	A	G	-0.20	0.03	1.30E-10	-0.04	0.05	.43

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs6511291	T	C	-0.12	0.02	6.89E-11	-0.02	0.03	.60
Diastolic blood pressure	rs6537762	A	C	-0.15	0.02	8.38E-18	0.03	0.03	.39
Diastolic blood pressure	rs6547850	T	G	-0.11	0.02	2.07E-10	0.02	0.03	.39
Diastolic blood pressure	rs6555205	T	C	-0.10	0.02	3.84E-08	-0.03	0.03	.21
Diastolic blood pressure	rs6580970	T	C	-0.17	0.02	4.03E-18	-0.05	0.04	.22
Diastolic blood pressure	rs658780	T	G	-0.12	0.02	4.73E-10	0.02	0.04	.57
Diastolic blood pressure	rs6602177	T	C	-0.12	0.02	6.52E-09	0.01	0.04	.82
Diastolic blood pressure	rs66502847	A	G	0.10	0.02	1.77E-08	-0.03	0.03	.39
Diastolic blood pressure	rs66533014	A	G	-0.14	0.03	1.35E-08	-0.12	0.05	1.98E-02
Diastolic blood pressure	rs66743416	T	C	0.16	0.02	2.83E-11	0.01	0.04	.83
Diastolic blood pressure	rs668459	T	C	-0.11	0.02	1.01E-10	0.01	0.03	.81
Diastolic blood pressure	rs66887589	T	C	-0.16	0.02	1.83E-20	-0.01	0.03	.65
Diastolic blood pressure	rs6708660	T	C	0.12	0.02	3.97E-11	0.09	0.03	9.96E-03
Diastolic blood pressure	rs6711082	T	C	-0.13	0.02	1.82E-12	0.03	0.03	.30
Diastolic blood pressure	rs6713398	A	C	-0.11	0.02	4.61E-09	-0.01	0.04	.86
Diastolic blood pressure	rs6715901	A	G	-0.14	0.02	2.76E-15	0.01	0.03	.86
Diastolic blood pressure	rs6742	T	C	0.18	0.02	1.96E-15	-0.04	0.04	.34
Diastolic blood pressure	rs67535236	A	G	0.17	0.02	1.39E-13	0.05	0.04	.15
Diastolic blood pressure	rs6758859	T	C	0.12	0.02	1.45E-11	0.05	0.03	.05
Diastolic blood pressure	rs68085857	T	C	0.19	0.02	9.83E-21	-0.01	0.03	.73
Diastolic blood pressure	rs6813719	A	G	0.12	0.02	1.58E-11	0.00	0.03	.95
Diastolic blood pressure	rs682681	T	C	-0.15	0.02	4.47E-15	0.03	0.04	.49
Diastolic blood pressure	rs6838416	A	G	-0.12	0.02	8.21E-11	-0.02	0.03	.53
Diastolic blood pressure	rs685926	T	C	0.11	0.02	1.14E-09	-0.13	0.03	1.91E-04
Diastolic blood pressure	rs6875967	A	G	0.13	0.02	1.21E-13	-0.01	0.03	.76
Diastolic blood pressure	rs6889240	A	G	0.12	0.02	1.05E-09	0.00	0.04	.94
Diastolic blood pressure	rs6902805	T	C	0.19	0.03	1.10E-12	-0.04	0.03	.22
Diastolic blood pressure	rs6905288	A	G	0.18	0.02	7.79E-23	0.00	0.03	1.00
Diastolic blood pressure	rs6912283	A	G	-0.13	0.02	2.49E-14	0.01	0.03	.60
Diastolic blood pressure	rs693974	T	C	-0.18	0.02	1.76E-25	-0.01	0.03	.68
Diastolic blood pressure	rs699	A	G	-0.24	0.02	1.30E-40	0.04	0.03	.17
Diastolic blood pressure	rs704067	A	G	-0.10	0.02	3.40E-08	0.00	0.03	1.00
Diastolic blood pressure	rs7043204	A	G	-0.16	0.02	5.41E-11	0.03	0.04	.45
Diastolic blood pressure	rs705696	A	G	-0.10	0.02	1.21E-08	-0.04	0.03	.19
Diastolic blood pressure	rs7082671	A	G	0.50	0.07	5.49E-13	-0.09	0.08	.29
Diastolic blood pressure	rs7087598	T	C	-0.12	0.02	2.49E-09	0.02	0.04	.55
Diastolic blood pressure	rs7090098	A	G	0.10	0.02	4.45E-08	0.06	0.03	.06
Diastolic blood pressure	rs7090758	T	C	-0.15	0.02	6.89E-19	-0.04	0.03	.16
Diastolic blood pressure	rs7101163	T	G	-0.21	0.04	1.95E-08	-0.06	0.06	.31

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs7115331	T	G	-0.13	0.02	3.92E-11	0.07	0.04	.06
Diastolic blood pressure	rs7116797	A	G	0.18	0.03	5.19E-11	0.03	0.04	.53
Diastolic blood pressure	rs7132088	T	C	-0.16	0.02	1.07E-18	0.02	0.04	.52
Diastolic blood pressure	rs71326977	A	C	-0.14	0.02	2.75E-09	0.14	0.03	3.37E-05
Diastolic blood pressure	rs71331756	T	C	0.21	0.04	4.06E-08	0.08	0.07	.25
Diastolic blood pressure	rs7134060	A	G	-0.11	0.02	1.13E-09	0.03	0.03	.31
Diastolic blood pressure	rs7134440	T	C	0.23	0.03	1.75E-12	-0.02	0.06	.72
Diastolic blood pressure	rs7136518	T	C	-0.10	0.02	4.48E-08	-0.09	0.03	1.21E-02
Diastolic blood pressure	rs714785	A	G	-0.26	0.05	1.53E-08	0.09	0.08	.28
Diastolic blood pressure	rs7155504	T	C	0.23	0.03	5.16E-13	0.05	0.06	.41
Diastolic blood pressure	rs7161281	A	G	-0.11	0.02	2.86E-09	-0.01	0.03	.76
Diastolic blood pressure	rs7171498	T	C	-0.11	0.02	6.23E-11	0.04	0.03	.10
Diastolic blood pressure	rs7184016	T	G	0.11	0.02	4.43E-08	0.00	0.03	.93
Diastolic blood pressure	rs7207617	A	G	-0.18	0.02	4.78E-23	0.05	0.03	.18
Diastolic blood pressure	rs7213273	A	G	-0.18	0.02	3.58E-23	0.04	0.03	.29
Diastolic blood pressure	rs7215084	T	C	0.11	0.02	1.17E-10	0.00	0.03	.90
Diastolic blood pressure	rs7217916	A	G	0.11	0.02	5.63E-10	-0.01	0.03	.78
Diastolic blood pressure	rs722783	A	G	-0.21	0.02	9.03E-24	0.04	0.03	.22
Diastolic blood pressure	rs7257694	T	C	0.18	0.02	6.28E-25	-0.03	0.03	.36
Diastolic blood pressure	rs72639047	A	G	-0.15	0.03	2.29E-09	-0.04	0.04	.25
Diastolic blood pressure	rs72663521	A	G	0.13	0.02	1.42E-08	0.06	0.03	.08
Diastolic blood pressure	rs7270523	A	G	0.16	0.03	6.23E-10	-0.06	0.04	.09
Diastolic blood pressure	rs72719149	T	C	-0.13	0.02	6.34E-12	0.02	0.03	.52
Diastolic blood pressure	rs72724166	A	G	0.15	0.02	8.60E-12	0.07	0.03	4.46E-02
Diastolic blood pressure	rs72759896	A	G	0.16	0.03	1.06E-08	0.04	0.06	.58
Diastolic blood pressure	rs72762705	T	C	-0.17	0.02	7.44E-15	-0.03	0.04	.47
Diastolic blood pressure	rs72786098	A	G	-0.33	0.05	3.05E-11	0.07	0.08	.43
Diastolic blood pressure	rs72796684	A	G	0.13	0.02	2.25E-10	-0.07	0.04	.06
Diastolic blood pressure	rs72827873	T	C	0.18	0.03	9.05E-10	0.01	0.04	.83
Diastolic blood pressure	rs72831343	T	G	0.49	0.02	4.77E-88	0.05	0.04	.17
Diastolic blood pressure	rs72833345	A	G	0.33	0.06	1.81E-08	0.00	0.09	.97
Diastolic blood pressure	rs72835405	T	C	-0.15	0.02	5.70E-12	-0.02	0.03	.54
Diastolic blood pressure	rs72842207	T	C	-0.21	0.02	1.10E-23	-0.01	0.03	.67
Diastolic blood pressure	rs72930904	T	C	-0.14	0.02	3.24E-09	0.01	0.04	.74
Diastolic blood pressure	rs72936986	A	C	0.11	0.02	3.33E-09	-0.04	0.03	.19
Diastolic blood pressure	rs72976750	T	C	-0.17	0.03	7.37E-12	0.00	0.05	.93
Diastolic blood pressure	rs72999033	T	C	0.28	0.04	5.95E-15	-0.07	0.06	.26
Diastolic blood pressure	rs73007642	T	C	0.23	0.04	5.65E-09	0.03	0.07	.72
Diastolic blood pressure	rs73033340	A	G	0.53	0.05	5.06E-24	0.00	0.08	.99

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs73175562	A	G	0.21	0.03	3.65E-11	-0.12	0.06	3.70E-02
Diastolic blood pressure	rs73197961	A	G	0.23	0.04	2.06E-08	0.04	0.05	.40
Diastolic blood pressure	rs73203495	A	G	-0.14	0.02	4.59E-09	0.05	0.03	.13
Diastolic blood pressure	rs7321688	A	C	0.15	0.02	1.99E-13	0.00	0.03	.90
Diastolic blood pressure	rs7350752	A	G	-0.15	0.03	1.97E-08	0.04	0.07	.50
Diastolic blood pressure	rs736801	T	C	-0.16	0.02	6.97E-18	0.02	0.03	.58
Diastolic blood pressure	rs73815678	T	C	-0.21	0.04	4.95E-08	-0.02	0.06	.69
Diastolic blood pressure	rs7387891	A	G	0.11	0.02	4.73E-09	0.03	0.03	.33
Diastolic blood pressure	rs74047618	T	C	-0.39	0.07	9.09E-09	-0.05	0.08	.48
Diastolic blood pressure	rs74048200	A	G	-0.20	0.03	1.47E-09	0.03	0.06	.67
Diastolic blood pressure	rs7406973	A	G	-0.12	0.02	1.16E-09	-0.02	0.03	.60
Diastolic blood pressure	rs740956	T	C	0.15	0.02	7.28E-18	-0.03	0.03	.32
Diastolic blood pressure	rs7418070	T	C	-0.14	0.02	1.30E-13	0.02	0.03	.41
Diastolic blood pressure	rs74439044	T	C	-0.35	0.03	1.38E-32	0.11	0.04	1.08E-02
Diastolic blood pressure	rs74734425	T	C	0.40	0.04	3.52E-22	-0.02	0.07	.80
Diastolic blood pressure	rs7479680	A	C	-0.18	0.03	2.39E-12	0.04	0.05	.39
Diastolic blood pressure	rs74926649	A	G	0.44	0.07	4.01E-10	-0.08	0.09	.38
Diastolic blood pressure	rs7500448	A	G	-0.13	0.02	1.14E-10	0.00	0.04	.92
Diastolic blood pressure	rs7513240	T	C	-0.11	0.02	3.11E-09	0.05	0.04	.20
Diastolic blood pressure	rs751984	T	C	0.39	0.03	1.38E-46	-0.07	0.05	.17
Diastolic blood pressure	rs75345455	T	C	-0.23	0.04	4.49E-08	-0.09	0.08	.28
Diastolic blood pressure	rs75397441	T	C	-0.18	0.03	5.47E-09	-0.05	0.07	.51
Diastolic blood pressure	rs75507123	T	G	-0.14	0.03	3.94E-08	-0.07	0.04	.07
Diastolic blood pressure	rs75511781	A	G	-0.37	0.05	2.45E-15	-0.05	0.08	.57
Diastolic blood pressure	rs75660984	A	G	0.25	0.04	5.41E-09	0.02	0.07	.83
Diastolic blood pressure	rs75718977	T	C	0.23	0.04	1.69E-08	-0.01	0.07	.82
Diastolic blood pressure	rs7576060	T	C	-0.10	0.02	2.05E-08	-0.01	0.03	.81
Diastolic blood pressure	rs7602129	T	C	0.12	0.02	1.80E-08	0.01	0.03	.86
Diastolic blood pressure	rs7606205	A	C	-0.13	0.02	2.36E-11	-0.01	0.04	.79
Diastolic blood pressure	rs7608483	A	C	0.12	0.02	2.83E-11	-0.01	0.03	.71
Diastolic blood pressure	rs7611674	T	G	0.16	0.02	1.67E-12	-0.01	0.04	.87
Diastolic blood pressure	rs76164690	T	G	-0.15	0.03	7.19E-10	-0.01	0.04	.71
Diastolic blood pressure	rs7623706	A	G	0.10	0.02	2.84E-08	-0.01	0.03	.84
Diastolic blood pressure	rs762384	T	C	0.15	0.02	1.97E-13	-0.01	0.04	.81
Diastolic blood pressure	rs76326501	A	C	0.36	0.03	2.17E-32	-0.02	0.07	.75
Diastolic blood pressure	rs76452347	T	C	-0.22	0.02	9.37E-23	-0.04	0.04	.39
Diastolic blood pressure	rs7694643	A	G	-0.13	0.02	3.07E-13	-0.01	0.03	.82
Diastolic blood pressure	rs76954792	T	C	0.12	0.02	5.06E-09	-0.03	0.04	.44
Diastolic blood pressure	rs7708525	T	C	-0.14	0.02	4.12E-11	0.05	0.03	.14

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs77151571	T	C	0.33	0.05	8.11E-11	-0.02	0.08	.85
Diastolic blood pressure	rs77307969	T	C	0.37	0.05	2.40E-11	0.14	0.09	.10
Diastolic blood pressure	rs7731530	A	C	0.14	0.02	6.41E-13	0.08	0.04	3.39E-02
Diastolic blood pressure	rs77323038	A	G	-0.30	0.03	2.88E-18	0.07	0.06	.21
Diastolic blood pressure	rs77463299	T	G	-0.22	0.04	1.19E-08	0.12	0.07	.11
Diastolic blood pressure	rs7753695	T	C	0.10	0.02	4.77E-09	0.01	0.03	.81
Diastolic blood pressure	rs7763102	A	C	0.11	0.02	2.61E-08	0.04	0.03	.17
Diastolic blood pressure	rs77651727	T	C	0.20	0.03	5.00E-09	0.07	0.10	.46
Diastolic blood pressure	rs7772884	T	C	0.10	0.02	3.77E-08	-0.03	0.03	.19
Diastolic blood pressure	rs77924615	A	G	-0.32	0.02	3.72E-45	-0.03	0.04	.45
Diastolic blood pressure	rs78151625	T	C	-0.19	0.02	1.04E-15	0.05	0.04	.20
Diastolic blood pressure	rs78474310	A	G	-0.24	0.04	9.74E-09	0.06	0.07	.44
Diastolic blood pressure	rs78550103	A	G	-0.18	0.02	3.48E-13	-0.03	0.04	.35
Diastolic blood pressure	rs78554005	T	G	-0.19	0.03	3.07E-09	0.03	0.06	.55
Diastolic blood pressure	rs78648104	T	C	-0.24	0.03	8.14E-15	0.05	0.06	.43
Diastolic blood pressure	rs786921	A	G	-0.11	0.02	8.63E-11	-0.02	0.03	.39
Diastolic blood pressure	rs78809139	A	G	-0.23	0.03	2.58E-15	0.01	0.05	.88
Diastolic blood pressure	rs78909293	T	C	0.32	0.04	7.31E-14	-0.11	0.06	.06
Diastolic blood pressure	rs78977588	A	C	-0.16	0.03	1.37E-08	-0.03	0.06	.57
Diastolic blood pressure	rs79013608	A	G	-0.28	0.05	2.06E-08	0.00	0.07	.95
Diastolic blood pressure	rs79043825	A	C	0.29	0.05	2.13E-10	-0.13	0.07	.06
Diastolic blood pressure	rs79094191	T	C	-0.40	0.05	2.42E-17	0.18	0.07	7.56E-03
Diastolic blood pressure	rs7917547	A	C	-0.18	0.02	2.11E-16	-0.07	0.04	.09
Diastolic blood pressure	rs79198283	A	G	-0.40	0.07	2.00E-08	0.02	0.10	.86
Diastolic blood pressure	rs7923191	A	G	-0.21	0.02	9.90E-23	0.02	0.04	.65
Diastolic blood pressure	rs7926335	T	C	0.18	0.02	2.05E-20	0.02	0.03	.50
Diastolic blood pressure	rs7927966	T	C	-0.15	0.02	2.85E-14	0.03	0.03	.37
Diastolic blood pressure	rs7933758	T	C	-0.11	0.02	2.58E-09	0.01	0.04	.76
Diastolic blood pressure	rs7951348	T	C	0.15	0.02	1.00E-18	0.04	0.03	.12
Diastolic blood pressure	rs79588470	T	C	0.22	0.04	1.16E-08	0.05	0.09	.61
Diastolic blood pressure	rs7959649	T	C	0.12	0.02	8.14E-09	0.02	0.03	.45
Diastolic blood pressure	rs7965392	A	G	0.11	0.02	4.16E-10	-0.01	0.03	.71
Diastolic blood pressure	rs7969332	A	C	0.10	0.02	2.00E-08	0.01	0.03	.75
Diastolic blood pressure	rs80095680	A	G	-0.16	0.02	2.81E-15	0.01	0.04	.78
Diastolic blood pressure	rs8014182	T	C	-0.19	0.03	3.94E-14	-0.01	0.04	.83
Diastolic blood pressure	rs80190728	A	G	0.34	0.06	1.37E-08	0.04	0.09	.67
Diastolic blood pressure	rs80262267	T	C	-0.29	0.05	1.93E-09	-0.14	0.08	.07
Diastolic blood pressure	rs8046697	T	C	-0.13	0.02	6.10E-13	0.04	0.03	.20
Diastolic blood pressure	rs8067056	T	C	0.15	0.02	8.31E-15	0.06	0.03	2.09E-02

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs8128234	T	C	0.12	0.02	3.97E-08	0.02	0.04	.69
Diastolic blood pressure	rs8192564	A	G	0.21	0.04	8.06E-09	-0.01	0.05	.87
Diastolic blood pressure	rs843078	A	G	-0.11	0.02	1.27E-09	-0.06	0.03	.06
Diastolic blood pressure	rs848309	T	C	-0.14	0.02	2.75E-15	0.01	0.03	.68
Diastolic blood pressure	rs851966	A	G	-0.10	0.02	1.30E-08	0.02	0.03	.50
Diastolic blood pressure	rs871677	T	C	-0.12	0.02	2.23E-10	0.02	0.04	.53
Diastolic blood pressure	rs875106	A	G	-0.13	0.02	1.71E-14	0.00	0.03	.93
Diastolic blood pressure	rs882624	T	C	-0.16	0.02	2.33E-17	-0.03	0.04	.47
Diastolic blood pressure	rs896312	T	C	0.15	0.02	5.72E-16	-0.02	0.03	.43
Diastolic blood pressure	rs908951	T	C	-0.20	0.02	7.73E-28	-0.03	0.03	.30
Diastolic blood pressure	rs911547	A	G	-0.20	0.02	9.48E-16	-0.05	0.03	.15
Diastolic blood pressure	rs9275224	A	G	-0.22	0.02	1.68E-31	0.04	0.03	.10
Diastolic blood pressure	rs9276898	T	C	0.11	0.02	6.37E-09	0.00	0.03	.86
Diastolic blood pressure	rs9321065	A	G	0.11	0.02	5.09E-10	-0.04	0.03	.14
Diastolic blood pressure	rs9326869	T	C	0.11	0.02	3.99E-08	0.01	0.03	.75
Diastolic blood pressure	rs9356837	A	G	-0.13	0.02	3.16E-08	0.00	0.04	.99
Diastolic blood pressure	rs9386780	A	G	0.10	0.02	1.46E-08	-0.02	0.03	.52
Diastolic blood pressure	rs9399136	T	C	0.12	0.02	3.77E-09	0.02	0.04	.60
Diastolic blood pressure	rs9399437	A	G	0.13	0.02	2.09E-10	0.00	0.03	1.00
Diastolic blood pressure	rs9401090	T	C	0.11	0.02	3.76E-08	-0.01	0.04	.74
Diastolic blood pressure	rs9419374	A	G	0.12	0.02	3.44E-10	-0.05	0.04	.15
Diastolic blood pressure	rs9420636	A	G	0.15	0.02	1.76E-11	-0.03	0.04	.53
Diastolic blood pressure	rs9431431	A	G	-0.13	0.02	1.71E-12	0.02	0.03	.50
Diastolic blood pressure	rs9456648	T	C	-0.12	0.02	2.76E-10	-0.02	0.04	.67
Diastolic blood pressure	rs9478282	T	C	-0.20	0.03	8.70E-13	0.02	0.04	.60
Diastolic blood pressure	rs9479509	A	G	-0.12	0.02	1.21E-09	0.01	0.03	.74
Diastolic blood pressure	rs9496614	T	C	0.13	0.02	1.63E-10	0.09	0.04	1.90E-02
Diastolic blood pressure	rs9508495	T	C	-0.19	0.02	1.34E-21	0.05	0.04	.21
Diastolic blood pressure	rs9526707	A	G	-0.12	0.02	6.59E-11	-0.04	0.03	.18
Diastolic blood pressure	rs9532243	A	C	0.13	0.02	1.09E-14	-0.03	0.03	.40
Diastolic blood pressure	rs954767	A	C	-0.15	0.02	4.24E-14	0.03	0.03	.33
Diastolic blood pressure	rs9563529	T	G	0.12	0.02	1.38E-08	0.03	0.03	.27
Diastolic blood pressure	rs9609429	T	C	0.12	0.02	6.32E-10	0.02	0.04	.62
Diastolic blood pressure	rs962369	T	C	0.17	0.02	6.02E-19	0.03	0.03	.30
Diastolic blood pressure	rs9638084	A	G	0.12	0.02	8.51E-11	0.00	0.03	.93
Diastolic blood pressure	rs9683091	A	C	0.12	0.02	1.97E-10	-0.06	0.03	.07
Diastolic blood pressure	rs9716164	T	C	0.10	0.02	7.22E-09	0.01	0.03	.78
Diastolic blood pressure	rs983353	A	G	-0.11	0.02	8.52E-09	0.00	0.03	.93
Diastolic blood pressure	rs9878967	T	C	-0.11	0.02	1.99E-08	0.03	0.04	.48

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Diastolic blood pressure	rs9913079	T	C	-0.15	0.02	4.17E-13	0.04	0.04	.31
Diastolic blood pressure	rs9922726	A	C	0.10	0.02	3.17E-08	-0.01	0.04	.71
Diastolic blood pressure	rs9932220	A	G	-0.16	0.02	3.76E-14	0.03	0.03	.38
Diastolic blood pressure	rs9932866	A	G	0.12	0.02	2.90E-10	-0.02	0.04	.58
Diastolic blood pressure	rs9937801	T	C	0.16	0.02	4.81E-19	0.03	0.03	.19
Diastolic blood pressure	rs9939182	T	C	0.25	0.04	1.29E-09	-0.06	0.06	.31
Diastolic blood pressure	rs994446	A	G	-0.22	0.02	6.01E-25	-0.02	0.03	.60
Diastolic blood pressure	rs9967367	T	C	0.14	0.02	2.04E-13	0.02	0.03	.45
Systolic blood pressure	rs1000423	T	C	0.41	0.03	6.50E-33	-0.03	0.03	.26
Systolic blood pressure	rs10008637	T	C	0.22	0.03	9.24E-13	0.04	0.03	.18
Systolic blood pressure	rs1001484	A	G	0.24	0.04	2.91E-10	-0.01	0.04	.81
Systolic blood pressure	rs10043077	T	C	-0.19	0.03	2.52E-09	-0.03	0.04	.47
Systolic blood pressure	rs10048404	T	C	-0.26	0.03	1.91E-16	0.00	0.04	.99
Systolic blood pressure	rs1006545	T	G	0.68	0.05	3.50E-46	-0.05	0.06	.39
Systolic blood pressure	rs10069690	T	C	0.31	0.04	4.47E-17	-0.02	0.03	.54
Systolic blood pressure	rs1009244	T	C	0.17	0.03	3.64E-08	-0.01	0.03	.70
Systolic blood pressure	rs10183431	T	C	-0.20	0.04	2.10E-08	0.02	0.04	.59
Systolic blood pressure	rs10189186	A	G	0.19	0.03	3.91E-10	-0.01	0.03	.77
Systolic blood pressure	rs1019264	A	G	-0.19	0.03	2.03E-09	-0.04	0.03	.14
Systolic blood pressure	rs10195252	T	C	0.23	0.03	4.21E-14	0.00	0.03	.92
Systolic blood pressure	rs10205364	T	C	0.19	0.03	2.92E-10	-0.02	0.03	.55
Systolic blood pressure	rs10207726	T	C	-0.21	0.03	8.06E-11	-0.02	0.03	.41
Systolic blood pressure	rs10214535	A	G	0.18	0.03	3.35E-08	0.01	0.04	.73
Systolic blood pressure	rs10224210	T	C	-0.38	0.03	1.60E-29	-0.02	0.03	.47
Systolic blood pressure	rs10254757	A	C	0.18	0.03	4.31E-09	-0.02	0.03	.45
Systolic blood pressure	rs10282122	T	C	-0.30	0.03	2.46E-20	0.03	0.04	.39
Systolic blood pressure	rs10421783	A	C	0.19	0.03	1.43E-09	0.00	0.04	.92
Systolic blood pressure	rs10425	A	G	-0.18	0.03	9.99E-09	0.04	0.03	.12
Systolic blood pressure	rs1043069	T	G	0.23	0.03	5.26E-14	0.00	0.04	.96
Systolic blood pressure	rs1044822	T	C	-0.25	0.04	5.16E-09	0.05	0.04	.14
Systolic blood pressure	rs10460108	A	G	0.21	0.03	1.12E-12	-0.05	0.03	.10
Systolic blood pressure	rs10468291	A	C	-0.19	0.03	9.38E-10	0.02	0.03	.50
Systolic blood pressure	rs1047891	A	C	-0.25	0.03	1.37E-14	0.00	0.03	.89
Systolic blood pressure	rs10493891	T	C	-0.28	0.03	1.28E-16	-0.02	0.04	.53
Systolic blood pressure	rs10501410	A	G	0.41	0.06	1.10E-11	0.02	0.05	.60
Systolic blood pressure	rs1057902	T	C	0.20	0.03	4.18E-11	0.00	0.03	.91
Systolic blood pressure	rs10743348	T	C	0.29	0.03	1.06E-17	0.05	0.04	.18
Systolic blood pressure	rs10746963	A	G	-0.22	0.04	2.05E-08	-0.01	0.03	.83
Systolic blood pressure	rs10761530	T	C	0.20	0.03	2.54E-11	-0.02	0.03	.53

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs1076485	T	C	0.34	0.05	1.19E-13	0.04	0.04	.40
Systolic blood pressure	rs10776752	T	G	0.82	0.06	4.61E-46	0.04	0.05	.36
Systolic blood pressure	rs10782230	A	G	0.21	0.03	2.91E-12	-0.04	0.03	.09
Systolic blood pressure	rs10817917	T	C	0.32	0.06	3.52E-08	-0.11	0.05	2.62E-02
Systolic blood pressure	rs10820855	T	C	-0.19	0.03	1.05E-08	-0.04	0.03	.29
Systolic blood pressure	rs10832013	T	G	0.19	0.03	5.88E-09	0.00	0.03	.93
Systolic blood pressure	rs10841520	T	C	-0.25	0.04	4.97E-11	0.02	0.04	.72
Systolic blood pressure	rs10875469	T	C	-0.20	0.03	1.04E-08	-0.01	0.04	.78
Systolic blood pressure	rs10895022	T	C	-0.26	0.04	1.23E-13	-0.03	0.03	.34
Systolic blood pressure	rs10923038	A	C	0.20	0.03	1.36E-10	0.03	0.03	.30
Systolic blood pressure	rs10930127	T	G	0.29	0.04	1.14E-12	-0.04	0.04	.31
Systolic blood pressure	rs10980408	T	C	-0.76	0.08	3.83E-20	0.05	0.06	.42
Systolic blood pressure	rs1098708	A	G	-0.20	0.03	8.21E-11	0.00	0.03	.86
Systolic blood pressure	rs11000852	T	C	0.22	0.03	1.53E-12	0.03	0.03	.30
Systolic blood pressure	rs11044793	T	C	0.30	0.05	1.05E-08	-0.01	0.05	.89
Systolic blood pressure	rs11074093	T	C	-0.19	0.03	4.58E-10	-0.08	0.03	2.42E-02
Systolic blood pressure	rs11105429	T	C	-0.39	0.03	6.77E-31	-0.01	0.04	.71
Systolic blood pressure	rs111346133	T	G	-0.20	0.03	6.85E-10	0.01	0.03	.78
Systolic blood pressure	rs11145807	A	G	0.21	0.03	3.54E-11	-0.03	0.04	.45
Systolic blood pressure	rs11159091	A	G	0.20	0.03	6.79E-11	-0.02	0.03	.48
Systolic blood pressure	rs11168254	T	G	0.42	0.07	1.53E-09	0.17	0.07	1.78E-02
Systolic blood pressure	rs11178008	T	C	0.23	0.04	1.82E-10	0.01	0.03	.69
Systolic blood pressure	rs11187142	T	C	0.33	0.05	2.53E-11	0.00	0.04	.98
Systolic blood pressure	rs11191384	A	G	-0.21	0.04	6.16E-09	0.03	0.03	.39
Systolic blood pressure	rs11191580	T	C	1.10	0.06	7.74E-89	0.06	0.04	.20
Systolic blood pressure	rs11196549	A	G	0.69	0.08	1.58E-18	0.05	0.06	.44
Systolic blood pressure	rs11199840	A	G	0.19	0.03	1.66E-10	0.01	0.03	.81
Systolic blood pressure	rs1122249	A	G	-0.35	0.03	1.54E-27	-0.06	0.03	.10
Systolic blood pressure	rs112260610	T	C	0.26	0.04	2.69E-09	0.02	0.04	.58
Systolic blood pressure	rs11252324	T	G	-0.42	0.06	3.61E-13	0.08	0.05	.07
Systolic blood pressure	rs112729575	A	G	0.38	0.07	4.73E-08	0.16	0.09	.08
Systolic blood pressure	rs1133400	A	G	-0.30	0.04	2.53E-15	0.01	0.03	.66
Systolic blood pressure	rs113656763	A	G	-0.55	0.09	9.50E-10	0.05	0.08	.51
Systolic blood pressure	rs114472600	T	C	-0.46	0.08	1.30E-09	-0.08	0.07	.29
Systolic blood pressure	rs114718455	A	G	-0.51	0.09	1.72E-08	-0.01	0.08	.93
Systolic blood pressure	rs11549015	T	C	0.22	0.04	4.94E-08	0.08	0.04	2.36E-02
Systolic blood pressure	rs115521166	A	G	0.71	0.09	1.54E-15	-0.09	0.09	.30
Systolic blood pressure	rs11563976	T	C	0.26	0.04	3.25E-12	0.01	0.04	.76
Systolic blood pressure	rs11579440	T	C	0.27	0.04	3.24E-10	-0.10	0.04	2.95E-02

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs11592107	A	G	0.30	0.03	1.55E-20	-0.01	0.03	.82
Systolic blood pressure	rs11593126	A	G	-0.44	0.06	7.35E-14	-0.06	0.08	.48
Systolic blood pressure	rs11596720	A	C	-0.30	0.05	2.55E-09	0.01	0.06	.88
Systolic blood pressure	rs11604310	T	C	-0.28	0.04	1.46E-11	0.02	0.04	.70
Systolic blood pressure	rs11609503	A	G	0.35	0.05	4.99E-15	0.04	0.04	.35
Systolic blood pressure	rs11623535	A	G	0.21	0.03	1.02E-09	0.02	0.03	.51
Systolic blood pressure	rs11629850	A	G	0.23	0.03	2.26E-14	-0.03	0.03	.21
Systolic blood pressure	rs11636952	T	C	0.53	0.03	4.22E-59	0.00	0.03	.91
Systolic blood pressure	rs11676702	T	C	-0.33	0.06	1.16E-08	-0.02	0.05	.72
Systolic blood pressure	rs11685352	A	G	-0.23	0.04	6.14E-09	-0.07	0.04	.09
Systolic blood pressure	rs11689667	T	C	0.20	0.03	6.66E-11	-0.01	0.03	.80
Systolic blood pressure	rs116917543	A	C	-0.63	0.09	1.79E-13	-0.06	0.07	.43
Systolic blood pressure	rs11692619	T	C	-0.21	0.03	1.26E-10	-0.02	0.04	.53
Systolic blood pressure	rs11694601	A	G	-0.19	0.03	6.41E-10	0.07	0.03	4.62E-02
Systolic blood pressure	rs117076050	A	G	0.49	0.08	9.76E-10	0.07	0.09	.45
Systolic blood pressure	rs11732143	A	G	0.25	0.03	2.90E-13	0.03	0.04	.48
Systolic blood pressure	rs11771693	A	G	0.18	0.03	1.90E-08	-0.05	0.03	.07
Systolic blood pressure	rs1177701	A	G	0.17	0.03	1.54E-08	0.01	0.03	.81
Systolic blood pressure	rs11862847	A	G	-0.17	0.03	2.29E-08	-0.04	0.03	.12
Systolic blood pressure	rs11868035	A	G	0.19	0.03	1.76E-08	0.05	0.03	.06
Systolic blood pressure	rs11872627	T	C	-0.30	0.04	1.34E-11	0.04	0.05	.45
Systolic blood pressure	rs11874246	T	C	0.29	0.03	3.23E-18	0.02	0.03	.43
Systolic blood pressure	rs11876341	A	G	-0.21	0.03	1.82E-10	0.00	0.04	.90
Systolic blood pressure	rs11983200	A	G	-0.30	0.05	7.20E-09	0.10	0.04	1.72E-02
Systolic blood pressure	rs11983783	T	C	0.18	0.03	9.48E-09	-0.02	0.03	.43
Systolic blood pressure	rs12042924	T	C	-0.18	0.03	2.62E-09	0.03	0.03	.41
Systolic blood pressure	rs12050196	T	C	0.21	0.03	6.31E-12	-0.01	0.03	.68
Systolic blood pressure	rs12050260	T	C	0.23	0.03	1.75E-12	-0.06	0.03	.11
Systolic blood pressure	rs12136922	A	G	0.20	0.03	2.69E-11	0.01	0.03	.58
Systolic blood pressure	rs12143164	T	C	-0.18	0.03	2.73E-08	0.00	0.04	.95
Systolic blood pressure	rs12147633	T	C	-0.54	0.09	2.60E-09	-0.11	0.10	.27
Systolic blood pressure	rs12149704	A	G	0.59	0.07	8.57E-18	-0.06	0.10	.56
Systolic blood pressure	rs12153395	A	G	-0.33	0.05	1.07E-11	0.02	0.07	.77
Systolic blood pressure	rs12221125	T	C	-0.21	0.04	1.95E-08	0.10	0.05	2.78E-02
Systolic blood pressure	rs12368199	A	G	-0.23	0.04	3.18E-08	-0.10	0.05	4.36E-02
Systolic blood pressure	rs12411044	A	G	-0.42	0.04	6.39E-30	0.00	0.04	.99
Systolic blood pressure	rs12446456	T	C	-0.30	0.03	2.97E-23	0.04	0.03	.15
Systolic blood pressure	rs12460791	A	G	0.23	0.04	1.11E-09	-0.03	0.04	.41
Systolic blood pressure	rs1248820	T	C	-0.18	0.03	2.28E-08	0.01	0.03	.58

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs12508469	A	C	0.33	0.06	4.11E-08	0.02	0.07	.78
Systolic blood pressure	rs12509595	T	C	-0.84	0.03	2.55E-138	-0.01	0.03	.78
Systolic blood pressure	rs12540271	A	G	0.23	0.03	3.82E-13	0.01	0.03	.76
Systolic blood pressure	rs12549801	A	G	-0.24	0.04	3.95E-11	0.01	0.04	.72
Systolic blood pressure	rs12570050	T	G	-0.21	0.03	7.11E-10	0.02	0.04	.50
Systolic blood pressure	rs12596945	A	C	0.19	0.03	5.03E-09	-0.01	0.03	.70
Systolic blood pressure	rs12599865	A	G	-0.34	0.06	2.13E-09	0.01	0.06	.82
Systolic blood pressure	rs12630450	A	G	0.29	0.03	7.74E-17	0.00	0.03	.98
Systolic blood pressure	rs12637573	A	G	-0.17	0.03	9.95E-09	-0.01	0.03	.65
Systolic blood pressure	rs12643599	A	G	0.31	0.03	1.23E-23	0.00	0.03	.93
Systolic blood pressure	rs1265102	A	G	-0.28	0.04	1.04E-13	-0.02	0.04	.55
Systolic blood pressure	rs12661604	A	G	0.18	0.03	9.87E-09	-0.02	0.03	.50
Systolic blood pressure	rs12664016	A	G	-0.32	0.06	2.83E-08	0.06	0.04	.13
Systolic blood pressure	rs12668436	T	C	-0.22	0.04	7.88E-10	0.04	0.04	.28
Systolic blood pressure	rs12693982	T	C	0.26	0.03	7.49E-17	-0.04	0.03	.17
Systolic blood pressure	rs12705383	T	C	-0.53	0.09	5.13E-09	-0.11	0.09	.24
Systolic blood pressure	rs12731646	T	C	-0.19	0.03	7.21E-10	0.02	0.03	.53
Systolic blood pressure	rs12752457	A	G	0.18	0.03	1.19E-08	-0.06	0.03	3.14E-02
Systolic blood pressure	rs12758643	T	C	-0.28	0.03	1.13E-16	-0.01	0.03	.65
Systolic blood pressure	rs1275988	T	C	-0.54	0.03	4.42E-69	-0.03	0.04	.40
Systolic blood pressure	rs12901664	T	C	0.18	0.03	9.60E-09	0.04	0.03	.14
Systolic blood pressure	rs12906962	T	C	-0.27	0.03	3.28E-16	0.02	0.03	.62
Systolic blood pressure	rs1290933	A	C	-0.28	0.03	3.17E-18	0.05	0.03	.10
Systolic blood pressure	rs13016772	T	C	0.25	0.04	1.23E-12	0.02	0.03	.45
Systolic blood pressure	rs13050104	A	G	0.19	0.03	1.88E-08	0.03	0.03	.30
Systolic blood pressure	rs13107261	A	G	-0.18	0.03	1.57E-08	0.02	0.03	.48
Systolic blood pressure	rs13143677	A	G	0.22	0.03	1.82E-11	0.06	0.04	.10
Systolic blood pressure	rs13149209	T	C	0.28	0.04	1.97E-14	-0.06	0.03	4.55E-02
Systolic blood pressure	rs13165038	T	C	-0.19	0.03	3.32E-09	0.06	0.04	.10
Systolic blood pressure	rs13179413	T	C	0.22	0.03	1.08E-10	-0.04	0.04	.29
Systolic blood pressure	rs13203975	A	G	0.28	0.05	4.46E-09	0.02	0.04	.53
Systolic blood pressure	rs13207962	A	G	-0.25	0.04	1.78E-12	0.01	0.03	.77
Systolic blood pressure	rs13227860	A	G	0.22	0.03	1.44E-10	-0.01	0.03	.78
Systolic blood pressure	rs13253358	T	C	0.21	0.03	1.13E-10	0.06	0.04	.10
Systolic blood pressure	rs13290326	T	C	-0.21	0.03	1.52E-12	0.00	0.03	.96
Systolic blood pressure	rs1331012	T	G	0.20	0.03	1.49E-09	-0.03	0.04	.40
Systolic blood pressure	rs13322269	A	G	-0.23	0.03	7.21E-13	-0.01	0.04	.74
Systolic blood pressure	rs1332813	T	C	0.22	0.03	2.32E-12	-0.02	0.03	.47
Systolic blood pressure	rs13412750	A	G	-0.29	0.03	2.33E-17	0.04	0.03	.15

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs1347345	A	G	-0.18	0.03	6.92E-09	0.03	0.03	.26
Systolic blood pressure	rs1368298	A	G	0.31	0.03	4.76E-24	0.02	0.03	.46
Systolic blood pressure	rs1375564	T	C	0.26	0.03	2.84E-16	-0.02	0.03	.58
Systolic blood pressure	rs1408945	T	G	-0.32	0.03	8.33E-26	0.01	0.03	.61
Systolic blood pressure	rs141212865	A	C	0.30	0.04	7.68E-15	-0.01	0.04	.70
Systolic blood pressure	rs141947880	T	C	0.45	0.07	4.08E-11	0.09	0.06	.11
Systolic blood pressure	rs1421203	T	C	-0.35	0.04	7.86E-19	0.06	0.03	.07
Systolic blood pressure	rs142378207	A	G	0.34	0.04	1.50E-14	0.04	0.04	.38
Systolic blood pressure	rs142449193	T	C	-0.45	0.07	7.86E-10	0.00	0.06	.96
Systolic blood pressure	rs143026724	A	G	-0.27	0.04	2.44E-13	0.05	0.03	.11
Systolic blood pressure	rs143167197	A	G	-0.43	0.06	2.31E-12	0.06	0.05	.26
Systolic blood pressure	rs1432564	T	C	-0.18	0.03	7.52E-09	-0.01	0.03	.61
Systolic blood pressure	rs1436138	A	G	0.31	0.03	4.73E-23	0.04	0.03	.25
Systolic blood pressure	rs143854972	A	G	0.43	0.07	8.89E-11	0.10	0.06	.11
Systolic blood pressure	rs145211473	A	G	0.75	0.11	1.86E-11	0.00	0.10	.97
Systolic blood pressure	rs145422110	T	C	0.85	0.13	6.13E-11	0.09	0.10	.37
Systolic blood pressure	rs1465091	A	C	-0.36	0.04	1.75E-20	0.01	0.03	.66
Systolic blood pressure	rs146816907	A	G	0.49	0.08	6.80E-10	0.00	0.08	.96
Systolic blood pressure	rs146856510	T	C	0.63	0.08	4.97E-15	-0.02	0.06	.81
Systolic blood pressure	rs148140538	T	C	-0.33	0.06	7.39E-09	0.02	0.05	.62
Systolic blood pressure	rs1486236	A	C	-0.23	0.03	2.96E-13	-0.02	0.03	.61
Systolic blood pressure	rs149193253	T	G	-0.85	0.12	8.07E-13	0.06	0.12	.61
Systolic blood pressure	rs1494649	T	C	0.31	0.03	8.36E-20	-0.04	0.04	.24
Systolic blood pressure	rs1502360	T	G	-0.18	0.03	1.36E-08	0.05	0.04	.14
Systolic blood pressure	rs151117229	T	C	0.61	0.08	3.14E-14	0.11	0.07	.11
Systolic blood pressure	rs1527351	T	C	0.21	0.03	1.00E-10	-0.03	0.03	.22
Systolic blood pressure	rs1535271	A	G	-0.26	0.04	6.78E-12	0.04	0.04	.36
Systolic blood pressure	rs1551355	T	C	0.21	0.04	3.89E-09	-0.03	0.03	.39
Systolic blood pressure	rs1569951	T	C	0.19	0.03	2.40E-09	-0.02	0.03	.53
Systolic blood pressure	rs1575290	T	C	0.20	0.03	5.59E-11	0.02	0.03	.53
Systolic blood pressure	rs1624064	T	C	-0.20	0.03	1.21E-10	-0.03	0.03	.38
Systolic blood pressure	rs1624823	A	G	0.34	0.03	4.26E-27	0.03	0.03	.36
Systolic blood pressure	rs1628869	A	G	0.17	0.03	2.02E-08	0.02	0.03	.43
Systolic blood pressure	rs1630736	T	C	-0.17	0.03	3.52E-08	0.03	0.03	.35
Systolic blood pressure	rs1657880	T	C	-0.29	0.05	7.44E-09	-0.01	0.06	.92
Systolic blood pressure	rs1684174	A	G	-0.19	0.03	4.46E-10	0.01	0.03	.64
Systolic blood pressure	rs16891474	T	G	-0.24	0.04	3.36E-08	-0.03	0.03	.32
Systolic blood pressure	rs16939357	T	C	0.31	0.04	1.37E-13	-0.01	0.03	.75
Systolic blood pressure	rs17035181	T	G	0.31	0.04	7.61E-13	0.03	0.04	.35

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs17115145	T	C	0.18	0.03	7.39E-09	-0.04	0.03	.24
Systolic blood pressure	rs17137303	T	G	-0.36	0.06	2.55E-08	0.02	0.05	.73
Systolic blood pressure	rs17171710	T	C	-0.41	0.05	1.13E-16	-0.05	0.04	.23
Systolic blood pressure	rs17173834	T	G	-0.34	0.05	7.60E-11	-0.01	0.04	.90
Systolic blood pressure	rs17208811	A	G	-0.38	0.06	5.30E-09	0.03	0.05	.60
Systolic blood pressure	rs17245822	A	C	-0.19	0.03	1.15E-09	-0.01	0.03	.73
Systolic blood pressure	rs17249754	A	G	-0.84	0.04	1.25E-97	-0.04	0.03	.24
Systolic blood pressure	rs17257081	A	G	0.23	0.04	6.35E-09	-0.04	0.03	.16
Systolic blood pressure	rs17470652	A	G	0.22	0.03	2.72E-12	-0.01	0.03	.77
Systolic blood pressure	rs17473424	A	G	0.53	0.05	1.25E-26	-0.01	0.04	.90
Systolic blood pressure	rs17607190	T	C	0.28	0.04	7.84E-11	0.05	0.04	.15
Systolic blood pressure	rs17627481	A	G	-0.55	0.07	7.18E-15	-0.03	0.06	.63
Systolic blood pressure	rs17712705	A	G	0.25	0.03	5.72E-15	-0.05	0.03	.09
Systolic blood pressure	rs17760259	T	C	-0.27	0.03	2.25E-18	0.02	0.03	.57
Systolic blood pressure	rs17812022	T	C	-0.36	0.05	5.65E-12	0.03	0.05	.46
Systolic blood pressure	rs17875473	T	C	0.33	0.06	2.66E-09	-0.12	0.08	.11
Systolic blood pressure	rs1790998	A	C	-0.21	0.03	9.10E-12	0.01	0.03	.73
Systolic blood pressure	rs1797912	A	C	0.17	0.03	3.79E-08	-0.03	0.03	.39
Systolic blood pressure	rs179972	T	C	0.18	0.03	5.46E-09	0.06	0.04	.11
Systolic blood pressure	rs1808192	A	G	-0.18	0.03	1.38E-08	-0.09	0.03	9.02E-03
Systolic blood pressure	rs1815614	A	G	0.23	0.03	3.73E-14	-0.02	0.03	.54
Systolic blood pressure	rs1848510	A	G	0.18	0.03	5.72E-09	-0.01	0.03	.62
Systolic blood pressure	rs1848994	A	G	0.20	0.03	1.79E-09	-0.05	0.03	.11
Systolic blood pressure	rs1863798	A	G	-0.21	0.03	1.20E-11	-0.11	0.03	8.19E-04
Systolic blood pressure	rs1871190	T	G	0.20	0.03	1.66E-09	0.00	0.04	.91
Systolic blood pressure	rs1879057	T	C	-0.33	0.04	1.67E-17	0.03	0.03	.25
Systolic blood pressure	rs1888693	A	G	0.39	0.03	4.69E-34	0.02	0.03	.42
Systolic blood pressure	rs1891392	T	C	0.23	0.03	9.02E-12	-0.01	0.03	.68
Systolic blood pressure	rs1891730	T	C	-0.18	0.03	7.74E-09	-0.05	0.03	.14
Systolic blood pressure	rs1906672	A	G	0.30	0.04	1.20E-16	-0.04	0.03	.25
Systolic blood pressure	rs1921151	A	G	0.30	0.04	1.27E-15	0.03	0.03	.38
Systolic blood pressure	rs1957563	T	C	0.36	0.03	2.32E-26	0.01	0.03	.71
Systolic blood pressure	rs1984195	A	G	0.24	0.03	1.77E-15	0.03	0.03	.31
Systolic blood pressure	rs1986971	A	G	0.26	0.03	1.61E-14	0.08	0.04	2.48E-02
Systolic blood pressure	rs1998107	A	G	-0.19	0.03	2.23E-10	0.04	0.03	.13
Systolic blood pressure	rs2009598	A	G	0.22	0.03	4.61E-13	-0.05	0.04	.12
Systolic blood pressure	rs2014408	T	C	0.52	0.04	1.26E-43	0.05	0.04	.25
Systolic blood pressure	rs2029969	A	G	-0.17	0.03	4.51E-08	-0.01	0.03	.79
Systolic blood pressure	rs2032451	T	G	0.54	0.04	1.56E-37	0.03	0.05	.48

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs2055120	A	G	-0.87	0.11	3.75E-16	-0.02	0.11	.86
Systolic blood pressure	rs2060664	T	C	0.22	0.03	4.06E-10	0.02	0.03	.56
Systolic blood pressure	rs2065498	T	G	-0.29	0.04	3.36E-13	-0.02	0.03	.47
Systolic blood pressure	rs2107595	A	G	0.42	0.04	7.37E-24	0.00	0.04	1.00
Systolic blood pressure	rs2118370	A	G	0.23	0.04	2.99E-09	0.03	0.04	.56
Systolic blood pressure	rs2126474	T	G	-0.26	0.03	1.87E-17	-0.03	0.03	.30
Systolic blood pressure	rs2156805	A	G	0.18	0.03	4.64E-09	0.04	0.03	.28
Systolic blood pressure	rs2161967	T	G	0.28	0.03	2.87E-20	-0.02	0.03	.54
Systolic blood pressure	rs2165846	A	G	0.18	0.03	1.03E-08	-0.02	0.03	.60
Systolic blood pressure	rs2177843	T	C	0.44	0.04	2.80E-24	0.05	0.04	.22
Systolic blood pressure	rs2206815	A	C	-0.33	0.03	5.52E-27	-0.06	0.03	.05
Systolic blood pressure	rs2238787	A	G	0.26	0.03	1.45E-14	0.02	0.03	.57
Systolic blood pressure	rs2239046	A	G	0.21	0.03	9.58E-11	-0.01	0.04	.79
Systolic blood pressure	rs2240365	T	C	0.42	0.07	1.33E-09	0.03	0.05	.58
Systolic blood pressure	rs2246754	T	C	0.25	0.04	1.17E-11	-0.03	0.04	.39
Systolic blood pressure	rs2249105	A	G	0.29	0.03	7.63E-21	-0.05	0.03	.06
Systolic blood pressure	rs2273171	T	C	-0.17	0.03	2.64E-08	0.00	0.04	.93
Systolic blood pressure	rs2285426	T	C	-0.27	0.05	1.36E-09	0.03	0.05	.56
Systolic blood pressure	rs2287019	T	C	0.22	0.04	3.68E-08	-0.03	0.04	.44
Systolic blood pressure	rs2289124	A	G	-0.31	0.04	1.14E-13	0.06	0.04	.16
Systolic blood pressure	rs2290263	A	G	0.27	0.04	3.11E-14	-0.01	0.03	.62
Systolic blood pressure	rs2290755	A	C	-0.23	0.04	4.69E-10	-0.07	0.05	.15
Systolic blood pressure	rs2291434	T	G	-0.26	0.03	5.10E-18	-0.04	0.03	.15
Systolic blood pressure	rs2291516	A	G	0.37	0.05	2.17E-13	-0.12	0.04	3.42E-03
Systolic blood pressure	rs2300481	T	C	0.20	0.03	1.56E-10	-0.02	0.03	.65
Systolic blood pressure	rs2306363	T	G	-0.44	0.04	5.24E-31	0.04	0.03	.21
Systolic blood pressure	rs2354862	A	C	0.25	0.03	2.42E-15	-0.02	0.04	.64
Systolic blood pressure	rs2384063	T	C	0.33	0.04	6.33E-20	-0.01	0.03	.70
Systolic blood pressure	rs2395622	T	C	-0.23	0.04	7.17E-09	-0.03	0.03	.33
Systolic blood pressure	rs2417189	T	G	0.24	0.03	1.03E-14	0.00	0.03	.96
Systolic blood pressure	rs2417849	T	C	0.27	0.03	1.82E-18	0.02	0.03	.48
Systolic blood pressure	rs2419077	T	G	0.20	0.03	1.07E-08	-0.03	0.03	.29
Systolic blood pressure	rs2421651	A	G	0.18	0.03	2.68E-09	0.02	0.03	.50
Systolic blood pressure	rs2427574	A	C	0.24	0.03	4.20E-14	-0.03	0.04	.44
Systolic blood pressure	rs246973	T	C	0.25	0.03	1.45E-13	0.09	0.04	2.44E-02
Systolic blood pressure	rs2470004	T	C	-0.35	0.04	1.28E-18	-0.03	0.03	.40
Systolic blood pressure	rs2480171	T	C	0.29	0.05	4.69E-10	-0.07	0.05	.17
Systolic blood pressure	rs2493291	T	C	0.42	0.04	1.85E-21	-0.01	0.04	.76
Systolic blood pressure	rs2498323	A	G	0.32	0.05	8.52E-10	-0.07	0.04	.10

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs2549732	A	G	-0.45	0.06	1.27E-14	0.03	0.05	.50
Systolic blood pressure	rs256741	A	C	0.17	0.03	4.50E-08	0.02	0.03	.35
Systolic blood pressure	rs2610990	A	G	-0.29	0.03	2.86E-17	0.02	0.03	.59
Systolic blood pressure	rs2611774	A	G	0.22	0.03	6.85E-12	-0.05	0.03	.08
Systolic blood pressure	rs2613765	A	G	-0.24	0.03	5.32E-15	-0.04	0.03	.17
Systolic blood pressure	rs2615000	T	C	-0.35	0.04	6.49E-17	-0.01	0.04	.76
Systolic blood pressure	rs2627316	A	G	-0.33	0.03	2.79E-28	0.03	0.03	.25
Systolic blood pressure	rs2643826	T	C	0.45	0.03	1.74E-48	-0.01	0.03	.71
Systolic blood pressure	rs2681489	A	C	0.23	0.04	5.14E-09	0.04	0.05	.41
Systolic blood pressure	rs2740441	A	G	0.22	0.03	7.70E-11	0.02	0.04	.56
Systolic blood pressure	rs2753960	T	G	0.45	0.03	2.66E-47	0.01	0.03	.72
Systolic blood pressure	rs2815063	A	C	0.28	0.05	1.76E-09	-0.03	0.05	.57
Systolic blood pressure	rs2833834	A	C	0.22	0.03	1.22E-10	0.07	0.04	4.39E-02
Systolic blood pressure	rs2838351	A	G	-0.23	0.03	7.41E-14	-0.05	0.03	.16
Systolic blood pressure	rs2851336	T	C	-0.17	0.03	2.11E-08	0.04	0.03	.11
Systolic blood pressure	rs28558491	T	C	-0.21	0.03	7.54E-10	-0.04	0.04	.29
Systolic blood pressure	rs28572357	A	C	-0.27	0.03	6.34E-19	0.00	0.03	.92
Systolic blood pressure	rs28578714	T	C	0.21	0.03	2.53E-10	0.05	0.03	.07
Systolic blood pressure	rs28611491	T	C	0.33	0.06	6.54E-09	0.03	0.05	.62
Systolic blood pressure	rs28621435	A	G	-0.30	0.05	6.47E-10	0.00	0.05	.95
Systolic blood pressure	rs28866311	T	G	-0.28	0.03	5.45E-20	-0.01	0.03	.70
Systolic blood pressure	rs2913920	T	C	0.24	0.04	1.62E-11	-0.07	0.04	.11
Systolic blood pressure	rs2943648	A	G	-0.26	0.03	2.61E-16	0.00	0.03	.86
Systolic blood pressure	rs2957468	A	G	0.25	0.03	1.59E-14	0.00	0.03	.96
Systolic blood pressure	rs2959010	A	G	0.26	0.04	1.49E-09	-0.03	0.04	.52
Systolic blood pressure	rs2966117	T	G	0.22	0.03	1.59E-13	0.02	0.03	.60
Systolic blood pressure	rs296797	T	C	0.22	0.03	2.16E-12	0.01	0.03	.77
Systolic blood pressure	rs2978456	T	C	-0.18	0.03	8.95E-09	0.04	0.03	.14
Systolic blood pressure	rs2979470	T	C	0.20	0.03	4.62E-11	0.01	0.03	.70
Systolic blood pressure	rs2983439	A	G	0.19	0.03	2.53E-10	-0.05	0.04	.16
Systolic blood pressure	rs3058639	T	C	-0.19	0.03	1.68E-08	-0.05	0.04	.20
Systolic blood pressure	rs3098186	T	C	-0.24	0.03	1.41E-15	-0.03	0.03	.31
Systolic blood pressure	rs3128334	A	G	0.21	0.03	1.41E-10	0.02	0.03	.54
Systolic blood pressure	rs3134950	A	C	0.37	0.03	7.67E-30	0.00	0.04	.90
Systolic blood pressure	rs314779	T	G	-0.21	0.03	1.79E-10	-0.02	0.04	.55
Systolic blood pressure	rs34025993	A	G	0.22	0.03	4.71E-13	-0.04	0.03	.27
Systolic blood pressure	rs34072724	A	G	-0.24	0.03	1.37E-15	0.00	0.03	.90
Systolic blood pressure	rs342130	A	G	0.19	0.03	1.34E-09	-0.04	0.03	.24
Systolic blood pressure	rs34297584	A	G	0.79	0.11	2.13E-12	-0.06	0.11	.59

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs34670304	A	G	-0.20	0.03	2.06E-10	0.05	0.04	.16
Systolic blood pressure	rs34688434	A	C	-0.49	0.06	7.90E-17	-0.01	0.07	.82
Systolic blood pressure	rs34703964	A	G	-0.22	0.03	8.46E-12	-0.01	0.04	.77
Systolic blood pressure	rs34727427	T	C	-0.24	0.03	4.02E-13	0.01	0.03	.76
Systolic blood pressure	rs34815435	T	C	-0.23	0.04	7.30E-09	-0.02	0.03	.59
Systolic blood pressure	rs34869093	A	G	-0.22	0.03	1.84E-12	0.05	0.04	.16
Systolic blood pressure	rs34905952	A	G	0.29	0.04	3.00E-12	-0.04	0.04	.30
Systolic blood pressure	rs34941092	A	G	-0.32	0.04	3.23E-14	0.03	0.04	.41
Systolic blood pressure	rs35213536	T	G	0.29	0.04	1.94E-16	0.02	0.03	.55
Systolic blood pressure	rs35413927	A	G	-0.30	0.03	5.25E-20	0.03	0.04	.42
Systolic blood pressure	rs35444	A	G	0.44	0.03	3.47E-45	0.05	0.03	.08
Systolic blood pressure	rs35519679	A	G	0.25	0.04	1.15E-12	-0.01	0.04	.84
Systolic blood pressure	rs35590893	A	G	-0.24	0.03	1.66E-12	-0.04	0.03	.18
Systolic blood pressure	rs35680304	T	C	0.27	0.03	3.76E-18	0.03	0.03	.37
Systolic blood pressure	rs35754956	A	G	-0.29	0.05	1.08E-09	-0.03	0.06	.57
Systolic blood pressure	rs35783704	A	G	-0.46	0.05	8.81E-20	-0.08	0.07	.23
Systolic blood pressure	rs365990	A	G	0.23	0.03	5.95E-13	-0.06	0.03	3.03E-02
Systolic blood pressure	rs3729931	A	G	-0.18	0.03	6.29E-09	-0.02	0.03	.54
Systolic blood pressure	rs3735533	T	C	-0.91	0.06	5.29E-56	-0.06	0.06	.38
Systolic blood pressure	rs3737136	A	G	-0.38	0.04	4.59E-24	0.03	0.03	.40
Systolic blood pressure	rs3741210	A	G	-0.20	0.04	9.26E-09	0.01	0.03	.66
Systolic blood pressure	rs3754944	A	C	0.18	0.03	9.30E-09	0.08	0.03	1.83E-02
Systolic blood pressure	rs3757387	T	C	0.19	0.03	4.01E-10	0.00	0.03	.85
Systolic blood pressure	rs3762946	A	G	0.23	0.04	6.84E-09	0.04	0.05	.36
Systolic blood pressure	rs3763917	A	C	0.21	0.04	1.82E-08	0.01	0.03	.63
Systolic blood pressure	rs377470	T	G	-0.22	0.04	2.01E-09	0.08	0.03	1.21E-02
Systolic blood pressure	rs3783412	A	G	0.20	0.03	1.85E-11	0.06	0.03	.08
Systolic blood pressure	rs3814700	T	C	0.39	0.06	1.18E-11	-0.09	0.06	.14
Systolic blood pressure	rs3821843	A	G	0.34	0.03	6.56E-24	0.03	0.04	.40
Systolic blood pressure	rs3827676	T	C	0.17	0.03	1.17E-08	0.01	0.03	.85
Systolic blood pressure	rs3843712	T	C	-0.34	0.05	1.91E-11	-0.02	0.04	.52
Systolic blood pressure	rs3847320	A	G	-0.19	0.03	2.82E-08	-0.09	0.04	2.19E-02
Systolic blood pressure	rs3860770	A	G	-0.27	0.03	1.20E-15	-0.01	0.03	.73
Systolic blood pressure	rs3915499	A	G	-0.21	0.03	1.36E-10	-0.03	0.04	.34
Systolic blood pressure	rs3918226	T	C	0.66	0.06	8.46E-31	-0.04	0.06	.49
Systolic blood pressure	rs3923060	T	C	0.19	0.03	3.64E-08	0.03	0.04	.44
Systolic blood pressure	rs3980686	T	G	-0.50	0.05	1.03E-24	0.03	0.04	.36
Systolic blood pressure	rs4129585	A	C	0.19	0.03	1.03E-09	0.03	0.03	.34
Systolic blood pressure	rs4143175	T	C	0.22	0.04	5.10E-10	0.00	0.04	.98

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs4233922	A	G	-0.19	0.03	1.90E-08	0.03	0.04	.41
Systolic blood pressure	rs42377	A	G	-0.32	0.03	1.69E-21	0.02	0.03	.37
Systolic blood pressure	rs4245930	A	G	-0.20	0.03	1.04E-10	-0.01	0.03	.63
Systolic blood pressure	rs4286632	A	G	0.21	0.03	7.64E-10	0.03	0.04	.45
Systolic blood pressure	rs4319878	T	C	0.17	0.03	3.77E-08	0.01	0.03	.67
Systolic blood pressure	rs4440615	A	G	-0.22	0.03	1.87E-12	-0.01	0.03	.86
Systolic blood pressure	rs4456714	T	C	-0.19	0.03	3.24E-08	0.01	0.04	.81
Systolic blood pressure	rs4480845	T	C	0.32	0.03	1.85E-23	0.05	0.03	.18
Systolic blood pressure	rs4496141	T	G	0.18	0.03	2.28E-09	0.03	0.03	.27
Systolic blood pressure	rs4553000	T	C	-0.20	0.03	1.09E-11	-0.01	0.03	.58
Systolic blood pressure	rs4573493	T	C	0.17	0.03	3.86E-08	-0.04	0.03	.32
Systolic blood pressure	rs4582532	A	G	-0.20	0.03	3.64E-11	-0.02	0.03	.35
Systolic blood pressure	rs464605	T	C	0.21	0.03	2.08E-09	0.01	0.03	.72
Systolic blood pressure	rs4651224	T	C	0.20	0.03	9.00E-11	-0.04	0.03	.23
Systolic blood pressure	rs4665624	A	C	0.18	0.03	1.35E-08	0.01	0.03	.73
Systolic blood pressure	rs4704514	T	C	0.27	0.03	3.92E-16	-0.07	0.04	.06
Systolic blood pressure	rs4712955	A	G	-0.19	0.03	7.42E-10	0.02	0.04	.58
Systolic blood pressure	rs4725376	A	G	-0.17	0.03	1.41E-08	0.02	0.03	.47
Systolic blood pressure	rs4725995	T	C	0.21	0.03	2.66E-10	-0.07	0.04	.06
Systolic blood pressure	rs4738141	A	G	-0.19	0.03	3.12E-08	-0.01	0.04	.70
Systolic blood pressure	rs4754196	A	G	-0.35	0.03	1.46E-30	-0.04	0.03	.10
Systolic blood pressure	rs4760701	A	G	-0.29	0.04	1.95E-15	0.06	0.03	.06
Systolic blood pressure	rs4793146	A	C	-0.42	0.05	1.34E-15	0.07	0.05	.11
Systolic blood pressure	rs4812536	A	G	0.27	0.03	4.09E-17	-0.01	0.03	.70
Systolic blood pressure	rs4842266	A	G	-0.23	0.03	7.92E-13	0.05	0.04	.19
Systolic blood pressure	rs4873492	T	C	0.34	0.04	1.61E-17	-0.05	0.04	.21
Systolic blood pressure	rs4888408	A	G	0.37	0.03	1.42E-32	-0.07	0.03	5.75E-03
Systolic blood pressure	rs4894188	T	C	0.18	0.03	6.82E-09	-0.06	0.03	.07
Systolic blood pressure	rs4908348	T	G	0.24	0.03	8.07E-13	0.01	0.03	.62
Systolic blood pressure	rs491205	A	G	0.33	0.03	2.58E-27	0.01	0.03	.73
Systolic blood pressure	rs4924570	T	C	-0.21	0.03	1.80E-11	-0.06	0.04	.08
Systolic blood pressure	rs4925159	A	G	0.22	0.03	9.66E-13	0.02	0.03	.44
Systolic blood pressure	rs4926923	T	C	0.32	0.05	2.56E-09	0.02	0.05	.60
Systolic blood pressure	rs4932373	A	C	-0.64	0.03	2.49E-83	0.06	0.04	.14
Systolic blood pressure	rs4948281	A	G	0.27	0.04	6.84E-11	0.01	0.04	.80
Systolic blood pressure	rs4948643	T	C	0.23	0.03	2.40E-11	-0.05	0.04	.19
Systolic blood pressure	rs4952668	A	G	-0.25	0.03	2.60E-15	-0.05	0.04	.16
Systolic blood pressure	rs4952948	A	G	-0.24	0.03	6.51E-15	0.04	0.03	.21
Systolic blood pressure	rs4957026	A	G	0.20	0.03	8.12E-10	0.02	0.03	.48

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs4961293	T	C	0.23	0.03	7.35E-14	0.01	0.03	.72
Systolic blood pressure	rs4980515	T	C	0.23	0.03	9.73E-14	0.02	0.03	.49
Systolic blood pressure	rs525271	T	C	0.23	0.03	1.67E-12	-0.02	0.03	.44
Systolic blood pressure	rs555015	A	G	0.20	0.03	1.00E-10	-0.04	0.03	.20
Systolic blood pressure	rs555625	T	C	0.43	0.06	7.61E-13	0.02	0.05	.67
Systolic blood pressure	rs55678414	T	G	-0.69	0.06	1.56E-27	0.03	0.04	.49
Systolic blood pressure	rs55732192	T	G	-0.34	0.05	1.15E-10	-0.03	0.04	.45
Systolic blood pressure	rs557526	A	G	-0.21	0.04	6.53E-09	-0.03	0.04	.46
Systolic blood pressure	rs55830103	T	G	-0.28	0.04	2.62E-11	0.05	0.05	.35
Systolic blood pressure	rs55924432	T	C	0.27	0.03	5.70E-17	0.02	0.03	.51
Systolic blood pressure	rs55944332	A	G	-0.26	0.04	1.79E-13	0.04	0.04	.36
Systolic blood pressure	rs55978930	A	G	-0.20	0.03	9.98E-10	0.04	0.04	.33
Systolic blood pressure	rs56014530	A	G	0.43	0.03	3.81E-38	0.00	0.04	.97
Systolic blood pressure	rs56085433	A	G	-0.25	0.04	8.21E-09	0.04	0.03	.24
Systolic blood pressure	rs56179563	A	G	-0.22	0.03	2.07E-11	-0.02	0.04	.65
Systolic blood pressure	rs56288724	A	G	-0.22	0.03	2.01E-12	0.07	0.03	9.15E-03
Systolic blood pressure	rs56334134	A	G	0.17	0.03	3.69E-08	-0.01	0.03	.80
Systolic blood pressure	rs56407827	T	C	0.36	0.03	2.78E-26	0.05	0.04	.25
Systolic blood pressure	rs56718386	T	C	0.33	0.05	1.04E-10	0.05	0.05	.28
Systolic blood pressure	rs56719405	A	G	0.36	0.07	3.88E-08	0.12	0.06	4.32E-02
Systolic blood pressure	rs569550	T	G	-0.58	0.03	1.33E-73	-0.04	0.03	.28
Systolic blood pressure	rs571689	T	C	0.23	0.03	6.77E-14	-0.07	0.03	1.03E-02
Systolic blood pressure	rs5742643	T	C	-0.22	0.03	1.53E-10	0.01	0.03	.78
Systolic blood pressure	rs57946343	T	C	0.72	0.04	2.10E-63	0.03	0.04	.38
Systolic blood pressure	rs59400568	A	G	0.22	0.04	2.88E-09	0.08	0.03	1.72E-02
Systolic blood pressure	rs598702	T	C	0.56	0.10	1.77E-08	0.01	0.08	.88
Systolic blood pressure	rs59980837	T	G	1.10	0.12	3.32E-21	-0.17	0.10	.08
Systolic blood pressure	rs60191654	A	G	-0.24	0.04	5.88E-10	-0.05	0.03	.12
Systolic blood pressure	rs6021247	A	G	0.23	0.03	9.80E-15	-0.02	0.03	.53
Systolic blood pressure	rs6031431	A	G	-0.26	0.03	7.05E-18	0.01	0.03	.87
Systolic blood pressure	rs603424	A	G	0.23	0.04	6.67E-09	-0.04	0.04	.27
Systolic blood pressure	rs6039211	A	G	0.28	0.03	1.94E-19	0.02	0.03	.36
Systolic blood pressure	rs6040316	T	C	-0.99	0.15	1.85E-11	-0.03	0.09	.76
Systolic blood pressure	rs604723	T	C	-0.66	0.03	2.55E-83	0.04	0.04	.24
Systolic blood pressure	rs60576102	T	C	0.18	0.03	1.33E-08	0.00	0.04	.98
Systolic blood pressure	rs6058088	T	G	0.28	0.04	1.14E-11	-0.01	0.04	.77
Systolic blood pressure	rs6062324	A	G	-0.33	0.04	1.18E-19	0.01	0.03	.64
Systolic blood pressure	rs60672471	T	C	0.28	0.05	1.49E-08	0.07	0.04	.11
Systolic blood pressure	rs606950	A	G	0.27	0.03	3.23E-18	-0.02	0.04	.50

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs6078093	A	G	-0.18	0.03	1.20E-09	-0.06	0.03	.09
Systolic blood pressure	rs6090907	A	G	-0.39	0.04	1.29E-19	-0.01	0.04	.86
Systolic blood pressure	rs60991988	T	G	0.38	0.05	2.82E-14	0.05	0.04	.20
Systolic blood pressure	rs6108787	T	G	-0.43	0.03	5.38E-46	0.05	0.03	4.35E-02
Systolic blood pressure	rs61148001	T	C	-0.26	0.04	2.10E-12	-0.04	0.04	.32
Systolic blood pressure	rs613872	T	G	-0.22	0.04	1.67E-08	0.00	0.04	.93
Systolic blood pressure	rs6141766	A	G	-0.31	0.04	9.94E-14	-0.04	0.03	.22
Systolic blood pressure	rs61572747	A	G	0.27	0.04	2.86E-14	-0.01	0.04	.80
Systolic blood pressure	rs61772592	A	G	-0.32	0.05	2.86E-12	0.01	0.04	.90
Systolic blood pressure	rs61861138	A	G	-0.24	0.03	7.18E-12	0.00	0.03	.97
Systolic blood pressure	rs61917655	T	C	0.34	0.05	2.68E-11	0.08	0.05	.13
Systolic blood pressure	rs61926302	T	C	0.61	0.08	1.97E-15	-0.07	0.08	.36
Systolic blood pressure	rs61929307	T	G	-0.19	0.03	1.79E-09	0.02	0.03	.55
Systolic blood pressure	rs61942627	T	C	0.36	0.06	8.52E-09	-0.12	0.07	.11
Systolic blood pressure	rs62039771	T	G	0.33	0.05	6.62E-11	-0.05	0.07	.50
Systolic blood pressure	rs62055084	T	C	0.30	0.04	5.94E-16	-0.07	0.04	.07
Systolic blood pressure	rs62059712	T	C	0.49	0.06	9.88E-18	-0.19	0.07	8.74E-03
Systolic blood pressure	rs62076103	A	G	-0.58	0.06	7.91E-22	-0.06	0.06	.31
Systolic blood pressure	rs62248289	T	C	0.28	0.04	1.39E-10	0.09	0.05	.06
Systolic blood pressure	rs62250937	T	C	0.32	0.06	7.28E-09	-0.03	0.06	.58
Systolic blood pressure	rs62301873	A	G	-0.30	0.05	1.60E-09	-0.01	0.04	.75
Systolic blood pressure	rs62309747	A	G	-0.22	0.03	1.59E-13	0.00	0.03	.91
Systolic blood pressure	rs62385094	T	C	0.44	0.06	1.47E-13	0.19	0.08	2.30E-02
Systolic blood pressure	rs62386478	T	C	-0.56	0.09	2.08E-10	0.00	0.08	.99
Systolic blood pressure	rs62421489	A	G	0.40	0.06	8.34E-13	-0.01	0.04	.75
Systolic blood pressure	rs62523863	A	G	0.27	0.04	2.87E-13	0.01	0.04	.80
Systolic blood pressure	rs6438857	T	C	0.27	0.03	3.13E-19	0.01	0.03	.57
Systolic blood pressure	rs6452769	A	G	-0.31	0.04	7.82E-17	0.06	0.04	.13
Systolic blood pressure	rs6457622	A	C	-0.32	0.03	1.33E-21	0.08	0.03	2.09E-03
Systolic blood pressure	rs6466878	T	C	0.20	0.03	1.54E-09	-0.08	0.04	3.23E-02
Systolic blood pressure	rs6485809	T	C	0.38	0.04	3.89E-25	-0.04	0.03	0.25
Systolic blood pressure	rs6490019	A	G	-0.29	0.03	6.61E-21	-0.02	0.03	0.35
Systolic blood pressure	rs6497759	A	G	-0.33	0.04	8.79E-18	-0.03	0.03	0.40
Systolic blood pressure	rs6534834	A	G	0.38	0.05	8.00E-15	0.00	0.04	0.93
Systolic blood pressure	rs6540125	T	G	0.20	0.03	1.21E-10	0.03	0.04	0.42
Systolic blood pressure	rs6567160	T	C	0.22	0.04	3.33E-10	-0.05	0.03	0.08
Systolic blood pressure	rs6570530	T	C	0.22	0.03	6.04E-13	0.00	0.03	0.91
Systolic blood pressure	rs658780	T	G	-0.20	0.03	5.29E-09	0.02	0.04	0.57
Systolic blood pressure	rs6699416	A	G	0.24	0.04	3.03E-09	0.04	0.03	0.20

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs6723509	T	C	0.25	0.04	7.61E-09	0.07	0.04	0.07
Systolic blood pressure	rs6734118	A	C	-0.32	0.04	1.42E-18	-0.02	0.03	0.55
Systolic blood pressure	rs6742	T	C	0.27	0.04	3.48E-12	-0.04	0.04	0.34
Systolic blood pressure	rs674249	T	G	-0.19	0.03	2.71E-08	0.00	0.04	0.94
Systolic blood pressure	rs6771917	T	C	-0.38	0.04	1.39E-26	-0.06	0.04	0.15
Systolic blood pressure	rs67720684	A	C	0.19	0.04	3.85E-08	0.00	0.03	0.99
Systolic blood pressure	rs6785824	A	G	0.17	0.03	3.30E-08	-0.01	0.03	0.74
Systolic blood pressure	rs67885470	T	C	-0.21	0.04	4.12E-08	0.01	0.04	0.77
Systolic blood pressure	rs6788984	A	G	0.30	0.04	3.81E-12	-0.09	0.04	3.05E-02
Systolic blood pressure	rs6806529	A	C	0.18	0.03	1.03E-08	0.01	0.03	0.84
Systolic blood pressure	rs68085857	T	C	0.27	0.04	1.68E-14	-0.01	0.03	0.73
Systolic blood pressure	rs6817306	T	C	-0.24	0.04	2.65E-08	0.01	0.03	0.76
Systolic blood pressure	rs6823767	T	C	-0.21	0.03	4.40E-10	-0.03	0.03	0.37
Systolic blood pressure	rs6870654	T	C	0.21	0.03	7.58E-10	-0.01	0.03	0.82
Systolic blood pressure	rs6884092	A	C	0.28	0.05	3.76E-08	0.03	0.05	0.53
Systolic blood pressure	rs6895454	T	C	-0.33	0.06	9.94E-09	-0.03	0.04	0.54
Systolic blood pressure	rs6905288	A	G	0.19	0.03	1.09E-09	0.00	0.03	1.00
Systolic blood pressure	rs6921291	T	C	0.36	0.04	1.58E-20	0.01	0.03	0.80
Systolic blood pressure	rs6959688	A	G	-0.23	0.03	4.22E-14	-0.08	0.03	1.97E-03
Systolic blood pressure	rs6977848	T	G	-0.18	0.03	2.15E-09	0.05	0.03	.15
Systolic blood pressure	rs699	A	G	-0.37	0.03	5.59E-34	0.04	0.03	.17
Systolic blood pressure	rs6995104	A	G	-0.20	0.03	3.12E-09	0.06	0.04	.15
Systolic blood pressure	rs7002397	T	G	0.23	0.04	2.97E-10	0.00	0.04	.91
Systolic blood pressure	rs7023828	T	C	-0.26	0.03	2.17E-17	-0.04	0.03	.13
Systolic blood pressure	rs702395	T	C	0.23	0.03	3.24E-14	0.02	0.03	.56
Systolic blood pressure	rs704	A	G	-0.17	0.03	1.94E-08	-0.04	0.03	.15
Systolic blood pressure	rs708117	A	G	0.29	0.03	1.59E-21	0.08	0.03	1.15E-03
Systolic blood pressure	rs7081435	T	C	0.22	0.04	1.49E-09	0.03	0.03	.39
Systolic blood pressure	rs7082671	A	G	0.76	0.12	2.50E-10	-0.09	0.08	.29
Systolic blood pressure	rs7083475	A	G	-0.22	0.04	1.49E-08	0.00	0.04	.96
Systolic blood pressure	rs709668	A	G	-0.29	0.04	5.96E-15	-0.01	0.04	.71
Systolic blood pressure	rs7107356	A	G	-0.46	0.03	1.63E-52	0.01	0.03	.80
Systolic blood pressure	rs7125196	T	C	0.44	0.05	7.31E-21	-0.10	0.05	4.42E-02
Systolic blood pressure	rs7132088	T	C	-0.20	0.03	2.59E-10	0.02	0.04	.52
Systolic blood pressure	rs7134677	T	C	-0.39	0.03	4.46E-31	-0.05	0.04	.18
Systolic blood pressure	rs7154723	A	G	0.25	0.03	2.72E-16	-0.02	0.03	.35
Systolic blood pressure	rs7156903	T	G	-0.19	0.03	5.36E-10	-0.04	0.03	.18
Systolic blood pressure	rs7161281	A	G	-0.28	0.03	2.34E-17	-0.01	0.03	.76
Systolic blood pressure	rs71648448	A	G	0.29	0.05	8.53E-10	0.09	0.04	3.71E-02

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs7165200	A	G	0.20	0.03	2.87E-11	-0.04	0.03	.16
Systolic blood pressure	rs718448	T	C	0.21	0.03	2.43E-09	-0.08	0.04	3.78E-02
Systolic blood pressure	rs7186298	T	C	-0.23	0.03	1.88E-14	-0.04	0.03	.16
Systolic blood pressure	rs7187540	A	C	-0.20	0.03	1.02E-08	0.03	0.04	.42
Systolic blood pressure	rs7213273	A	G	-0.40	0.03	6.24E-37	0.04	0.03	.29
Systolic blood pressure	rs7218351	A	G	0.22	0.03	1.34E-11	0.03	0.04	.43
Systolic blood pressure	rs7246865	A	G	0.28	0.03	1.05E-15	-0.02	0.04	.67
Systolic blood pressure	rs7250497	A	G	0.20	0.03	1.16E-10	-0.03	0.03	.31
Systolic blood pressure	rs7255933	A	G	0.23	0.03	2.44E-11	-0.01	0.03	.80
Systolic blood pressure	rs72632819	T	G	0.19	0.03	2.40E-08	-0.04	0.03	.19
Systolic blood pressure	rs72688070	T	C	-0.27	0.04	2.82E-11	-0.03	0.03	.31
Systolic blood pressure	rs7270523	A	G	0.34	0.05	2.65E-13	-0.06	0.04	.09
Systolic blood pressure	rs72741390	T	C	-0.21	0.03	1.87E-09	-0.02	0.04	.62
Systolic blood pressure	rs72786098	A	G	-0.50	0.09	1.18E-08	0.07	0.08	.43
Systolic blood pressure	rs72827805	T	C	0.44	0.05	9.68E-19	0.01	0.04	.79
Systolic blood pressure	rs72834453	T	G	-0.32	0.05	2.95E-12	0.02	0.05	.67
Systolic blood pressure	rs72842207	T	C	-0.20	0.04	3.14E-08	-0.01	0.03	.67
Systolic blood pressure	rs72847885	A	G	0.24	0.03	3.08E-14	-0.03	0.03	.21
Systolic blood pressure	rs72915331	T	G	-0.25	0.05	3.93E-08	0.11	0.04	8.92E-03
Systolic blood pressure	rs72923992	A	G	0.41	0.07	1.61E-08	-0.01	0.07	.89
Systolic blood pressure	rs72931748	A	G	0.40	0.05	6.40E-14	-0.01	0.06	.92
Systolic blood pressure	rs73005719	T	C	-0.42	0.07	3.62E-09	-0.04	0.07	.54
Systolic blood pressure	rs73049928	A	G	-0.24	0.04	1.20E-09	0.04	0.05	.43
Systolic blood pressure	rs7306710	T	C	-0.24	0.03	1.03E-15	0.05	0.03	.10
Systolic blood pressure	rs73075659	A	G	0.40	0.03	5.52E-35	-0.04	0.04	.30
Systolic blood pressure	rs73088122	T	C	-0.26	0.04	4.83E-09	-0.03	0.04	.46
Systolic blood pressure	rs73119684	A	C	-0.21	0.04	2.58E-08	-0.02	0.04	.68
Systolic blood pressure	rs73164066	T	C	-0.22	0.03	3.18E-11	-0.02	0.04	.61
Systolic blood pressure	rs73171158	T	C	-0.18	0.03	3.51E-08	-0.05	0.04	.18
Systolic blood pressure	rs73187288	A	C	-0.28	0.05	1.04E-08	-0.08	0.04	.06
Systolic blood pressure	rs73201163	T	C	-0.27	0.05	3.44E-09	-0.01	0.05	.82
Systolic blood pressure	rs7331680	T	G	0.41	0.04	3.35E-22	-0.02	0.03	.62
Systolic blood pressure	rs733329	T	C	0.30	0.05	3.09E-11	-0.01	0.05	.79
Systolic blood pressure	rs7340705	T	C	-0.24	0.03	4.87E-14	0.01	0.03	.73
Systolic blood pressure	rs73683180	A	G	-0.35	0.05	2.02E-11	0.00	0.05	.94
Systolic blood pressure	rs7377083	A	C	-0.19	0.03	7.67E-10	0.03	0.03	.41
Systolic blood pressure	rs73815678	T	C	-0.47	0.07	8.42E-12	-0.02	0.06	.69
Systolic blood pressure	rs7386288	T	C	-0.29	0.04	3.56E-16	0.03	0.04	.35
Systolic blood pressure	rs7394746	T	C	0.23	0.03	9.08E-14	-0.02	0.03	.45

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs74026308	T	G	0.24	0.04	3.28E-09	-0.03	0.03	.35
Systolic blood pressure	rs74048200	A	G	-0.42	0.06	1.90E-13	0.03	0.06	.67
Systolic blood pressure	rs7406973	A	G	-0.20	0.03	4.14E-09	-0.02	0.03	.60
Systolic blood pressure	rs741066	T	C	0.22	0.03	2.29E-11	-0.02	0.04	.64
Systolic blood pressure	rs7412	T	C	-0.43	0.06	4.04E-14	0.02	0.05	.69
Systolic blood pressure	rs74179970	A	G	0.41	0.06	6.83E-13	-0.01	0.05	.88
Systolic blood pressure	rs743241	A	G	0.20	0.03	1.74E-11	0.01	0.03	.84
Systolic blood pressure	rs74439044	T	C	-0.42	0.05	1.38E-16	0.11	0.04	1.08E-02
Systolic blood pressure	rs74501188	A	G	0.20	0.04	3.00E-08	0.05	0.03	.16
Systolic blood pressure	rs7460241	A	G	-0.43	0.07	1.34E-08	0.01	0.05	.83
Systolic blood pressure	rs7479680	A	C	-0.24	0.04	3.51E-08	0.04	0.05	.39
Systolic blood pressure	rs749209	T	C	-0.17	0.03	3.38E-08	0.05	0.03	.13
Systolic blood pressure	rs74923473	T	C	0.27	0.05	6.78E-09	0.00	0.04	.97
Systolic blood pressure	rs74926649	A	G	0.78	0.12	1.64E-10	-0.08	0.09	.38
Systolic blood pressure	rs7500448	A	G	0.22	0.04	1.98E-10	0.00	0.04	.92
Systolic blood pressure	rs75088623	A	G	0.20	0.03	5.10E-09	0.01	0.04	.86
Systolic blood pressure	rs7514579	A	C	0.22	0.04	5.45E-10	0.02	0.04	.58
Systolic blood pressure	rs7532754	T	C	0.19	0.03	1.12E-09	-0.01	0.03	.69
Systolic blood pressure	rs75345455	T	C	-0.49	0.07	3.26E-11	-0.09	0.08	.28
Systolic blood pressure	rs75497489	T	C	0.24	0.04	1.00E-09	0.06	0.04	.09
Systolic blood pressure	rs75511781	A	G	-0.59	0.08	7.13E-13	-0.05	0.08	.57
Systolic blood pressure	rs75559245	A	G	0.31	0.05	3.69E-09	0.02	0.05	.63
Systolic blood pressure	rs7562	T	C	0.23	0.03	3.26E-14	-0.02	0.03	.58
Systolic blood pressure	rs7578940	T	G	0.18	0.03	1.10E-09	-0.04	0.03	.11
Systolic blood pressure	rs75906312	A	G	-0.29	0.05	4.66E-08	-0.10	0.07	.17
Systolic blood pressure	rs75961402	A	G	0.27	0.04	1.95E-10	0.02	0.04	.52
Systolic blood pressure	rs7600439	A	G	-0.18	0.03	1.19E-09	-0.04	0.03	.19
Systolic blood pressure	rs7606205	A	C	-0.18	0.03	3.06E-08	-0.01	0.04	.79
Systolic blood pressure	rs7615099	A	G	0.19	0.03	3.90E-09	-0.06	0.04	.10
Systolic blood pressure	rs7630377	T	C	0.17	0.03	7.30E-09	-0.02	0.03	.42
Systolic blood pressure	rs76452347	T	C	-0.30	0.04	7.13E-14	-0.04	0.04	.39
Systolic blood pressure	rs7665985	T	C	0.18	0.03	1.35E-08	-0.01	0.03	.79
Systolic blood pressure	rs76719272	T	C	-0.27	0.05	2.97E-09	0.11	0.06	.07
Systolic blood pressure	rs767717	T	C	0.22	0.03	1.92E-12	-0.02	0.03	.47
Systolic blood pressure	rs7683728	T	C	-0.37	0.03	2.43E-33	0.04	0.03	.23
Systolic blood pressure	rs77151571	T	C	0.57	0.09	1.24E-10	-0.02	0.08	.85
Systolic blood pressure	rs7725413	T	C	-0.20	0.04	3.07E-08	-0.02	0.04	.59
Systolic blood pressure	rs77307969	T	C	0.58	0.10	2.28E-09	0.14	0.09	.10
Systolic blood pressure	rs77402945	T	C	-0.24	0.04	2.25E-08	-0.05	0.04	.15

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs7751856	A	C	0.20	0.03	1.68E-09	-0.05	0.03	4.14E-02
Systolic blood pressure	rs77594100	A	C	-0.51	0.09	1.47E-08	-0.04	0.08	.62
Systolic blood pressure	rs7765526	A	G	0.20	0.03	5.88E-11	0.03	0.03	.36
Systolic blood pressure	rs7772884	T	C	0.17	0.03	2.24E-08	-0.03	0.03	.19
Systolic blood pressure	rs778124	A	G	0.30	0.03	1.45E-21	0.02	0.03	.36
Systolic blood pressure	rs77924615	A	G	-0.41	0.04	1.12E-25	-0.03	0.04	.45
Systolic blood pressure	rs78109339	T	C	0.51	0.09	2.84E-08	-0.10	0.07	.19
Systolic blood pressure	rs78405116	T	G	-0.72	0.12	2.51E-09	-0.07	0.09	.42
Systolic blood pressure	rs78426429	A	G	0.27	0.05	1.15E-08	0.00	0.06	.97
Systolic blood pressure	rs78474310	A	G	-0.47	0.07	1.51E-10	0.06	0.07	.44
Systolic blood pressure	rs78550103	A	G	-0.28	0.04	4.45E-11	-0.03	0.04	.35
Systolic blood pressure	rs78638044	A	G	0.28	0.05	1.16E-08	0.08	0.06	.23
Systolic blood pressure	rs78648104	T	C	-0.43	0.05	2.37E-15	0.05	0.06	.43
Systolic blood pressure	rs786923	T	C	-0.31	0.03	2.83E-23	-0.03	0.03	.35
Systolic blood pressure	rs7874646	T	C	-0.21	0.04	4.25E-08	0.06	0.03	.06
Systolic blood pressure	rs79033729	T	C	0.58	0.08	3.14E-12	-0.14	0.08	.08
Systolic blood pressure	rs79092282	T	C	-0.26	0.05	4.02E-09	-0.06	0.04	.12
Systolic blood pressure	rs79119657	A	G	-0.23	0.04	2.29E-09	-0.06	0.04	.15
Systolic blood pressure	rs79149713	A	C	-0.20	0.04	2.54E-08	0.01	0.05	.82
Systolic blood pressure	rs79177297	T	G	0.34	0.06	9.61E-09	-0.01	0.05	.91
Systolic blood pressure	rs79208229	T	G	0.38	0.06	1.99E-11	0.02	0.07	.75
Systolic blood pressure	rs7923191	A	G	-0.37	0.04	1.10E-22	0.02	0.04	.65
Systolic blood pressure	rs7925678	A	G	-0.19	0.03	2.74E-08	0.01	0.03	.61
Systolic blood pressure	rs7926335	T	C	0.31	0.03	2.52E-20	0.02	0.03	.50
Systolic blood pressure	rs7927515	A	C	0.23	0.03	1.05E-12	-0.05	0.03	.17
Systolic blood pressure	rs79682447	A	G	0.50	0.08	6.02E-10	-0.08	0.06	.20
Systolic blood pressure	rs7976167	T	C	0.18	0.03	3.81E-08	0.09	0.03	1.00E-02
Systolic blood pressure	rs79932633	A	C	-0.27	0.05	3.10E-08	-0.03	0.06	.65
Systolic blood pressure	rs8003103	A	G	-0.18	0.03	3.60E-08	-0.02	0.03	.46
Systolic blood pressure	rs80045342	A	G	-0.33	0.06	2.12E-08	0.06	0.06	.30
Systolic blood pressure	rs8014182	T	C	-0.33	0.04	5.23E-14	-0.01	0.04	.83
Systolic blood pressure	rs8065350	A	G	0.22	0.04	2.89E-09	0.03	0.04	.44
Systolic blood pressure	rs8077276	A	G	-0.29	0.03	5.15E-21	0.03	0.03	.32
Systolic blood pressure	rs8142376	T	C	0.17	0.03	2.20E-08	-0.01	0.03	.67
Systolic blood pressure	rs848309	T	C	-0.25	0.03	5.98E-16	0.01	0.03	.68
Systolic blood pressure	rs848445	T	C	-0.20	0.03	2.28E-09	-0.01	0.03	.76
Systolic blood pressure	rs849138	A	G	-0.19	0.03	3.99E-10	-0.02	0.03	.52
Systolic blood pressure	rs851966	A	G	-0.18	0.03	7.02E-09	0.02	0.03	.50
Systolic blood pressure	rs863930	T	G	-0.19	0.03	3.98E-10	-0.03	0.03	.31

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
Systolic blood pressure	rs869396	A	C	-0.21	0.03	4.12E-12	-0.03	0.03	.33
Systolic blood pressure	rs871004	A	G	0.23	0.03	1.65E-13	-0.01	0.03	.83
Systolic blood pressure	rs879619	A	G	-0.30	0.04	1.82E-11	-0.03	0.04	.51
Systolic blood pressure	rs908951	T	C	-0.23	0.03	7.14E-13	-0.03	0.03	.30
Systolic blood pressure	rs911547	A	G	-0.31	0.04	7.76E-13	-0.05	0.03	.15
Systolic blood pressure	rs9257594	T	C	0.22	0.04	1.93E-08	0.05	0.03	.07
Systolic blood pressure	rs9294987	T	C	-0.19	0.03	6.25E-10	0.05	0.03	.10
Systolic blood pressure	rs9298280	T	G	-0.22	0.03	4.51E-11	-0.02	0.04	.67
Systolic blood pressure	rs9311344	A	G	0.23	0.04	7.52E-09	0.04	0.03	.25
Systolic blood pressure	rs9349379	A	G	0.27	0.03	1.31E-17	0.02	0.03	.40
Systolic blood pressure	rs9394578	A	C	0.19	0.03	2.56E-08	0.02	0.03	.47
Systolic blood pressure	rs9401913	A	G	0.52	0.03	3.66E-65	0.03	0.03	.29
Systolic blood pressure	rs9449350	T	C	-0.22	0.03	1.19E-11	-0.02	0.03	.54
Systolic blood pressure	rs9508495	T	C	-0.36	0.04	6.34E-24	0.05	0.04	.21
Systolic blood pressure	rs952160	T	C	-0.18	0.03	9.49E-09	-0.01	0.03	.75
Systolic blood pressure	rs9526707	A	G	-0.20	0.03	2.77E-10	-0.04	0.03	.18
Systolic blood pressure	rs9532243	A	C	0.22	0.03	8.17E-14	-0.03	0.03	.40
Systolic blood pressure	rs954767	A	C	-0.21	0.03	7.53E-10	0.03	0.03	.33
Systolic blood pressure	rs9549328	T	C	0.29	0.04	7.91E-16	-0.03	0.03	.27
Systolic blood pressure	rs960225	A	C	-0.39	0.05	6.92E-14	-0.08	0.06	.19
Systolic blood pressure	rs9608690	A	G	-0.37	0.06	6.13E-10	-0.06	0.06	.31
Systolic blood pressure	rs962369	T	C	0.22	0.03	1.43E-11	0.03	0.03	.30
Systolic blood pressure	rs9634314	A	G	-0.39	0.06	4.43E-12	0.01	0.04	.90
Systolic blood pressure	rs9650417	A	G	-0.20	0.04	2.16E-08	0.01	0.04	.79
Systolic blood pressure	rs9716164	T	C	0.18	0.03	3.40E-09	0.01	0.03	.78
Systolic blood pressure	rs974266	A	C	0.27	0.03	7.73E-19	0.01	0.03	.67
Systolic blood pressure	rs977184	T	C	-0.18	0.03	4.86E-09	0.01	0.04	.78
Systolic blood pressure	rs9869437	A	C	-0.20	0.03	3.22E-10	-0.07	0.03	3.99E-02
Systolic blood pressure	rs9875380	T	C	-0.18	0.03	6.53E-09	0.02	0.03	.46
Systolic blood pressure	rs9885577	T	C	0.23	0.03	6.53E-13	0.03	0.03	.39
Systolic blood pressure	rs9889153	A	G	0.20	0.04	3.11E-08	0.00	0.03	.89
Systolic blood pressure	rs9903182	A	G	-0.42	0.05	9.61E-16	0.04	0.04	.39
Systolic blood pressure	rs994446	A	G	-0.35	0.04	1.87E-20	-0.02	0.03	.60
Systolic blood pressure	rs9970807	T	C	-0.31	0.05	1.61E-09	-0.06	0.04	.16
C-reactive protein	rs10027182	G	A	0.01	0.00	2.20E-08	0.02	0.04	.63
C-reactive protein	rs10083137	A	G	0.05	0.01	5.20E-20	-0.02	0.06	.79
C-reactive protein	rs10095930	C	T	-0.03	0.00	1.90E-38	-0.03	0.04	.47
C-reactive protein	rs10106298	G	A	-0.01	0.00	7.20E-12	-0.02	0.03	.49
C-reactive protein	rs1045075	G	A	-0.01	0.00	1.30E-08	-0.01	0.03	.76

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs10453441	A	G	-0.01	0.00	4.10E-08	-0.05	0.03	.12
C-reactive protein	rs10485179	C	T	0.02	0.00	5.90E-13	0.02	0.03	.52
C-reactive protein	rs1052067	G	A	0.02	0.00	1.50E-11	0.04	0.03	.22
C-reactive protein	rs1053005	T	C	0.02	0.00	1.10E-09	0.04	0.04	.32
C-reactive protein	rs10750766	C	A	-0.01	0.00	6.00E-10	0.02	0.03	.57
C-reactive protein	rs10752652	T	C	-0.02	0.00	1.70E-18	-0.06	0.03	4.82E-02
C-reactive protein	rs10760691	A	G	-0.02	0.00	4.10E-14	0.00	0.03	.99
C-reactive protein	rs10802505	A	G	-0.02	0.00	1.10E-19	-0.01	0.04	.76
C-reactive protein	rs10806385	A	G	0.01	0.00	4.70E-09	-0.02	0.03	.54
C-reactive protein	rs10864086	C	A	0.02	0.00	4.90E-13	-0.03	0.04	.40
C-reactive protein	rs10880872	T	C	-0.01	0.00	1.50E-08	-0.01	0.03	.72
C-reactive protein	rs10908428	C	T	0.01	0.00	5.80E-09	0.00	0.03	.90
C-reactive protein	rs10924372	C	T	0.01	0.00	6.00E-12	-0.04	0.03	.21
C-reactive protein	rs10925019	C	T	-0.03	0.00	8.40E-28	0.04	0.04	.32
C-reactive protein	rs10933240	C	T	-0.02	0.00	1.70E-09	0.00	0.03	.89
C-reactive protein	rs10957159	G	A	0.02	0.00	2.50E-08	0.05	0.04	.23
C-reactive protein	rs11000760	G	A	-0.01	0.00	5.20E-13	0.05	0.03	4.27E-02
C-reactive protein	rs11012732	A	G	-0.01	0.00	1.20E-09	-0.03	0.03	.28
C-reactive protein	rs11047139	C	T	-0.01	0.00	1.40E-10	0.02	0.03	.46
C-reactive protein	rs11065026	C	T	0.04	0.00	4.90E-25	0.00	0.07	.98
C-reactive protein	rs11065390	G	A	-0.06	0.01	8.00E-17	0.03	0.07	.71
C-reactive protein	rs11065422	G	A	0.04	0.00	5.10E-65	-0.06	0.04	.08
C-reactive protein	rs11078597	T	C	0.02	0.00	4.20E-13	0.06	0.03	.06
C-reactive protein	rs111247170	C	T	-0.06	0.01	1.90E-27	0.04	0.08	.63
C-reactive protein	rs111313184	A	G	-0.03	0.00	2.30E-29	0.03	0.05	.47
C-reactive protein	rs111363146	T	C	-0.02	0.00	9.70E-09	-0.06	0.04	.13
C-reactive protein	rs11158975	C	A	-0.01	0.00	2.20E-10	0.03	0.04	.45
C-reactive protein	rs112001928	A	G	-0.04	0.01	7.20E-10	-0.01	0.08	.86
C-reactive protein	rs11203006	A	G	-0.02	0.00	1.50E-08	0.00	0.04	.97
C-reactive protein	rs11210869	A	G	0.01	0.00	1.10E-12	0.07	0.03	1.08E-02
C-reactive protein	rs11222703	C	T	-0.01	0.00	3.50E-08	-0.04	0.03	.21
C-reactive protein	rs11231161	A	G	0.01	0.00	3.60E-09	-0.06	0.03	3.91E-02
C-reactive protein	rs112585178	G	T	0.06	0.01	1.70E-29	-0.03	0.10	.74
C-reactive protein	rs112695172	G	A	-0.07	0.01	1.70E-22	0.01	0.09	.89
C-reactive protein	rs112750178	T	C	-0.01	0.00	2.20E-09	0.03	0.04	.47
C-reactive protein	rs112819557	T	C	0.07	0.01	7.20E-30	-0.02	0.07	.79
C-reactive protein	rs112843476	G	A	0.03	0.00	4.40E-10	0.06	0.06	.32
C-reactive protein	rs112873424	T	C	0.05	0.01	9.80E-15	0.00	0.08	.99
C-reactive protein	rs113004644	C	T	-0.02	0.00	7.40E-09	0.08	0.05	.13

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs113638533	C	T	-0.03	0.00	1.10E-11	0.04	0.06	.46
C-reactive protein	rs113720253	A	G	-0.03	0.00	3.10E-41	-0.04	0.03	.19
C-reactive protein	rs114294368	C	T	-0.04	0.01	1.20E-10	-0.01	0.08	.95
C-reactive protein	rs114943742	T	C	0.06	0.01	3.20E-18	0.06	0.09	.55
C-reactive protein	rs114947103	T	C	-0.02	0.00	6.00E-09	-0.04	0.03	.27
C-reactive protein	rs115023714	G	A	0.03	0.01	4.50E-08	0.09	0.08	.27
C-reactive protein	rs115106760	G	A	0.05	0.01	1.60E-13	0.10	0.10	.32
C-reactive protein	rs11568828	T	C	-0.02	0.00	5.90E-09	-0.05	0.06	.38
C-reactive protein	rs11577023	T	C	0.02	0.00	2.30E-13	-0.03	0.04	.35
C-reactive protein	rs11582273	C	T	-0.02	0.00	3.70E-13	-0.07	0.04	.08
C-reactive protein	rs116059394	A	G	-0.05	0.00	3.60E-27	-0.05	0.09	.54
C-reactive protein	rs11611673	A	G	0.09	0.01	8.50E-43	0.03	0.08	.66
C-reactive protein	rs116141616	G	A	-0.03	0.01	1.30E-08	-0.01	0.08	.89
C-reactive protein	rs116248193	A	G	-0.05	0.01	1.60E-16	0.07	0.07	.30
C-reactive protein	rs11648261	A	G	-0.01	0.00	6.10E-09	-0.01	0.03	.75
C-reactive protein	rs116493147	C	A	-0.05	0.01	1.70E-14	-0.06	0.07	.41
C-reactive protein	rs11667640	C	T	-0.05	0.00	5.70E-28	0.02	0.05	.71
C-reactive protein	rs116702045	G	A	0.13	0.01	6.90E-134	-0.11	0.10	.29
C-reactive protein	rs11672020	A	G	0.02	0.00	2.30E-13	-0.01	0.03	.84
C-reactive protein	rs11682186	C	T	-0.01	0.00	8.20E-09	0.03	0.03	.38
C-reactive protein	rs11693537	G	A	-0.01	0.00	3.00E-12	0.04	0.03	.12
C-reactive protein	rs11693697	T	C	0.02	0.00	1.80E-08	-0.02	0.05	.64
C-reactive protein	rs116971887	G	T	0.12	0.00	1.70E-121	-0.03	0.08	.66
C-reactive protein	rs11708067	A	G	-0.01	0.00	1.80E-09	0.02	0.03	.55
C-reactive protein	rs11777625	T	C	-0.02	0.00	5.80E-24	0.00	0.03	.99
C-reactive protein	rs117803005	A	G	0.05	0.01	4.10E-10	-0.03	0.08	.69
C-reactive protein	rs117976328	G	A	0.07	0.01	5.60E-33	-0.08	0.08	.26
C-reactive protein	rs11813176	A	G	-0.02	0.00	6.90E-09	-0.05	0.03	.14
C-reactive protein	rs1186055	C	A	0.01	0.00	1.80E-10	0.03	0.04	.50
C-reactive protein	rs11881756	T	C	-0.03	0.00	3.50E-28	0.02	0.06	.73
C-reactive protein	rs12054057	G	A	-0.02	0.00	4.80E-08	-0.01	0.04	.87
C-reactive protein	rs12059682	T	C	-0.05	0.00	4.50E-75	-0.02	0.03	.48
C-reactive protein	rs12083537	A	G	0.06	0.00	2.00E-147	0.02	0.03	.60
C-reactive protein	rs12114452	T	C	-0.02	0.00	1.60E-08	-0.03	0.05	.61
C-reactive protein	rs12138486	C	T	-0.02	0.00	2.60E-12	0.02	0.04	.69
C-reactive protein	rs12140107	A	G	0.04	0.00	4.20E-42	0.02	0.05	.77
C-reactive protein	rs12141189	T	C	0.02	0.00	5.50E-21	-0.06	0.03	.06
C-reactive protein	rs1222925	C	T	-0.01	0.00	3.40E-09	-0.05	0.04	.21
C-reactive protein	rs12406117	G	A	-0.01	0.00	8.10E-09	0.00	0.03	.91

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs12443906	C	T	0.01	0.00	3.10E-09	0.04	0.04	.27
C-reactive protein	rs12448756	A	G	0.02	0.00	1.90E-20	0.01	0.04	.67
C-reactive protein	rs12516176	T	C	-0.02	0.00	3.00E-11	0.01	0.04	.80
C-reactive protein	rs12605081	A	G	-0.01	0.00	6.40E-09	-0.01	0.03	.83
C-reactive protein	rs1264368	G	A	-0.02	0.00	3.50E-13	-0.01	0.04	.82
C-reactive protein	rs12726645	G	A	-0.02	0.00	9.00E-11	-0.02	0.03	.49
C-reactive protein	rs1290898	G	A	-0.02	0.00	2.40E-08	0.06	0.07	.37
C-reactive protein	rs1292067	G	T	0.02	0.00	1.00E-24	0.03	0.03	.45
C-reactive protein	rs12966114	T	G	0.01	0.00	2.10E-09	0.02	0.04	.50
C-reactive protein	rs12993460	A	C	-0.01	0.00	2.40E-11	0.04	0.03	.20
C-reactive protein	rs13058527	G	A	0.01	0.00	6.30E-11	0.04	0.04	.27
C-reactive protein	rs13062093	T	G	-0.01	0.00	1.40E-08	-0.03	0.03	.20
C-reactive protein	rs13066686	C	A	0.01	0.00	1.60E-11	-0.01	0.03	.84
C-reactive protein	rs13081778	A	G	-0.01	0.00	1.90E-12	0.04	0.04	.30
C-reactive protein	rs13106834	A	G	0.01	0.00	1.20E-10	-0.01	0.03	.69
C-reactive protein	rs13279694	A	G	0.03	0.00	3.70E-10	-0.02	0.08	.84
C-reactive protein	rs13336129	T	C	0.03	0.00	2.20E-11	0.00	0.08	.96
C-reactive protein	rs1351787	G	A	0.02	0.00	3.60E-09	-0.02	0.04	.50
C-reactive protein	rs1362489	T	C	0.01	0.00	1.70E-09	0.00	0.03	.94
C-reactive protein	rs1371614	C	T	0.03	0.00	2.60E-29	0.01	0.03	.74
C-reactive protein	rs138692741	C	T	0.04	0.01	7.20E-13	0.01	0.09	.93
C-reactive protein	rs1391789	G	A	-0.02	0.00	3.80E-15	0.03	0.03	.37
C-reactive protein	rs140502640	C	T	-0.03	0.00	2.30E-08	0.01	0.07	.91
C-reactive protein	rs141106010	C	T	-0.07	0.01	7.50E-40	0.07	0.09	.43
C-reactive protein	rs1412444	C	T	-0.03	0.00	1.10E-35	0.00	0.03	.99
C-reactive protein	rs143786651	C	T	0.04	0.00	1.30E-20	-0.01	0.07	.93
C-reactive protein	rs1441043	A	G	-0.01	0.00	6.00E-10	0.05	0.04	.18
C-reactive protein	rs145280738	C	T	-0.07	0.00	7.70E-53	0.12	0.09	.17
C-reactive protein	rs146470402	C	T	0.04	0.00	9.00E-19	0.02	0.10	.84
C-reactive protein	rs1465338	C	T	0.04	0.00	2.10E-79	0.02	0.03	.55
C-reactive protein	rs147830103	G	A	-0.04	0.01	5.60E-10	0.02	0.09	.87
C-reactive protein	rs148023052	G	A	-0.03	0.00	2.20E-19	-0.04	0.05	.43
C-reactive protein	rs148692790	C	T	-0.11	0.01	5.00E-63	0.03	0.11	.80
C-reactive protein	rs1492914	T	C	-0.01	0.00	3.50E-10	-0.04	0.04	.37
C-reactive protein	rs1495017	A	C	0.01	0.00	6.70E-09	0.03	0.04	.45
C-reactive protein	rs1495745	T	G	0.01	0.00	9.00E-12	-0.04	0.03	.14
C-reactive protein	rs149667424	C	T	-0.03	0.00	1.30E-09	0.03	0.06	.62
C-reactive protein	rs150194856	C	T	-0.04	0.01	1.30E-14	-0.07	0.07	.33
C-reactive protein	rs150832462	C	T	0.03	0.00	3.00E-08	-0.09	0.06	.13

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs1546721	T	C	0.01	0.00	3.40E-08	0.00	0.03	.94
C-reactive protein	rs1562302	G	A	-0.03	0.00	4.50E-26	-0.02	0.04	.63
C-reactive protein	rs157512	T	C	-0.01	0.00	1.10E-08	0.01	0.03	.68
C-reactive protein	rs157580	G	A	0.08	0.00	1.00E-200	0.01	0.03	.60
C-reactive protein	rs1635852	T	C	0.01	0.00	1.00E-11	-0.01	0.03	.57
C-reactive protein	rs1647254	A	G	0.02	0.00	1.20E-12	0.06	0.04	.17
C-reactive protein	rs1688031	T	C	0.02	0.00	1.00E-12	-0.01	0.04	.90
C-reactive protein	rs17040284	G	A	-0.01	0.00	2.30E-08	0.03	0.04	.51
C-reactive protein	rs17138478	C	A	-0.03	0.00	2.90E-28	-0.09	0.06	.12
C-reactive protein	rs17308476	C	T	-0.02	0.00	1.80E-11	-0.01	0.05	.75
C-reactive protein	rs17366139	C	A	-0.02	0.00	1.30E-09	0.00	0.06	.00
C-reactive protein	rs17400019	A	G	0.02	0.00	7.00E-10	0.02	0.06	.81
C-reactive protein	rs17417252	A	G	-0.01	0.00	4.70E-09	-0.04	0.03	.19
C-reactive protein	rs174373	T	C	0.02	0.00	1.20E-09	-0.03	0.04	.41
C-reactive protein	rs17539995	G	A	-0.02	0.00	1.00E-12	-0.03	0.05	.58
C-reactive protein	rs17661793	G	A	-0.03	0.00	1.20E-12	0.02	0.07	.76
C-reactive protein	rs17717355	G	T	-0.03	0.00	1.00E-16	0.02	0.06	.75
C-reactive protein	rs1800693	T	C	0.02	0.00	4.50E-23	-0.02	0.03	.44
C-reactive protein	rs1800919	A	C	0.02	0.00	4.20E-18	-0.01	0.04	.83
C-reactive protein	rs1800961	C	T	0.11	0.01	8.20E-75	-0.05	0.08	.55
C-reactive protein	rs1845854	T	C	-0.04	0.01	3.70E-13	-0.02	0.07	.81
C-reactive protein	rs1878658	A	G	0.02	0.00	1.40E-08	-0.04	0.03	.28
C-reactive protein	rs1880241	A	G	0.02	0.00	1.60E-31	-0.06	0.03	.05
C-reactive protein	rs1886008	T	C	0.02	0.00	3.60E-09	-0.02	0.05	.71
C-reactive protein	rs1933736	T	C	-0.02	0.00	1.90E-21	0.03	0.03	.32
C-reactive protein	rs1985157	T	C	-0.02	0.00	1.10E-15	-0.04	0.04	.29
C-reactive protein	rs199954423	A	G	0.04	0.00	3.00E-17	-0.07	0.07	.26
C-reactive protein	rs2011689	A	G	0.01	0.00	5.10E-09	0.02	0.03	.48
C-reactive protein	rs204907	A	G	-0.05	0.00	1.80E-30	-0.02	0.05	.73
C-reactive protein	rs2066715	C	T	0.02	0.00	2.00E-08	0.00	0.07	.98
C-reactive protein	rs2066992	G	T	0.05	0.00	1.50E-27	0.02	0.05	.73
C-reactive protein	rs2068888	G	A	0.02	0.00	5.20E-17	0.04	0.03	.08
C-reactive protein	rs2075803	A	G	0.01	0.00	4.60E-10	0.01	0.03	.69
C-reactive protein	rs2110944	T	C	-0.02	0.00	1.60E-14	-0.04	0.03	.23
C-reactive protein	rs2131925	G	T	-0.01	0.00	1.70E-12	-0.01	0.03	.76
C-reactive protein	rs2161037	G	A	-0.02	0.00	8.80E-28	0.03	0.03	.35
C-reactive protein	rs2161374	C	T	0.02	0.00	7.30E-17	0.04	0.03	.21
C-reactive protein	rs2207132	G	A	-0.05	0.01	4.40E-17	0.00	0.07	1.00
C-reactive protein	rs2239222	A	G	-0.03	0.00	3.40E-57	-0.01	0.03	.74

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs2250010	C	T	-0.02	0.00	1.50E-16	-0.05	0.03	.09
C-reactive protein	rs2265189	A	G	0.01	0.00	4.20E-12	-0.02	0.04	.66
C-reactive protein	rs2269434	T	C	0.02	0.00	1.80E-29	0.03	0.03	.31
C-reactive protein	rs2311597	A	G	0.01	0.00	9.70E-09	0.04	0.03	.27
C-reactive protein	rs2409750	A	C	0.02	0.00	4.60E-08	0.01	0.04	.83
C-reactive protein	rs2432195	C	T	-0.02	0.00	4.90E-10	-0.06	0.03	.07
C-reactive protein	rs2442749	T	C	0.02	0.00	8.30E-14	-0.01	0.03	.78
C-reactive protein	rs2472682	A	C	0.01	0.00	2.10E-08	0.03	0.03	.35
C-reactive protein	rs2542170	T	C	-0.02	0.00	8.60E-27	-0.03	0.03	.30
C-reactive protein	rs2570231	C	T	0.01	0.00	2.10E-09	0.06	0.03	1.77E-02
C-reactive protein	rs2606227	T	C	0.01	0.00	3.60E-09	0.05	0.04	.12
C-reactive protein	rs2645435	A	G	0.02	0.00	1.70E-08	0.02	0.04	.70
C-reactive protein	rs2647971	T	C	-0.01	0.00	1.50E-09	0.04	0.03	.22
C-reactive protein	rs2681780	C	T	-0.02	0.00	1.80E-23	-0.07	0.03	1.13E-02
C-reactive protein	rs2700938	T	C	-0.02	0.00	1.10E-29	-0.06	0.03	2.19E-02
C-reactive protein	rs2721961	T	G	0.03	0.00	5.30E-33	-0.02	0.04	.63
C-reactive protein	rs2767486	A	G	-0.02	0.00	2.30E-21	-0.06	0.03	.07
C-reactive protein	rs2808474	C	T	-0.01	0.00	3.10E-08	0.03	0.04	.37
C-reactive protein	rs282306	C	T	-0.02	0.00	6.30E-11	-0.03	0.05	.49
C-reactive protein	rs2836875	G	A	0.02	0.00	2.80E-11	-0.01	0.04	.69
C-reactive protein	rs2836882	G	A	0.03	0.00	5.60E-45	0.04	0.03	.13
C-reactive protein	rs28399607	T	C	0.05	0.00	1.80E-25	-0.03	0.09	.78
C-reactive protein	rs28399637	G	A	0.06	0.00	1.20E-164	0.00	0.03	.98
C-reactive protein	rs288183	T	G	0.02	0.00	7.40E-09	0.04	0.04	.37
C-reactive protein	rs2927482	G	A	0.05	0.00	1.10E-90	-0.04	0.04	.25
C-reactive protein	rs2957664	G	A	-0.01	0.00	6.00E-11	0.01	0.03	.65
C-reactive protein	rs2961111	C	T	-0.02	0.00	6.00E-10	-0.02	0.03	.64
C-reactive protein	rs2965162	C	T	-0.03	0.00	1.10E-25	0.01	0.05	.75
C-reactive protein	rs2965169	A	C	-0.03	0.00	2.00E-56	-0.01	0.03	.76
C-reactive protein	rs2970901	G	T	-0.01	0.00	1.80E-10	0.03	0.04	.46
C-reactive protein	rs3014201	T	C	0.01	0.00	2.40E-10	-0.01	0.03	.84
C-reactive protein	rs3094512	G	A	-0.01	0.00	3.40E-08	-0.02	0.04	.61
C-reactive protein	rs3095122	A	G	0.01	0.00	1.30E-08	-0.03	0.03	.30
C-reactive protein	rs3099478	C	T	0.02	0.00	1.60E-16	-0.01	0.04	.72
C-reactive protein	rs310630	A	G	-0.01	0.00	9.70E-09	-0.06	0.04	.08
C-reactive protein	rs3116654	A	G	0.09	0.00	1.00E-200	-0.02	0.04	.55
C-reactive protein	rs3125326	A	C	-0.01	0.00	2.30E-09	0.01	0.03	.73
C-reactive protein	rs3134133	G	A	0.01	0.00	3.10E-09	-0.02	0.03	.49
C-reactive protein	rs33951980	C	T	0.03	0.00	2.00E-25	0.15	0.06	9.26E-03

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs340005	G	A	-0.03	0.00	7.20E-51	0.04	0.03	.15
C-reactive protein	rs34234296	G	A	0.01	0.00	1.10E-09	0.02	0.03	.53
C-reactive protein	rs34298354	C	T	0.03	0.00	3.90E-16	-0.03	0.04	.42
C-reactive protein	rs34419562	G	A	-0.04	0.00	1.20E-27	0.01	0.06	.90
C-reactive protein	rs34761529	C	T	0.02	0.00	4.40E-09	0.02	0.03	.53
C-reactive protein	rs34874378	G	A	0.05	0.00	2.30E-22	0.18	0.06	4.77E-03
C-reactive protein	rs35057129	G	A	-0.01	0.00	6.80E-10	0.06	0.04	.10
C-reactive protein	rs35582280	T	C	-0.01	0.00	9.10E-09	-0.01	0.03	.79
C-reactive protein	rs35650976	C	T	0.01	0.00	4.60E-08	-0.05	0.04	.18
C-reactive protein	rs35881303	A	G	0.01	0.00	3.70E-11	-0.03	0.03	.32
C-reactive protein	rs3733892	A	C	0.02	0.00	7.90E-16	0.01	0.04	.76
C-reactive protein	rs3738028	C	A	-0.01	0.00	1.70E-09	-0.03	0.04	.46
C-reactive protein	rs3746778	G	A	0.01	0.00	7.10E-10	0.05	0.04	.16
C-reactive protein	rs3768321	G	T	-0.03	0.00	5.30E-37	-0.06	0.03	.08
C-reactive protein	rs3774063	C	T	-0.02	0.00	1.30E-11	0.02	0.05	.68
C-reactive protein	rs3789988	G	A	0.04	0.01	3.30E-11	0.07	0.07	.29
C-reactive protein	rs3791340	T	C	-0.01	0.00	1.10E-10	-0.01	0.03	.86
C-reactive protein	rs3808348	C	T	0.02	0.00	5.90E-18	0.01	0.03	.70
C-reactive protein	rs3826559	G	A	-0.01	0.00	6.80E-11	0.01	0.03	.60
C-reactive protein	rs3865444	C	A	0.02	0.00	4.00E-18	0.03	0.03	.27
C-reactive protein	rs4084164	A	G	0.01	0.00	5.00E-10	0.00	0.03	.97
C-reactive protein	rs41288829	C	T	-0.05	0.01	3.30E-13	0.13	0.09	.13
C-reactive protein	rs4133213	C	A	0.08	0.00	1.00E-200	-0.01	0.03	.68
C-reactive protein	rs4141160	A	G	0.01	0.00	5.20E-11	0.00	0.03	.91
C-reactive protein	rs4141168	A	G	-0.02	0.00	5.60E-13	0.07	0.04	.08
C-reactive protein	rs4148155	A	G	0.02	0.00	8.90E-12	-0.08	0.04	.07
C-reactive protein	rs420957	G	T	-0.02	0.00	1.10E-11	0.02	0.04	.52
C-reactive protein	rs4239504	C	T	0.02	0.00	9.40E-13	0.03	0.04	.48
C-reactive protein	rs4252041	C	T	-0.03	0.00	1.00E-09	-0.15	0.06	1.64E-02
C-reactive protein	rs4431051	C	T	0.01	0.00	1.30E-10	0.01	0.03	.64
C-reactive protein	rs4506495	T	C	-0.02	0.00	5.20E-09	-0.02	0.04	.65
C-reactive protein	rs4516268	C	A	0.01	0.00	1.50E-08	0.06	0.03	.07
C-reactive protein	rs45558633	C	T	0.02	0.00	4.60E-08	0.06	0.09	.51
C-reactive protein	rs4656241	T	C	-0.09	0.00	1.00E-200	-0.05	0.04	.18
C-reactive protein	rs4658403	C	T	0.02	0.00	1.20E-09	0.01	0.03	.84
C-reactive protein	rs4665972	T	C	0.07	0.00	1.00E-200	0.01	0.03	.75
C-reactive protein	rs4704780	A	C	-0.02	0.00	6.90E-11	0.07	0.05	.18
C-reactive protein	rs4711325	A	G	0.01	0.00	1.80E-08	0.00	0.03	1.00
C-reactive protein	rs4714508	A	G	-0.02	0.00	1.60E-15	-0.02	0.03	.56

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs4755720	C	T	0.02	0.00	1.00E-14	0.03	0.03	.32
C-reactive protein	rs4764939	C	T	0.02	0.00	6.40E-17	0.00	0.03	.89
C-reactive protein	rs4788867	T	C	-0.01	0.00	4.70E-11	0.01	0.03	.84
C-reactive protein	rs4789084	T	C	0.01	0.00	2.30E-08	0.01	0.03	.70
C-reactive protein	rs480958	G	A	0.01	0.00	9.30E-09	0.02	0.03	.54
C-reactive protein	rs4865540	C	A	-0.02	0.00	1.40E-10	0.04	0.04	.37
C-reactive protein	rs4871827	G	A	-0.01	0.00	7.00E-11	0.01	0.03	.66
C-reactive protein	rs4915287	A	G	-0.02	0.00	1.30E-10	-0.04	0.04	.27
C-reactive protein	rs541619	A	G	0.08	0.00	1.00E-200	-0.04	0.03	.19
C-reactive protein	rs543874	A	G	-0.02	0.00	6.20E-10	-0.03	0.03	.44
C-reactive protein	rs55642653	G	A	-0.02	0.00	3.40E-09	0.01	0.04	.82
C-reactive protein	rs55665939	A	G	-0.02	0.00	1.40E-12	-0.09	0.03	2.14E-03
C-reactive protein	rs55695634	C	T	-0.01	0.00	3.40E-08	-0.02	0.04	.64
C-reactive protein	rs55855238	T	C	-0.02	0.00	7.40E-31	-0.05	0.04	.20
C-reactive protein	rs55941618	G	A	0.02	0.00	3.80E-13	-0.05	0.04	.19
C-reactive protein	rs56189574	A	G	0.02	0.00	2.50E-21	-0.01	0.03	.84
C-reactive protein	rs56192838	T	C	0.02	0.00	4.20E-11	-0.01	0.06	.92
C-reactive protein	rs56261258	C	T	0.04	0.00	9.80E-41	0.06	0.06	.34
C-reactive protein	rs56821385	T	C	-0.03	0.01	4.00E-08	-0.09	0.08	.28
C-reactive protein	rs57167043	G	A	0.02	0.00	8.40E-09	0.03	0.04	.43
C-reactive protein	rs57550938	G	A	-0.02	0.00	2.50E-08	0.03	0.04	.48
C-reactive protein	rs58287327	G	A	-0.02	0.00	1.50E-10	0.01	0.04	.77
C-reactive protein	rs58542926	C	T	-0.04	0.00	1.40E-25	0.03	0.05	.53
C-reactive protein	rs58581511	T	G	0.01	0.00	2.50E-08	-0.01	0.04	.82
C-reactive protein	rs58770366	A	G	-0.01	0.00	1.50E-08	0.02	0.03	.50
C-reactive protein	rs58846684	G	A	0.09	0.01	1.50E-35	-0.02	0.09	.85
C-reactive protein	rs59316512	A	G	0.04	0.01	1.00E-08	-0.02	0.08	.77
C-reactive protein	rs59737437	C	T	0.01	0.00	1.00E-08	0.00	0.04	.99
C-reactive protein	rs601338	G	A	-0.02	0.00	2.60E-27	0.07	0.03	5.59E-03
C-reactive protein	rs6017342	A	C	-0.01	0.00	4.60E-09	-0.02	0.03	.54
C-reactive protein	rs6020459	T	C	-0.02	0.00	4.20E-15	0.02	0.04	.67
C-reactive protein	rs60239918	C	T	0.03	0.01	1.30E-08	-0.04	0.07	.58
C-reactive protein	rs6073958	T	C	0.03	0.00	2.40E-30	-0.03	0.03	.29
C-reactive protein	rs6138537	A	G	-0.02	0.00	5.00E-13	0.01	0.03	.58
C-reactive protein	rs613872	G	T	-0.02	0.00	8.70E-09	0.00	0.04	.93
C-reactive protein	rs61542988	C	T	0.03	0.00	4.20E-30	0.01	0.04	.75
C-reactive protein	rs61742729	C	T	-0.04	0.01	1.10E-09	-0.01	0.10	.92
C-reactive protein	rs61753391	G	A	-0.04	0.01	1.90E-10	0.01	0.08	.92
C-reactive protein	rs61806853	T	C	0.04	0.00	2.00E-19	-0.03	0.06	.66

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs61945773	T	C	0.01	0.00	7.00E-09	0.02	0.03	.58
C-reactive protein	rs61980636	C	T	0.02	0.00	1.10E-10	0.08	0.04	.07
C-reactive protein	rs62011286	G	A	0.01	0.00	7.60E-12	0.03	0.04	.46
C-reactive protein	rs62020680	G	A	-0.02	0.00	7.00E-11	0.00	0.05	.96
C-reactive protein	rs62039690	G	A	0.02	0.00	7.10E-09	0.01	0.06	.91
C-reactive protein	rs62039703	C	T	-0.01	0.00	1.70E-09	0.00	0.04	.95
C-reactive protein	rs62092069	G	A	0.01	0.00	3.50E-08	0.01	0.03	.71
C-reactive protein	rs62106258	T	C	0.03	0.00	4.50E-11	-0.06	0.06	.32
C-reactive protein	rs62118504	A	G	-0.03	0.00	6.10E-36	-0.05	0.03	.17
C-reactive protein	rs62121122	G	A	-0.02	0.00	9.00E-10	-0.09	0.05	.07
C-reactive protein	rs62158591	C	A	-0.02	0.00	4.30E-08	0.08	0.05	.12
C-reactive protein	rs62171038	C	T	0.02	0.00	4.70E-10	0.11	0.05	1.57E-02
C-reactive protein	rs62217799	G	T	-0.02	0.00	1.70E-24	-0.03	0.04	.38
C-reactive protein	rs62244890	T	C	0.01	0.00	4.30E-08	-0.06	0.04	.09
C-reactive protein	rs62282070	T	C	0.02	0.00	7.70E-11	-0.07	0.04	.09
C-reactive protein	rs623011	A	G	0.02	0.00	7.80E-14	-0.05	0.03	.06
C-reactive protein	rs62389532	A	G	0.03	0.00	5.70E-13	-0.03	0.05	.60
C-reactive protein	rs62451586	G	A	0.02	0.00	1.60E-08	-0.06	0.05	.20
C-reactive protein	rs62490334	C	T	-0.02	0.00	8.50E-09	-0.03	0.04	.46
C-reactive protein	rs62491814	G	A	0.02	0.00	1.70E-14	0.00	0.03	.99
C-reactive protein	rs62513191	T	C	-0.03	0.00	5.20E-11	0.04	0.08	.62
C-reactive protein	rs6265	C	T	0.02	0.00	7.50E-19	0.04	0.03	.19
C-reactive protein	rs6443429	A	C	0.01	0.00	2.10E-08	-0.06	0.04	.08
C-reactive protein	rs6486122	C	T	-0.03	0.00	2.60E-39	-0.03	0.03	.27
C-reactive protein	rs6519133	T	C	0.03	0.00	2.30E-53	0.01	0.03	.69
C-reactive protein	rs653170	C	T	-0.01	0.00	2.40E-09	-0.02	0.03	.49
C-reactive protein	rs6601299	T	C	-0.07	0.00	7.70E-101	-0.08	0.04	.06
C-reactive protein	rs663015	T	C	-0.02	0.00	1.40E-18	-0.03	0.03	.21
C-reactive protein	rs66744209	A	G	-0.02	0.00	2.30E-22	-0.04	0.04	.40
C-reactive protein	rs6682100	T	C	0.04	0.01	6.20E-12	-0.02	0.07	.75
C-reactive protein	rs668799	C	T	-0.02	0.00	5.30E-15	0.00	0.03	.90
C-reactive protein	rs67156297	G	A	-0.03	0.00	6.60E-50	0.01	0.04	.85
C-reactive protein	rs674833	G	A	0.01	0.00	5.40E-10	0.01	0.04	.70
C-reactive protein	rs67514550	C	T	-0.02	0.00	1.40E-08	-0.07	0.07	.28
C-reactive protein	rs67516067	G	A	-0.02	0.00	1.40E-09	0.09	0.05	.05
C-reactive protein	rs6792725	A	G	0.02	0.00	1.30E-13	0.02	0.04	.59
C-reactive protein	rs68085814	G	A	0.01	0.00	4.10E-09	0.00	0.03	.88
C-reactive protein	rs684016	C	A	-0.01	0.00	2.00E-10	-0.01	0.03	.70
C-reactive protein	rs6840517	A	G	-0.01	0.00	8.20E-10	0.01	0.03	.80

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs6845703	G	A	-0.02	0.00	1.20E-11	-0.03	0.03	.21
C-reactive protein	rs687339	C	T	0.03	0.00	1.40E-25	0.02	0.03	.41
C-reactive protein	rs6920220	G	A	-0.02	0.00	7.20E-18	0.00	0.03	.94
C-reactive protein	rs6961634	G	A	0.03	0.00	1.60E-20	-0.05	0.04	.22
C-reactive protein	rs6962836	A	G	-0.02	0.00	2.40E-13	0.03	0.04	.52
C-reactive protein	rs704017	A	G	0.02	0.00	9.00E-19	-0.02	0.03	.42
C-reactive protein	rs7084062	A	G	-0.02	0.00	1.20E-14	0.05	0.04	.17
C-reactive protein	rs7102088	C	T	0.01	0.00	7.30E-11	0.03	0.03	.32
C-reactive protein	rs71322200	C	A	-0.02	0.00	2.80E-09	-0.04	0.05	.43
C-reactive protein	rs71353230	G	A	-0.02	0.00	1.70E-13	0.02	0.04	.52
C-reactive protein	rs7150135	C	T	0.01	0.00	1.80E-11	0.00	0.04	.93
C-reactive protein	rs7171864	G	A	-0.01	0.00	6.00E-09	-0.01	0.04	.70
C-reactive protein	rs7189954	C	T	-0.02	0.00	3.50E-15	-0.03	0.03	.34
C-reactive protein	rs7196852	G	A	0.02	0.00	1.40E-16	-0.03	0.04	.47
C-reactive protein	rs7208791	G	A	-0.02	0.00	5.60E-15	0.03	0.03	.32
C-reactive protein	rs7248421	C	T	0.04	0.00	4.30E-28	0.02	0.05	.65
C-reactive protein	rs72634814	G	A	0.01	0.00	8.30E-11	-0.02	0.04	.58
C-reactive protein	rs72636644	G	A	-0.02	0.00	1.30E-08	-0.06	0.05	.22
C-reactive protein	rs72660319	G	A	-0.02	0.00	3.60E-10	0.00	0.05	.94
C-reactive protein	rs72694393	G	T	0.02	0.00	1.90E-14	0.02	0.03	.50
C-reactive protein	rs72771996	G	A	-0.03	0.00	8.90E-11	0.04	0.05	.43
C-reactive protein	rs72795810	G	T	0.03	0.01	4.50E-08	0.00	0.07	.95
C-reactive protein	rs7280982	G	A	-0.02	0.00	1.70E-12	0.00	0.04	.91
C-reactive protein	rs7292074	C	A	0.02	0.00	3.50E-16	0.01	0.05	.85
C-reactive protein	rs72959041	G	A	0.05	0.00	8.00E-29	0.05	0.07	.46
C-reactive protein	rs7303035	T	C	0.02	0.00	9.20E-17	0.02	0.03	.49
C-reactive protein	rs73137144	A	G	0.02	0.00	3.70E-11	-0.04	0.05	.44
C-reactive protein	rs73188545	A	G	-0.01	0.00	1.30E-08	0.05	0.03	.14
C-reactive protein	rs7319102	G	A	0.02	0.00	7.00E-12	0.03	0.03	.34
C-reactive protein	rs7341051	A	G	0.02	0.00	1.10E-08	-0.08	0.04	.06
C-reactive protein	rs73455693	G	A	0.03	0.01	1.30E-09	-0.08	0.07	.24
C-reactive protein	rs73577882	T	C	-0.05	0.01	6.30E-14	-0.03	0.06	.58
C-reactive protein	rs7412	C	T	-0.10	0.00	9.70E-149	-0.02	0.05	.69
C-reactive protein	rs7430935	T	C	0.01	0.00	2.10E-08	-0.01	0.04	.77
C-reactive protein	rs74580701	A	G	0.03	0.01	1.60E-10	0.03	0.07	.67
C-reactive protein	rs74607435	T	C	-0.04	0.00	9.20E-20	-0.07	0.06	.24
C-reactive protein	rs74733149	A	G	-0.12	0.00	1.00E-200	-0.05	0.07	.49
C-reactive protein	rs74873433	T	C	-0.04	0.00	1.90E-23	-0.08	0.06	.22
C-reactive protein	rs7488791	G	A	0.01	0.00	5.70E-09	-0.01	0.03	.86

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs75064168	G	A	-0.02	0.00	8.00E-09	-0.01	0.07	.92
C-reactive protein	rs7528419	A	G	-0.02	0.00	2.50E-12	-0.01	0.03	.78
C-reactive protein	rs7529640	G	A	0.01	0.00	2.10E-11	0.04	0.03	.22
C-reactive protein	rs7537072	T	C	0.01	0.00	1.60E-10	0.02	0.03	.36
C-reactive protein	rs75388820	G	A	-0.03	0.00	3.70E-13	0.02	0.06	.78
C-reactive protein	rs7550711	C	T	-0.04	0.01	4.40E-08	-0.15	0.09	.08
C-reactive protein	rs7579338	G	A	-0.01	0.00	2.50E-08	-0.03	0.03	.35
C-reactive protein	rs76289529	C	T	0.05	0.01	5.70E-20	-0.02	0.09	.81
C-reactive protein	rs769662	G	A	0.01	0.00	1.10E-08	0.03	0.03	.24
C-reactive protein	rs77013776	A	C	0.24	0.01	1.00E-200	0.26	0.11	1.45E-02
C-reactive protein	rs77189911	T	C	0.03	0.00	6.40E-10	-0.13	0.06	4.78E-02
C-reactive protein	rs77254471	C	T	0.11	0.01	6.90E-36	0.02	0.12	.89
C-reactive protein	rs77509028	G	T	-0.07	0.01	9.50E-16	0.04	0.09	.69
C-reactive protein	rs7770370	A	G	0.02	0.00	8.90E-14	-0.10	0.03	2.94E-03
C-reactive protein	rs77704739	T	C	0.05	0.00	1.00E-21	0.01	0.07	.90
C-reactive protein	rs77994623	C	T	-0.05	0.00	2.20E-65	0.00	0.03	.93
C-reactive protein	rs78063634	C	A	-0.02	0.00	6.90E-12	-0.02	0.04	.57
C-reactive protein	rs78128878	T	C	-0.02	0.00	1.10E-08	0.07	0.05	.21
C-reactive protein	rs78200104	C	T	-0.03	0.01	2.40E-09	0.10	0.09	.27
C-reactive protein	rs78343493	G	A	-0.02	0.00	9.20E-10	0.03	0.04	.42
C-reactive protein	rs787488	A	G	0.01	0.00	7.60E-11	-0.02	0.04	.52
C-reactive protein	rs78912080	A	G	-0.03	0.00	6.70E-15	0.00	0.10	1.00
C-reactive protein	rs79101008	C	A	0.03	0.00	2.10E-17	0.03	0.07	.64
C-reactive protein	rs79111922	T	G	0.03	0.00	4.70E-12	-0.03	0.08	.75
C-reactive protein	rs79219014	G	T	0.08	0.01	1.50E-38	0.02	0.09	.82
C-reactive protein	rs79551159	G	A	-0.20	0.00	1.00E-200	0.02	0.05	.64
C-reactive protein	rs7956514	T	G	-0.02	0.00	1.10E-12	-0.03	0.03	.37
C-reactive protein	rs79753070	G	A	0.05	0.01	2.10E-13	0.16	0.13	.22
C-reactive protein	rs79896703	T	G	-0.02	0.00	3.30E-08	-0.01	0.06	.84
C-reactive protein	rs7993752	C	A	0.01	0.00	1.30E-10	-0.06	0.03	.06
C-reactive protein	rs80257887	G	A	0.04	0.01	6.10E-16	0.02	0.08	.85
C-reactive protein	rs8034216	C	T	-0.01	0.00	1.50E-10	0.02	0.03	.51
C-reactive protein	rs8040040	C	T	0.02	0.00	3.20E-19	0.01	0.03	.84
C-reactive protein	rs8059619	C	T	-0.01	0.00	6.20E-12	-0.02	0.03	.49
C-reactive protein	rs8126001	C	T	0.01	0.00	5.70E-13	-0.03	0.03	.44
C-reactive protein	rs8178824	C	T	-0.06	0.01	6.20E-24	0.17	0.09	.05
C-reactive protein	rs855679	T	C	-0.02	0.00	2.70E-08	-0.02	0.05	.76
C-reactive protein	rs885949	T	C	-0.02	0.00	2.90E-09	-0.05	0.03	.12
C-reactive protein	rs895251	T	C	0.02	0.00	1.90E-15	-0.03	0.03	.28

Supplementary Table 7. Continued

Exposure	SNP	EA	AA	Exposure			Outcome		
				Beta	SE	P Value	Beta	SE	P Value
C-reactive protein	rs8978	C	T	-0.01	0.00	8.10E-11	-0.02	0.03	.47
C-reactive protein	rs9263760	G	A	-0.02	0.00	3.50E-10	0.10	0.04	1.08E-02
C-reactive protein	rs9263869	T	C	-0.01	0.00	8.80E-09	-0.02	0.04	.51
C-reactive protein	rs9388766	T	C	-0.02	0.00	1.70E-27	-0.01	0.03	.64
C-reactive protein	rs9427431	T	C	-0.01	0.00	1.10E-08	0.00	0.03	.89
C-reactive protein	rs9604045	G	T	0.02	0.00	1.00E-19	0.00	0.04	.93
C-reactive protein	rs9632944	A	G	0.02	0.00	7.70E-10	0.05	0.04	.21
C-reactive protein	rs966038	G	A	-0.01	0.00	2.00E-08	0.03	0.04	.40
C-reactive protein	rs9738365	C	A	-0.02	0.00	3.20E-16	0.05	0.03	.09
C-reactive protein	rs9788721	C	T	0.01	0.00	3.10E-08	-0.02	0.03	.44
C-reactive protein	rs9929143	C	A	0.02	0.00	4.00E-08	-0.03	0.05	.44
C-reactive protein	rs9939450	T	C	0.01	0.00	1.40E-09	-0.01	0.03	.71
C-reactive protein	rs9947450	C	T	0.03	0.01	3.60E-09	0.09	0.06	.14
C-reactive protein	rs9951447	T	C	0.01	0.00	1.50E-08	-0.01	0.03	.75
C-reactive protein	rs9964712	C	T	0.03	0.00	3.10E-09	-0.02	0.06	.81

AA, alternative allele; EA, effect allele; COVID-19, coronavirus disease 2019; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-B, homeostatic model assessment for beta cell function; HOMA-IR, homeostatic model assessment for insulin resistance; IV, instrumental variable; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD Activity Score; SNP, single nucleotide polymorphism.

Supplementary Table 8. The Instrument Strength and MR Power in Our TSMR Analyses

Exposure	n	Sample size	I^2	R^2	F Statistic	MR Power
NAFLD	5	429,963	0.96	0.16	16572.45	0.15
Serum alanine aminotransferase level	40	164,197	0.99	0.03	111.16	0.07
NAS (IVs provided by Namjou B et al)	2	235	0.00	0.72	300.46	0.35
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	16	235	0.95	0.31	6.12	0.08
Fibrosis stage (IVs provided by Namjou B et al)	3	235	0.89	0.55	95.15	0.11
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	52	235	0.91	0.93	45.92	0.15
Grade of steatosis (IVs provided by Anstee QM et al)	2	1,483	0.98	0.02	14.26	0.18
NAS (IVs provided by Anstee QM et al)	1	1,483	NA	0.05	80.02	0.06
Fibrosis stage (IVs provided by Anstee QM et al)	1	1,483	NA	0.04	60.30	0.05
Body mass index	81	322,154	0.98	0.07	293.47	1.00
Waist circumference	44	232,101	0.98	0.05	272.25	1.00
Hip circumference	54	213,038	0.98	0.06	261.41	1.00
Waist-to-hip ratio	34	212,248	0.92	0.04	280.79	0.41
Type 2 diabetes	29	111,309	0.98	0.01	53.27	0.05
Fasting glucose	98	200,622	0.99	0.22	567.73	0.14
Fasting insulin	40	151,013	0.98	0.12	498.61	0.97
2-h glucose	13	63,396	0.97	0.02	111.56	0.55
HbA1c	106	146,806	0.99	0.45	1133.27	1.00
HOMA-B	11	36,466	0.98	0.10	361.30	0.90
HOMA-IR	9	37,037	0.98	0.01	31.61	0.43
Coronary heart disease	43	184,305	0.98	0.02	82.09	0.06
Serum total cholesterol	29	21,491	0.98	0.09	73.99	0.29
Serum total triglycerides	11	21,545	0.98	0.04	86.02	0.07
Total cholesterol in LDL	39	21,559	0.99	0.12	73.13	0.25
Total cholesterol in HDL	18	21,555	0.98	0.06	75.06	0.15
Apolipoprotein B	23	20,690	0.99	0.08	72.96	0.43
Diastolic blood pressure	689	757,601	0.98	0.04	48.16	0.05
Systolic blood pressure	650	757,601	0.98	0.02	28.26	0.05
C-reactive protein	410	418,642	0.99	0.36	580.61	1.00

CI, confidence interval; COVID-19, coronavirus disease 2019; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-B, homeostatic model assessment for beta cell function; HOMA-IR, homeostatic model assessment for insulin resistance; IV, instrumental variable; LDL, low-density lipoprotein; MR, Mendelian randomization; NA, not available; NAFLD; nonalcoholic fatty liver disease; OR, odds ratio; TSMR, 2-sample Mendelian randomization.

Supplementary Table 9. The Causal Effect of the Risk Factors on Severe COVID-19

Exposure	Method	n	Beta	SE	P	Het-P	Ple-P	OR (95% CI)
Nonalcoholic fatty liver diseases	IVW	5	-0.03	0.05	.61	.55	.50	0.97 (0.88–1.08)
Nonalcoholic fatty liver diseases	MR-Egger	5	-0.11	0.12	.43	.48	.50	0.90 (0.70–1.14)
Nonalcoholic fatty liver diseases	Weighted median	5	-0.05	0.06	.45	NA	.50	0.95 (0.85–1.08)
Nonalcoholic fatty liver diseases	MR-PRESSO	5	-0.03	0.05	.59	NA	NA	0.97 (0.88–1.07)
Serum alanine aminotransferase level	IVW	40	0.03	0.05	.47	.59	.46	1.03 (0.95–1.13)
Serum alanine aminotransferase level	MR-Egger	40	-0.03	0.09	.78	.57	.46	0.98 (0.82–1.17)
Serum alanine aminotransferase level	Weighted median	40	0.05	0.07	.53	NA	.46	1.05 (0.91–1.21)
Serum alanine aminotransferase level	MR-PRESSO	40	0.03	0.04	.46	NA	NA	1.03 (0.95–1.11)
NAS (IVs provided by Namjou B et al)	IVW	2	0.02	0.02	.39	.39	NA	1.02 (0.98–1.05)
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	IVW	16	-0.01	0.01	.23	.61	.90	0.99 (0.98–1.01)
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	MR-Egger	16	-0.01	0.03	.69	.53	.90	0.99 (0.94–1.05)
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	Weighted median	16	-0.01	0.01	.33	NA	.90	0.99 (0.97–1.01)
NAS (IVs with $P < 1e-5$ provided by Namjou B et al)	MR-PRESSO	16	-0.01	0.01	.22	NA	NA	0.99 (0.97–1.01)
Fibrosis stage (IVs provided by Namjou B et al)	IVW	3	0.01	0.03	.87	.03	.29	1.01 (0.94–1.08)
Fibrosis stage (IVs provided by Namjou B et al)	MR-Egger	3	-0.09	0.05	.32	.26	.29	0.91 (0.83–1.01)
Fibrosis stage (IVs provided by Namjou B et al)	MR-Egger SIMEX	3	-0.09	0.03	.12	NA	NA	0.91 (0.86–0.97)
Fibrosis stage (IVs provided by Namjou B et al)	Weighted median	3	0.00	0.03	.89	NA	.29	1.00 (0.95–1.05)
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	IVW	52	0.01	0.01	.21	.63	.01	1.01 (1.00–1.02)
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	MR-Egger	52	-0.02	0.01	.10	.83	.01	0.98 (0.96–1.00)
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	Weighted median	52	0.00	0.01	.96	NA	.01	1.00 (0.98–1.02)
Fibrosis stage (IVs with $P < 1e-5$ provided by Namjou B et al)	MR-PRESSO	52	0.01	0.01	.19	NA	NA	1.01 (0.99–1.03)
Grade of steatosis (IVs provided by Anstee QM et al)	IVW	2	0.07	0.09	.41	.34	NA	1.08 (0.90–1.29)
NAS (IVs provided by Anstee QM et al)	Wald ratio	1	-0.01	0.07	.91	NA	NA	0.99 (0.87–1.13)
Fibrosis stage (IVs provided by Anstee QM et al)	Wald ratio	1	-0.01	0.07	.91	NA	NA	0.99 (0.86–1.15)
Body mass index	IVW	81	0.55	0.1	7.65E-09	.19	.22	1.73 (1.44–2.08)
Body mass index	MR-Egger	81	0.22	0.28	.42	.21	.22	1.25 (0.73–2.15)
Body mass index	Weighted median	81	0.51	0.14	1.79E-04	NA	.22	1.67 (1.28–2.19)

Supplementary Table 9. Continued

Exposure	Method	n	Beta	SE	<i>P</i>	Het- <i>P</i>	Ple- <i>P</i>	OR (95% CI)
Body mass index	MR-PRESSO	81	0.55	0.09	1.41E-07	NA	NA	1.73 (1.45–2.07)
Waist circumference	IWW	44	0.57	0.13	2.58E-05	.07	.66	1.76 (1.35–2.29)
Waist circumference	MR-Egger	44	0.77	0.47	.11	.06	.66	2.16 (0.85–5.43)
Waist circumference	Weighted median	44	0.56	0.17	8.71E-04	NA	.66	1.75 (1.26–2.43)
Waist circumference	MR-PRESSO	44	0.56	0.13	1.29E-04	NA	NA	1.75 (1.36–2.26)
Hip circumference	IWW	54	0.29	0.11	7.26E-03	.08	.79	1.33 (1.08–1.65)
Hip circumference	MR-Egger	54	0.37	0.33	.26	.07	.79	1.45 (0.76–2.74)
Hip circumference	Weighted median	54	0.35	0.15	1.60E-02	NA	.79	1.42 (1.07–1.89)
Hip circumference	MR-PRESSO	54	0.29	0.11	9.66E-03	NA	NA	1.34 (1.08–1.66)
Waist-to-hip ratio	IWW	34	0.09	0.17	.61	.03	.37	1.09 (0.78–1.53)
Waist-to-hip ratio	MR-Egger	34	-0.51	0.68	.46	.03	.37	0.60 (0.16–2.28)
Waist-to-hip ratio	Weighted median	34	0.20	0.22	.37	NA	.37	1.22 (0.79–1.88)
Waist-to-hip ratio	MR-PRESSO	34	0.09	0.17	.62	NA	NA	1.09 (0.78–1.53)
Type 2 diabetes	IWW	29	-0.01	0.03	.88	.68	.12	1.00 (0.94–1.06)
Type 2 diabetes	MR-Egger	29	-0.1	0.07	.14	.76	.12	0.90 (0.79–1.03)
Type 2 diabetes	Weighted median	29	-0.02	0.05	.67	NA	.12	0.98 (0.89–1.08)
Type 2 diabetes	MR-PRESSO	29	0.00	0.03	.87	NA	NA	1.00 (0.94–1.06)
Fasting glucose	IWW	98	0.02	0.14	.90	.00	.12	1.02 (0.78–1.33)
Fasting glucose	MR-Egger	98	-0.31	0.25	.21	.00	.12	0.73 (0.45–1.19)
Fasting glucose	Weighted median	98	-0.09	0.17	.59	NA	.12	0.91 (0.65–1.28)
Fasting glucose	MR-PRESSO Outlier-corrected	98	-0.07	0.12	.55	NA	NA	0.93 (0.74–1.18)
Fasting insulin	IWW	40	0.11	0.22	.60	.45	.38	1.12 (0.74–1.71)
Fasting insulin	MR-Egger	40	-0.44	0.66	.51	.44	.38	0.64 (0.18–2.36)
Fasting insulin	Weighted median	40	0.37	0.33	.25	NA	.38	1.45 (0.77–2.74)
Fasting insulin	MR-PRESSO	40	0.11	0.21	.60	NA	NA	1.12 (0.74–1.68)
2-h glucose	IWW	13	0.14	0.18	.44	.00	.09	1.15 (0.81–1.63)
2-h glucose	MR-Egger	13	-0.68	0.47	.18	.00	.09	0.51 (0.20–1.27)
2-h glucose	Weighted median	13	-0.11	0.13	.38	NA	.09	0.90 (0.70–1.15)
2-h glucose	MR-PRESSO Outlier-corrected	13	0.02	0.09	.85	NA	NA	1.02 (0.86–1.22)
HbA1c	IWW	106	0.25	0.2	.22	.00	.69	1.28 (0.86–1.89)
HbA1c	MR-Egger	106	0.12	0.39	.77	.00	.69	1.12 (0.53–2.39)
HbA1c	Weighted median	106	0.22	0.27	.42	NA	.69	1.24 (0.74–2.09)
HbA1c	MR-PRESSO Outlier-corrected	106	0.23	0.17	.19	NA	NA	1.26 (0.9–1.76)
HOMA-B	IWW	11	-0.12	0.28	.67	.84	.52	0.89 (0.51–1.55)
HOMA-B	MR-Egger	11	-0.53	0.67	.45	.81	.52	0.59 (0.16–2.20)
HOMA-B	Weighted median	11	0.20	0.38	.60	NA	.52	1.22 (0.58–2.56)
HOMA-B	MR-PRESSO	11	-0.12	0.21	.59	NA	NA	0.89 (0.59–1.34)
HOMA-IR	IWW	9	0.20	0.21	.34	.47	.38	1.22 (0.81–1.84)
HOMA-IR	MR-Egger	9	0.37	0.28	.22	.45	.38	1.45 (0.84–2.51)
HOMA-IR	Weighted median	9	0.36	0.25	.16	NA	.38	1.43 (0.87–2.35)

Supplementary Table 9. Continued

Exposure	Method	n	Beta	SE	P	Het-P	Ple-P	OR (95% CI)
HOMA-IR	MR-PRESSO	9	0.20	0.20	.35	NA	NA	1.22 (0.83–1.81)
Coronary heart disease	IVW	43	-0.02	0.06	.75	.00	.60	0.98 (0.88–1.09)
Coronary heart disease	MR-Egger	43	-0.08	0.13	.54	.00	.60	0.93 (0.73–1.18)
Coronary heart disease	Weighted median	43	-0.04	0.06	.53	NA	.60	0.96 (0.85–1.09)
Coronary heart disease	MR-PRESSO Outlier-corrected	43	-0.04	0.04	.34	NA	NA	0.96 (0.89–1.04)
Serum total cholesterol	IVW	29	-0.05	0.04	.28	.77	.73	0.95 (0.88–1.04)
Serum total cholesterol	MR-Egger	29	-0.02	0.09	.79	.73	.73	0.98 (0.83–1.15)
Serum total cholesterol	Weighted median	29	-0.08	0.07	.21	NA	.73	0.92 (0.81–1.05)
Serum total cholesterol	MR-PRESSO	29	-0.05	0.04	.23	NA	NA	0.95 (0.88–1.03)
Serum total triglycerides	IVW	11	0.02	0.07	.78	.64	.40	1.02 (0.89–1.17)
Serum total triglycerides	MR-Egger	11	-0.19	0.25	.46	.62	.40	0.83 (0.51–1.34)
Serum total triglycerides	Weighted median	11	-0.10	0.09	.30	NA	.40	0.91 (0.76–1.09)
Serum total triglycerides	MR-PRESSO	11	0.02	0.06	.76	NA	NA	1.02 (0.91–1.15)
Total cholesterol in LDL	IVW	39	-0.04	0.05	.33	.00	.50	0.96 (0.88–1.05)
Total cholesterol in LDL	MR-Egger	39	-0.09	0.08	.27	.00	.50	0.92 (0.79–1.07)
Total cholesterol in LDL	Weighted median	39	-0.06	0.05	.23	NA	.50	0.94 (0.85–1.04)
Total cholesterol in LDL	MR-PRESSO	39	-0.06	0.03	.07	NA	NA	0.94 (0.89–1.00)
Total cholesterol in HDL	IVW	18	0.04	0.05	.43	.31	.15	1.04 (0.94–1.16)
Total cholesterol in HDL	MR-Egger	18	0.22	0.13	.10	.39	.15	1.24 (0.97–1.59)
Total cholesterol in HDL	Weighted median	18	0.09	0.07	.20	NA	.15	1.10 (0.95–1.27)
Total cholesterol in HDL	MR-PRESSO	18	0.04	0.05	.44	NA	NA	1.04 (0.94–1.15)
Apolipoprotein B	IVW	23	-0.07	0.04	.13	.83	.99	0.93 (0.86–1.02)
Apolipoprotein B	MR-Egger	23	-0.07	0.08	.43	.79	.99	0.94 (0.79–1.10)
Apolipoprotein B	Weighted median	23	-0.09	0.07	.18	NA	.99	0.92 (0.80–1.04)
Apolipoprotein B	MR-PRESSO	23	-0.07	0.04	.08	NA	NA	0.93 (0.86–1.01)
Diastolic blood pressure	IVW	689	-0.01	0.01	.27	.00	.63	0.99 (0.97–1.01)
Diastolic blood pressure	MR-Egger	689	0.00	0.03	.96	.00	.63	1.00 (0.95–1.05)
Diastolic blood pressure	Weighted median	689	-0.01	0.01	.46	NA	.63	0.99 (0.97–1.02)
Diastolic blood pressure	MR-PRESSO Outlier-corrected	689	-0.01	0.01	.36	NA	NA	0.99 (0.97–1.01)
Systolic blood pressure	IVW	650	0.00	0.01	.70	.00	.62	1.00 (0.99–1.01)
Systolic blood pressure	MR-Egger	650	0.01	0.01	.75	.00	.62	1.01 (0.98–1.03)
Systolic blood pressure	Weighted median	650	0.01	0.01	.24	NA	.62	1.01 (0.99–1.03)
Systolic blood pressure	MR-PRESSO Outlier-corrected	650	0.00	0.01	.62	NA	NA	1.00 (0.98–1.02)
C-reactive protein	IVW	410	0.12	0.07	.10	.57	.44	1.12 (0.98–1.29)
C-reactive protein	MR-Egger	410	0.04	0.12	.71	.56	.44	1.05 (0.83–1.31)
C-reactive protein	Weighted median	410	0.10	0.12	.41	NA	.44	1.11 (0.87–1.40)
C-reactive protein	MR-PRESSO	410	0.12	0.07	.10	NA	NA	1.13 (0.98–1.29)

For a binary exposure (ie, nonalcoholic fatty liver disease, type 2 diabetes, coronary heart disease), the effect of the exposure on severe COVID-19 is expressed the change in severe COVID-19 for each 2.72-fold increase in the exposure.

CI, confidence interval; COVID-19, coronavirus disease 2019; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-B, homeostatic model assessment for beta cell function; HOMA-IR, homeostatic model assessment for insulin resistance; IV, instrumental variable; IVW, inverse variance weighted; LDL, low-density lipoprotein; NA, not available; OR, odds ratio.